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ABSTRACT 
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and it is one of 
the leading causes of men’s cancer deaths in the developed countries. It can be 
considered as a continuum of neoplasms with aggressiveness ranging from cancers 
with no effect on the patients’ life expectancy to highly aggressive cancers. Contrary 
to all other solid-organ cancers, PCa diagnosis is not traditionally based on imaging 
or visual examination (e.g. endoscopy), but systematic biopsies. Convincing evidence 
of prostate MRIs’ high sensitivity in detecting clinically significant PCa (CSPCa) and 
tendency to discriminate insignificant PCas have recently been published. However, 
the role of imaging is still under debate. Additionally, infectious prostate biopsy 
complications have increased lately, which has been suspected to have risen from a 
globally increasing antibiotic resistance e.g. an increased resistance to an antibiotic 
prophylaxis. 
In the first substudy, we prospectively investigated the prevalence of transrectal 
prostate biopsy complications. The rate of complications was low, even though 
intestinal bacterial antibiotic resistance for prophylaxis was significant. In the second 
substudy, we prospectively determined the prevalence and risk factors for antibiotic 
resistance of intestinal Escherichia coli in men undergoing prostate biopsies. A rate 
of fluoroquinolone resistant Escherichia coli was 13% while international traveling 
was a significant risk factor. In the third substudy, we externally validated an optimal 
combination strategy of PSA density and MRI score for selecting men to prostate 
biopsies. Like in the study to be validated, PSA density has only a minor additional 
value to the MRI score. In the fourth substudy, we investigated an impact of prostate 
MRI in an initial PCa diagnostics. In a prospective study cohort using prebiopsy 
prostate MRI, the rate of CSPCa was significantly higher in initial biopsies and 
significantly few CSPCa were diagnosed during the follow-up comparing to a cohort 
with traditional PCa diagnostics. In the fifth substudy, we analyzed performance 
measures of MRI in CSPCa diagnostics. In the substudy, MRI demonstrated an 
excellent negative predictive value in ruling out CSPCa. 
As a conclusion, prebiopsy prostate MRI should be performed to all men in a 
suspicion of localized prostate cancer. A biopsy decision should be based on men’s 
individual risk for having significant PCa in the patient level. From a point of view of 
an individual man, the most significant risk for an unnecessary biopsy could be a 
diagnosis of insignificant PCa, not a lethal complication. 
KEYWORDS: prostate, cancer, diagnostics, biparametric, mri, negative, predictive 
value, fluoroquinolone, resistance, e.coli, escherichia coli,  
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TIIVISTELMÄ 
Eturauhassyöpä (PCa) on miesten yleisin syöpä ja toiseksi yleisin syöpäkuolemien 
aiheuttaja kehittyneissä maissa. Sitä voidaan pitää jatkumona merkityksettömistä ja 
elinajanennusteeseen vaikuttamattomista syövistä erittäin aggressiivisiin syöpiin. 
Toisin kuin muiden kiinteiden elinten syöpien suhteen, PCa:ää ei perinteisesti ole 
diagnosoitu kuvantamisen tai tähystystutkimusten/inspektion perusteella vaan 
systemaattisilla biopsioilla. MRI:sta on viime aikoina julkaistu vakuuttavaa näyttöä 
sen korkeasta herkkyydestä kliinisesti merkittävien eturauhassyöpien (CSPCa) 
suhteen ja taipumuksesta jättää merkityksettömät syövät löytämättä. Kuvantamisella 
ei kuitenkaan ole vielä vakiintunutta roolia diagnostiikassa. Lisäksi eturauhas-
biopsioista seuraavien infektioiden määrä on lisääntynyt, minkä epäillään johtuvan 
maailmanlaajuisesti lisääntyneestä antibioottiresistenssistä eli toisin sanoen 
lisääntyneestä resistenssistä profylaktiselle antibiootille. 
Ensimmäisessä osatyössä tutkimme eturauhasbiopsioiden komplikaatioita 
prospektiivisessa aineistossa, joita todettiin vähän huolimatta merkittävästä anti-
bioottiresistenssistä annetulle profylaksialle. Toisessa osatyössä tutkimme prospek-
tiivisesti suoliston Escherichia colin antibioottiresistenssin vallitsevuutta ja sen 
riskitekijöitä eturauhasbiopsioitavilla miehillä. Tutkimuksessa fluorokinoloni-
resistentti Escherichia coli todettiin 13 %:lla. Ulkomaanmatkailu oli tälle merkittävä 
riskitekijä. Kolmannessa osatyössä validoimme optimaalista strategiaa PSA tiheyden 
ja MRI tuloksen yhdistelmälle biopsoitavien miesten valinnassa. Kuten validoitavassa 
tutkimuksessa, PSA tiheyden tuoma lisäarvo oli vähäinen. Neljännessä osatyössä 
tutkimme MRI:n vaikutusta CSPCa:n primääridiagnostiikassa. Prospektiivisessa 
aineistossa MRI kuvattuja miehiä, CSPCa:n määrä ensimmäisissä biopsioissa oli 
merkittävästi korkeampi ja seurannassa todettujen CSPCa:n määrä merkittävästi 
alempi verrattuna perinteisellä diagnostiikalla tutkittuihin. Viidennessä osatyössä 
tutkimme MRI:n tehokkuusarvoja CSPCa:n diagnostiikassa. Totesimme MRI:n 
negatiivisen ennustearvon olevan erinomainen CSPCa:n poissulussa. 
Yhteenvetona, MRI pitäisi tehdä ennen biopsioita kaikille miehille, joilla 
epäillään paikallista PCa:ää. Päätös biopsioista tulisi perustua yksilölliseen riskiin 
potilaskohtaisesti merkittävälle PCa:lle. Yksittäisen miehen näkökulmasta, 
mahdollisesti oleellisin riski tarpeettomilla biopsioilla on merkityksettömän PCa:n 
diagnoosi, ei hengenvaarallinen biopsiakomplikaatio. 
AVAINSANAT: eturauhassyöpä, eturauhasbiopsiat, diagnostiikka, mri, bipara-
metrinen, fluorokinoloniresistenssi, escherichia coli, e. coli  
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Abbreviations 
3CEF 3rd generations cephalosporins 
5ARI 5-alphareductase 
ADC apparent diffusion coefficient 
ADT androgen deprivation therapy 
AUC area under the receiver operating characteristic curve  
BCR biochemical recurrence 
BPH benign prostate hyperplasia 
bpMRI biparametric MRI 
CI confidence interval 
CSPCa clinically significant prostate cancer 
CT computer tomography 
DCA decision curve analysis 
DCE dynamic contrast enhanced imaging 
DR detection rate 
DRE digital rectal examination 
DWI diffusion weighted imaging 
E. coli Escherichia coli 
EAU European association of urology 
EBRT external beam radiotherapy 
ESBL extended-spectrum beta-lactamase 
EUCAST The European Committee on Antimicrobial Susceptibility Testing 
GGG Gleason Grade Group 
HIFU high intensity focused ultrasound 
IDC-P intraductal carcinoma of prostate 
INR international normalized ratio 
insPCa clinically insignificant prostate cancer 
IQR interquartile range 
mpMRI multiparametric MRI 
MRI magnetic resonance imaging 
NECP neuroendocrine cancer of prostate 
NICE National Institute of Health and Care Excellence 
NPV negative predictive value 
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OR odds ratio 
PCa prostate cancer 
PET positron emission tomography 
PHI prostate health index 
PI-RADS Prostate Imaging Reporting and Data System  
PPV positive predictive value 
PSA prostate specific antigen 
PCA3 prostate cancer gene 3 
RCT randomized, controlled trial 
RR relative risk 
T2W T2-weighted imaging 
TRUS transrectal ultrasound 
TRUS-Bx transrectal, ultrasound guided prostate biopsies 
TURP transurethral resection of prostate 
TYKS Turku University Hospital  
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1 Introduction 
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and it is one of 
the leading causes of men’s cancer deaths in the developed countries (Center et al., 
2012; Fitzmaurice et al., 2015; Torre et al., 2015). In addition, according to an 
estimation, PCa causes 11% of cancer-related health care costs in the European Union 
(Luengo-Fernandez et al., 2013). Prostate cancer can be considered as a continuum of 
neoplasms with aggressiveness ranging from cancers with no effect on the patients’ 
life expectancy to highly aggressive cancers (Barocas et al., 2017; Bell et al., 2015; 
Bill-Axelson et al., 2018; Epstein, Zelefsky, et al., 2016; Jahn et al., 2015). Hence, not 
all PCas demand a definitive treatment. After an introduction of a prostate specific 
antigen (PSA) for clinical use in the 1980s, which was initially recommended for the 
surveillance of PCa after radical treatments, the number of PCa diagnoses has 
dramatically increased (Center et al., 2012; Stamey et al., 1987). The increase in PCa 
diagnoses is mainly a consequence of opportunistic PSA testing. However, a 
corresponding trend is not seen in PCa mortality (Center et al., 2012). Although, after 
the introduction of PSA, PCa is diagnosed more in an earlier stage (Seikkula et al., 
2017). 
Usually, a localized PCa gives no symptoms, or the symptoms cannot be 
distinguished from common and benign conditions, for example benign prostate 
hyperplasia (Hollingsworth & Wilt, 2014). Suspicion of a localized PCa in 
symptomatic and also in asymptomatic men derives usually from an increased PSA 
level or an abnormal finding in digital rectal examination (DRE) (Mottet et al., 2018; 
NICE, 2019). Contrary to all other solid-organ cancers, PCa diagnosis is not 
traditionally based on imaging or visual examination (e.g. endoscopy), but random 
biopsies (i.e. systematic biopsies) from the prostate (Mottet et al., 2018; NICE, 2019). 
Even if the systematic biopsies are usually taken under transrectal ultrasound (TRUS) 
guidance, the sensitivity of TRUS in detecting PCa is low. TRUS is mainly used for 
the guidance of biopsy cores, not primarily to visualize pathological lesions (Halpern 
& Strup, 2000; Onur et al., 2004; Smeenge et al., 2012). The role of imaging, which 
usually means prostate magnetic resonance imaging (MRI) in PCa diagnostics is still 
under debate (Mottet et al., 2018). In addition, the guidelines do not primarily 
recommend to take biopsies only from suspicious lesions visible in MRI, since all 
significant lesions may not be visible in MRI (Mottet et al., 2018; NICE, 2019). Thus, 
Juha Knaapila 
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systematic biopsies still remain to be a cornerstone of the PCa diagnostics (Mottet et 
al., 2018).  
The traditional diagnostic protocol is suboptimal for modern diagnostic demands. 
Firstly, PSA is an organ-specific, not cancer-specific marker. The probability of PCa 
rises along with rising PSA level, thus there is no threshold level for PSA to rule out 
clinically significant PCa (CSPCa) (Thompson et al., 2006). PCa screening using PSA 
has also been widely studied, however, it seems not to decrease PCa-specific or 
overall mortality and thus it is not recommended by the guidelines (Ilic et al., 2013; 
Mottet et al., 2018; NICE, 2019). Additionally, DREs have very low sensitivity to 
PCa (Catalona et al., 1994; Naji et al., 2018). 
After a suspicion of PCa has emerged, the traditional diagnostic protocol with 
systematic biopsies cannot rule out CSPCa even with moderate probability, because 
systematic biopsies give only limited information about the whole prostate gland 
pathology (Ahdoot et al., 2020; Drost et al., 2019; Hu et al., 2012). In addition, PCa 
is commonly a multifocal disease, thus systematic biopsies may not present the most 
malignant histology of the gland (Choi et al., 2019). Therefore, the biopsy procedure 
should be repeated, when a suspicion of a PCa or its more malignant histology, 
prevails. 
Repeated prostate biopsies obviously increase the probability of biopsy-related 
complications. Urinary tract infection is the most significant complication following 
transrectal ultrasound guided prostate biopsies (TRUS-Bx). Infectious prostate biopsy 
complications have increased lately, which has been suspected to have risen from a 
globally increasing antibiotic resistance e.g. an increased resistance to an antibiotic 
prophylaxis (Borghesi et al., 2016; Carignan et al., 2012; CDDEP, 2016; Lahdensuo 
et al., 2016; Mottet et al., 2018; Nam et al., 2013). Prostate biopsies taken via a 
transperineal approach might be a safer procedure, however, it is demanding for 
outpatient use due to a demand for spinal anesthesia (Eldred-Evans et al., 2016; Xue 
et al., 2017). 
Systematic (contrary to lesion-specific) prostate biopsies also include an 
additional issue: diagnoses of clinically insignificant PCas (insPCa). The deficiencies 
in contemporary diagnostics in ruling out CSPCa drifts to radical treatments of 
cancers with a low malignant potential, which contains a potential to major adverse 
effects. 
Convincing evidence of prostate MRIs’ high sensitivity in detecting CSPCa, and 
its tend to discriminate insPCas, has recently been presented (Ahmed et al., 2017; 
Kasivisvanathan et al., 2018; Moldovan et al., 2017; Rouvière et al., 2019; van der 
Leest et al., 2019). The future in PCa diagnostics seems to drift towards the use of 
prostate MRI as an essential part of initial PCa diagnostics. In addition, other imaging 
modalities e.g. various ultrasound applications, biomarkers and gene analytics are 
under intensive research (Kretschmer & Tilki, 2017; Sarkar & Das, 2016). There are 
still issues e.g. in the validation of the methods and breakthrough is not likely in the 
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near future. Hence, the histological diagnosis of PCa still remains to be the base for 
all the treatment planning and it is not evident that biopsies will be abandoned in PCa 
diagnostics. Thus, a safe biopsy procedure remains a key issue also in the future. 
 14 
2 Review of the literature 
2.1 Characteristics of prostate cancer 
2.1.1 Prostate gland and its function 
The prostate gland’s function is the production of seminal plasma, which provides a 
suitable environment for the survival and function of spermatozoa (Wein et al., 2016). 
Anatomically, it is divided into four histologically distinct regions: the central zone, 
peripheral zone, transitional zone and fibromuscular stroma (McNeal, 1981). The 
central zone is located in the basis of the prostate, which is the most adjacent part to 
the urinary bladder, and includes an orifice where prostatic ducts drain into the urethra 
(verumontanum). The peripheral zone is the largest part of the glandular prostate, and 
it surrounds the prostatic urethra distally from the verumontanum and lateral and 
posterior parts of the prostate; thus it is the only region of the prostate which could be 
reached by DRE (Aaron et al., 2016; McNeal, 1981). Two thirds of PCas are located 
in the peripheral zone (McNeal et al., 1988; Terris et al., 1995). The transitional zone 
surrounds the urethra proximally from the verumontanum and it is a typical origin of 
benign prostate hyperplasia (BPH) (McNeal, 1981). The fibromuscular stroma is a 
non-glandular region covering the prostate anteriorly from the bladder neck to the 
apex of the prostate (McNeal, 1981). 
2.1.2 Incidence, etiology and risk factors 
There is not an unambiguous way to define the worldwide incidence and mortality 
rates for cancer. It is especially difficult for PCa, which constitutes a significant 
proportion of indolent cancers diagnosed by an extensive PSA screening. Variation is 
also derived from the definitions and registries used. However, several general 
assumptions can be made. 
Prostate cancer is the most common cancer in men by total incidence, but just 
in the 8th place in total cancer mortality in men (Fitzmaurice et al., 2015). 
Comparing age standardized incidence rates, PCa is the second most common 
cancer in men worldwide after lung cancer in both developed and non-developed 
countries (Bray et al., 2018). Using the age standardized mortality rates, PCa is the 
Review of the literature 
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6th most common cancer to cause cancer-related deaths in developed countries, and 
the second most common in non-developed countries (Bray et al., 2018). Age 
standardized incidence has a major geographical variation: The highest age 
standardized incidence rates are in Western, high-income regions, Australia/New 
Zealand, Europe and North America, and the lowest in Asia (Bray et al., 2018). The 
highest and the lowest region had about a 17-fold difference in incidence (Bray et 
al., 2018). However, a similar difference is not seen in mortality rates, which vary 
only with about eight-fold magnitude (Bray et al., 2018). In Finland, 5446 PCa were 
diagnosed and 912 men died from PCa in 2017, which makes it the most common 
diagnosed cancer and the second most common cancer to cause cancer-related 
deaths in men (Suomen Syöpärekisteri, 2019). 
Etiology of PCa is largely unknown. The well-established risk factors for PCa are 
advanced age, ethnicity, hormonal status and family history including genetic factors 
(Bostwick et al., 2004; Rawla, 2019). 
Advanced age is the most prominent risk factor for PCa, and it is suspect to 
arise mainly from oxidative processes (Bostwick et al., 2004). In Finland, PCa is 
commonly diagnosed in men aged 65–69 years, but it is extremely rare in men 
younger than 40 years of age (Suomen Syöpärekisteri, 2017). Ethnicity-related 
differences in incidence and mortality are significant. Incidence of PCa is highest 
in African-Americans; they also likely present more advanced disease and their 
stage-specific mortality is worse than in white men in the United States (Bostwick 
et al., 2004). Variation by ethnicity is suspected to derive from environmental and 
demographic factors in addition to genetics (Bostwick et al., 2004; Rawla, 2019). 
According to the traditional ”androgen hypothesis” which was introduced already 
in the 1940s, PCa is an androgen-dependent cancer (Rawla, 2019). In addition, 
androgen deprivation therapy (ADT) is known to be effective as a treatment 
especially in advanced PCa. However, the role of androgens in the carcinogenesis 
of PCa is controversial and high androgen levels have no clear connection to the 
development or severity of a PCa, although men with low free testosterone levels 
might be in lower risk for PCa (Bostwick et al., 2004; Michaud et al., 2015; Watts 
et al., 2018). 
Evidence is quite consistent about the significance of family history to the PCa 
risk, and it is noted to include an even stronger association to family history than in 
colon and breast cancer (Bostwick et al., 2004). Prostate cancer diagnosed in first-
degree relatives is highly associated with one’s risk for PCa diagnosis and PCa related 
death, and the risk cumulates with an increasing number of first-degree relatives 
having PCa and their younger age in PCa diagnosis (Brandt et al., 2009). Familial PCa 
is reported to be more fatal than incidental PCas (Hemminki, 2012). Also many 
genetic factors have been associated with PCa, and significant germline mutations as 
BRCA and HOXB13 should be noted as risk factors for PCa (Lynch et al., 2016). 
Especially BRCA2 mutations is associated with an adverse prognosis (Castro et al., 
Juha Knaapila 
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2015). As a conclusion, familial PCa should be suspected when first-degree relatives 
have PCa diagnoses especially in younger age, or in case of known germline 
mutations. 
After introduction of PSA testing in the middle of the 1980s, the incidence rate 
as well as the age standardized incidence rate of PCa have dramatically increased, 
especially in the developed countries; however, the trend has stabilized in recent 
years (Center et al., 2012; Fitzmaurice et al., 2015). A corresponding trend is not 
seen with mortality rates (Center et al., 2012). In the Nordic countries, the trend is 
even more prominently seen, as presented in comparison to trends of breast cancer 
(Figure 1). From the late 1980s, age standardized incidence of PCa doubled to the 
year 2005, and since, a slight decrease is seen (Kvåle et al., 2017). According to a 
recent data from Finnish Cancer Registry, the incidence of PCa in Finland is again 
increasing (Suomen Syöpärekisteri, 2017). The age-standardized mortality rate has 
slightly increased over the decades to the middle of the 1990s, subsequently only a 
moderate decreasing trend is seen in the mortality rates (Kvåle et al., 2017; Suomen 
Syöpärekisteri, 2017). In addition, a stage-migration is seen in diagnosed PCas 
which are nowadays diagnosed and treated in an earlier stage (Mouraviev et al., 
2011; Seikkula et al., 2017). Although an introduction of PSA has indisputably the 
foremost effect on the increased PCa incidence, also the aging of the population 
from the 1980s should be noted. 
Review of the literature 
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Figure 1.  Observed age‐standardized rates of prostate and breast cancer incidence and mortality 
in Denmark, Finland, Norway and Sweden (three‐year moving averages, all ages). Figure 
from study of Kvåle et al., reprinted with a permission (Kvåle et al., 2017). 
 
2.1.3 Pathology and staging 
Hanahan et al. have presented the six hallmarks of cancer originally in the year 2000 
and the work was revised in 2011 (Hanahan & Weinberg, 2000, 2011). The hallmarks 
comprise biological capabilities acquired during the multistep development of human 
tumors (Hanahan & Weinberg, 2000, 2011). The hallmarks include: sustaining 
proliferative signaling, evading growth suppressors, activating invasion and 
metastasis, enabling replicative immortality, inducing angiogenesis and resisting cell 
death (Hanahan & Weinberg, 2011). Prostate cancer includes a wide range of 
neoplasms with different malignant potential, thus low-grade PCas’ status as a cancer 
has been questioned in the light of the mentioned hallmarks (Ahmed et al., 2012). 
Juha Knaapila 
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The vast majority of prostate neoplasms are adenocarcinomas. Classification of 
adenocarcinomas is still based on the Gleason grading system, which was originally 
introduced by Gleason et al. in 1966 (Gleason, 1966). During the last 50 years, 
surprisingly slight modifications have been made to the original grading system 
(Epstein et al., 2005). However, in 2014, the International Society of Urological 
Pathology (ISUP) consensus conference presented a proposal for a new grading 
system, which is based on the original Gleason scoring system (Epstein, Egevad, et 
al., 2016). The original system is based on prostate tissue morphology graded to 1–5, 
and the Gleason score is calculated by using the sum of first and, if present, the second 
most common pattern seen in the prostate specimen. If there is only one type of pattern 
seen, the second most common value is the same as the first one. Thus, the Gleason 
score can theoretically be between 2–10. However, patterns 1–2 are rarely reported, 
because they are recognized as biologically similar as the Gleason pattern 3, and the 
Gleason score is practically always between 6–10 (Epstein et al., 2005). The new 
grading system, which ISUP introduced in 2014, divides PCas to Gleason grade 
groups (Table 1, [GGG]) 1–5, aiming to correspond more accurately to the prognosis 
of current cancer (Epstein, Egevad, et al., 2016). 
Table 1. ISUP Gleason grade group system (Epstein, Egevad, et al., 2016). 
Gleason score ISUP Gleason grade group (GGG) 
3+3 1 
3+4 2 
4+3 3 
4+4, 3+5, 5+3 4 
4+5, 5+4, 5+5 5 
 
Intraductal carcinoma of the prostate (IDC-P) is a histological subtype of 
adenocarcinomas, and it is independently associated with a worse prognosis (Guo & 
Epstein, 2006; Tsuzuki, 2015). In prostatectomy specimen, IDC-P is also associated 
with other adverse prognostic markers, including higher lesion size and Gleason score 
(Wilcox et al., 1998). In the 2014 ISUP consensus conference, it was discovered that 
an IDC-P without invasive carcinoma should not be assigned a Gleason grade 
(Epstein, Egevad, et al., 2016).  
Cribriform PCa is a histological pattern, primarily graded as a subtype of Gleason 
3+3, however its significance to prognosis has not been realized until the last decades 
(Iczkowski et al., 2018). The cribriform pattern is associated with adverse prognostic 
features independently from an underlying Gleason pattern (Iczkowski et al., 2018). 
In the 2014 ISUP consensus conference, it was also discovered that cribriform glands 
should be assigned a Gleason pattern 4, regardless of the morphology (Epstein, 
Egevad, et al., 2016). 
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Neuroendocrine carcinoma (NECP) is an aggressive subtype of PCa. It consists 
of heterogeneous types of carcinomas differentiated from neuroendocrine cells of 
prostate (Parimi et al., 2014). The majority of NECPs are small cell carcinomas, which 
can be considered as identical with small cell carcinoma of the lung (Parimi et al., 
2014; Wein et al., 2016). It occurs in about a half of the cases in pure form without 
concomitant adenocarcinoma, or it may also occur with adenocarcinoma or have been 
developed from it (Parimi et al., 2014; Wein et al., 2016). It has been presumed that 
differentiation to NECP could be linked to androgen resistance following long-term 
ADT, and the degree of neuroendocrine differentiation increases along with PCa 
adenocarcinoma progression and in response to ADT (Parimi et al., 2014). Typically, 
NECP is not producing PSA and it is resistant to ADT (Parimi et al., 2014). Other 
extremely rare types of PCas are mucinous carcinoma, lymphomas and mesenchymal 
tumors i.e. sarcomas. In addition, urothelial carcinoma could occur in prostate also 
without a concomitant bladder involvement. 
Prostate cancer is commonly a multifocal cancer; thus, there could be 
histologically different-graded cancer focuses in the same gland (Wein et al., 2016). 
A tumor focus with the largest volume (index lesion) is presumed to be a main driving 
factor for tumor progression and cancer prognosis and most satellite lesions do not 
appear to be life-threatening (Mouraviev et al., 2011). The genetic background of the 
multiple tumors in the same prostate is under discussion, however it seems that there 
is significant genetic alteration among tumor foci (Wei et al., 2017). In the study of 
Choi et al., PCa occurred as multifocal in 60.5% and bilateral in 82% of cases in a 
large series of prostatectomy specimens (Choi et al., 2019). According to the 
aforementioned study, the index tumor has often, but not always, the most malignant 
histology of the gland: in 6.7% of specimens the secondary tumor on the contralateral 
lobe had higher Gleason score than the primary tumor (Choi et al., 2019). 
2.1.4 Prognosis, treatments and natural course 
As a whole, PCa is a cancer with a good prognosis; after a PCa diagnosis, 92% of men 
are alive at five years and in general, an 80-year-old man has only a 1.6% risk of dying 
from PCa in Finland (Suomen Syöpärekisteri, 2017). Thus, PCa could be considered 
mostly as a chronic disease of aging men. However, the statistics relate only that a 
majority of PCas are cancers with good prognosis, but they discriminate the fact that 
PCa is a very heterogeneous group of malignancies from indolent to highly aggressive 
cancers. 
In a landmark study of Epstein et al., the authors presented an independent and 
substantial influence of the cancer grade to a biochemical recurrence (BCR) rate when 
PCa is treated with radical prostatectomy or radiation therapy (Epstein, Zelefsky, et 
al., 2016). In the study, Gleason scores were grouped to the GGGs based on a 
prognosis and in this new grade grouping system differentiate PCas elegantly by a 
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prognosis (Epstein, Zelefsky, et al., 2016). Biochemical recurrence free rates after 
prostatectomy stratified by GGGs are demonstrated in Figure 2 (Epstein, Zelefsky, et 
al., 2016). As an example of significance of PCa histological grade, men treated with 
radical prostatectomy and having Gleason ≤6 PCa in prostatectomy specimen, a five-
year BCR rate was 96% (95% confidence interval [CI] 95–96%), whereas in men with 
Gleason score 8–10, the rate was 26% (95% CI 23–30%) (Epstein, Zelefsky, et al., 
2016).  
Figure 2. Recurrence-free progression following radical prostatectomy stratified by prostatectomy 
Gleason grade. Green line: Gleason score 6, grade group 1. Orange line: Gleason score 
3 + 4, grade group 2. Dark blue line: Gleason score 4 + 3, grade group 3. Brown line: 
Gleason score 8, grade group 4. Gray line: Gleason score ≥9, grade group 5. Figure from 
the study of Epstein et al., reprinted with a permission (Epstein, Zelefsky, et al., 2016). 
 
Although a BCR precedes almost exclusively the clinical progression of PCa, not all 
patients with BCR die of PCa (Brockman et al., 2015; Killian et al., 1985; Kuriyama 
et al., 1981; Partin, Pound, Clemens, Epstein, & Walsh, 1993). However, the power 
of the GGGs to also predict PCa-specific mortality has been recently retrospectively 
validated in a Finnish prostatectomy cohort (Erickson et al., 2018). Additionally, a 
similar significance of the cancer grade for the prognosis is seen in the mortality rates 
in a prospective SPCG-4 study where 3/88 (3.4%) men having Gleason score 2–6 PCa 
in prostatectomy specimen died from PCa in a mean follow-up of 23 years (Bill-
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Axelson et al., 2018). The relative age-group adjusted risk for death from PCa 
increases in men having Gleason score 3+4, 4+3 and 8–9 to 1.91, 11.78 and 20.06 in 
prostatectomy specimen, respectively. Interestingly, when the surgical margin status 
and extraprostatic extension were taken into account in a multivariate analysis, the 
risk for death from PCa was practically equal (0.99) comparing Gleason 3+3 to 
Gleason 3+4 (Bill-Axelson et al., 2018). 
Clinical and pathological staging of PCa with Tumor Node Metastasis (TNM) 
classification was reassessed in 2010 at American Joint Committee on Cancer to 
correspond more accurately with the prognosis of PCa (Table 2) (Cheng et al., 2012). 
The system classifies PCa to various prognostic groups by a tumor extent and 
spreading. However, the histological grade of PCa also remains an important and 
independent prognostic factor in addition to surgical margin status and extracapsular 
extension in prostatectomy specimen, especially in high grade PCas (Bill-Axelson et 
al., 2018; Catalona & Smith, 1998; Cheng et al., 1999; Epstein, Zelefsky, et al., 2016; 
Pound et al., 1997). As linked to the mentioned parameters, an initial PSA level 
predicts the pathological stage and spreading of a PCa (Gleave et al., 1996; Partin et 
al., 1997; Thompson et al., 2004). Today in the PSA era, the significance of 
preoperative clinical stage for prognosis after radical prostatectomy has been 
questioned (Catalona & Smith, 1998; Reese et al., 2010). 
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Table 2. American Joint Committee on Cancer clinical and pathological TNM classification of 
prostatic tumors (Cheng et al., 2012). 
clinical TNM classification  pathological TNM classification 
TX Primary tumour cannot be assessed  pTX – 
T0 No evidence of primary tumor  pT0 – 
T1 Clinically inapparent tumor neither palpable nor visible by imaging 
 pT1 There is no pathological T1 classification 
T1a Tumor incidental histological finding in ≤5% of tissue resected 
 pT1a – 
T1b Tumor incidental histological finding in >5% of tissue resected 
 pT1b – 
T1c Tumor identified by needle biopsy (e.g. because of elevated PSA) 
 pT1c – 
T2 Tumor confined within prostate  pT2 Organ confined 
T2a Tumor involves ≤one‐half of one lobe  pT2a Unilateral, one‐half of one side or less 
T2b Tumor involves >one‐half of one lobe but not both lobes  pT2b Unilateral, involving more than one‐half of side but not both sides 
T2c Tumor involves both lobes  pT2c Bilateral disease 
T3 Tumor extends through the prostate capsule 
 pT3 Extraprostatic extension 
T3a Extracapsular extension (unilateral or bilateral) 
 pT3a 
Extraprostatic extension or 
microscopic invasion of bladder 
neck 
T3b Tumor invades seminal vesicle(s)  pT3b Seminal vesicle invasion 
T4 
Tumor is fixed or invades adjacent 
structures other than seminal vesicles 
such as external sphincter, rectum, 
bladder, levator muscles, and/or pelvic 
wall 
 pT4 Invasion of rectum, levator muscle, and/or pelvic wall 
NX Regional lymph nodes were not assessed  pNX Regional nodes not sampled 
N0 No regional lymph node metastasis  pN0 No positive regional nodes 
N1 Metastases in regional lymph node(s)  pN1 Metastases in regional node(s) 
M0 No distant metastasis  pM0 No distant metastasis 
M1 Distant metastasis  pM1 Distant metastasis 
M1a Non‐regional lymph node(s)  pM1a Non‐regional lymph node(s) 
M1b Bone(s)  pM1b Bone(s) 
M1c Other site(s) with or without bone disease 
 
pM1c 
Other site(s) with or without bone 
disease. When more than one site 
of metastasis is present, the most 
advanced category is used. pM1c is 
most advanced 
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The tumor volume in prostatectomy specimen has a significant influence on the 
prognosis; larger tumor volumes have been associated with more aggressive behavior 
of a PCa (D'Amico, Whittington, Malkowicz, Schultz, Kaplan, et al., 1998; D'Amico 
et al., 1997; McNeal et al., 1986; McNeal et al., 1988). This became distinctly evident  
in a study of Bostwick et al., where men with PCa volume of 0.5 ml, 10 ml, and 20 
ml had a probability to have metastases in 2.8%, 29.5% and 87.4%, respectively 
(Bostwick et al., 1993). Traditionally, PCa lesions smaller than 0.5 ml are considered 
unlikely to reach a clinically significant size in an aspect of long doubling time of 
PCa, however this threshold is nowadays assumed to be too restrictive (Stamey et al., 
1993; Ting et al., 2015; Wolters et al., 2011). Nonetheless, independently from tumor 
volume, the PCa stage, histological grade and surgical margin status are still the most 
important prognostic parameters of PCa (Epstein, Zelefsky, et al., 2016; Han et al., 
2001; Kupelian et al., 1996; Wein et al., 2016). Therefore, tumor volume is more like 
an additional parameter, linked with stage and grade when evaluating the 
aggressiveness of PCa. The classic “Epstein criteria” for insPCa in prostatectomy 
specimen (index tumor volume of <0.5 cm3, no Gleason 4 or 5 pattern, and organ 
confined pT2 disease) takes these into account (Epstein et al., 1994; Van der Kwast 
& Roobol, 2013). 
Gleason 3+3 (GGG 1) graded PCa is commonly considered as insPCa without 
almost any metastatic potential (Eggener et al., 2015; Ross et al., 2012). Therefore its 
status as a cancer has been questioned (Ahmed et al., 2012). However, a Gleason 3+3 
PCa diagnosed in prostate biopsies cannot be assumed as insignificant without 
additional parameters since the biopsies give only limited information about the whole 
gland pathology. Hence, the true pathology is only available from a pathological 
analysis of prostatectomy or autopsy specimen. The issue is nicely demonstrated in 
the results of an SPCG-study, where radical prostatectomy and watchful waiting were 
prospectively compared in 15 years’ follow-up period: When low risk PCa was 
defined by Gleason score < 7 and PSA level < 10 ng/ml, intention-to-treat analysis 
showed cumulative PCa specific mortality in 6.8% of men in the prostatectomy group 
and in 11% of men in the watchful waiting group without a statistically significant 
difference between the treatment modalities (Bill-Axelson et al., 2011). However, 
when the biopsy results were compared with a prostatectomy specimen, in 6 of 7 men 
who died from PCa in the prostatectomy group, the Gleason score was upgraded in a 
prostatectomy specimen (Bill-Axelson et al., 2011). Additionally, it has been 
hypothesized that Gleason 3+3 PCas, especially tumors with high volume, could 
evolve to a CSPCa in the course of time (Lepor & Donin, 2014; Wein et al., 2016; 
Whittemore et al., 1991). However, the evidence concerning this potential is not 
entirely coherent and it might be a result of sampling error i.e. initial biopsies did not 
hit the highest grade PCa foci in the gland. 
D’Amico et al. introduced a division in to the four groups for pretreatment risk of 
PCa for BCR using the prognostic factors described above (D'Amico, Whittington, 
Juha Knaapila 
 24
Malkowicz, Schultz, Blank, et al., 1998). The system with only minor modifications 
is widely adopted as a risk stratification strategy in the management of PCa (Mottet 
et al., 2018; NICE, 2019; Sanda et al., 2018). Table 3 presents the risk grouping 
according to the European Association of Urology (EAU) guidelines (Mottet et al., 
2018). 
Table 3. EAU risk groups for BCR of localized and locally advanced PCa (Mottet et al., 2018). The 
cT category only refers to the DRE finding (Mottet et al., 2018). 
Low risk Intermediate risk High risk 
PSA < 10 ng/ml, 
Gleason score < 7 
(ISUP grade group 1) 
and cT1-cT2a 
PSA 10-20 ng/ml or 
Gleason score = 7 (ISUP 
grade group 2–3) or cT2b 
PSA > 20 ng/ml or 
Gleason score > 7 
(ISUP grade group 3–
5) or cT2c 
any PSA 
any Gleason score 
(any ISUP grade) 
cT3–4 or cN+ 
Localized Locally advanced 
 
The prognosis of a PCa additionally and obviously depends from treatments chosen 
and recently the topic has been under intensive and interesting research. The 
traditional radical treatments for clinically localized PCa are prostatectomy and 
various radiation therapy modalities (Mottet et al., 2018). Radiation therapy is also 
used as a part of multimodal therapy in locally advanced PCa (Mottet et al., 2018). 
Both treatment modalities include significant adverse effects, but they are currently 
the two available potentially curative treatments for PCa. After a prostatectomy, 17–
29% of men have some level of urinary incontinence and a significant proportion (19–
56% with varying definitions) of men have erectile dysfunction at the timepoint of 12 
months (De Carlo et al., 2014). For some patients, these disorders remain permanent. 
Radiation therapy is better tolerated at least in a short term; however, it can cause 
urinary and bowel irritation symptoms during the therapy which usually subside. 
However, late complications after the most commonly used conventionally fractioned 
external beam radiation therapy (EBRT) also exist, more commonly gross hematuria 
(10–14%), rectal bleeding (19–28%), and urinary obstruction (6–9%) (Matta et al., 
2019). The complication rates are mainly higher in other radiation therapy modalities 
(Matta et al., 2019). 
Because of the significant adverse effects of the radical treatments, for low-risk 
patients who are suitable for radical treatments, active surveillance is also a viable 
option. An active surveillance patient is followed intensively with PSA 
measurements, clinical status, repeated prostate biopsies and nowadays, also with 
MRI (Mottet et al., 2018; van den Bergh et al., 2007). If there are signs of disease 
progression, active treatment still remains an option. In frail patients and patients with 
low life expectancy, all stages of PCas could be treated with passive surveillance 
(“watchful waiting”) where ADT is initiated only after symptomatic progression 
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(Mottet et al., 2018). In a patient with a locally advanced or metastasized PCa, ADT 
is recommended, with or without additional chemotherapy (Mottet et al., 2018). 
In a large, prospective ProtecT study, prostatectomy, radiation therapy and active 
surveillance as treatment alternatives for clinically localized PCa were compared in a 
randomized setting (Neal et al., 2019). In the study, active surveillance was performed 
with repeated PSA measurements, and within a 10-years surveillance period, roughly 
40% were referred to active treatment (Neal et al., 2019). After 10 years, there were 
no statistically significant differences in PCa specific or overall mortality among the 
randomized treatment modality groups (Neal et al., 2019). However, there was 
significantly more metastatic progression in the active surveillance group, and when 
the radical treatment groups were combined and compared to the active surveillance 
group, a reduction in the PCa specific death rate was noted in the radically treated 
group (Neal et al., 2019). Understandably, there were substantially less adverse effects 
in the active surveillance group comparing to radically treated men (Neal et al., 2019). 
In the PIVOT trial, prostatectomy and active surveillance were compared in 
randomized setting in clinically localized PCa (Wilt et al., 2017). During almost 20 
years of follow-up (median 12.7 years), no statistically significant difference in PCa 
specific mortality was seen between the groups, and definitive treatment occurred in 
about 20% of patients the in surveillance group (Wilt et al., 2017). In SPCG-4 study, 
men with localized PCa were randomly assigned to the prostatectomy group and 
watchful waiting group (n=695) and 29 years’ follow-up data were analyzed. The 
study results favor prostatectomy: after 23 years of follow-up, the mean years of life 
gained in the prostatectomy group were 2.9 and the results are even more prominent 
in younger (<65 years) patients (Bill-Axelson et al., 2018). Significantly lower 
mortality was observed in the prostatectomy group, both death from any cause 
(relative risk [RR] prostatectomy vs. watchful waiting, 95% CI: 0.74, 0.62–0.87) and 
death from PCa (RR prostatectomy vs. watchful waiting, 95% CI: 0.55, 0.41–0.74) 
(Bill-Axelson et al., 2018). 
Although PCa is commonly a multifocal disease, due to the invasiveness and 
significant adverse effects of the radical treatments, there is emerging research 
concerning mini-invasive, cancer-focused therapies for PCa, i.e. high intensity 
focused ultrasound (HIFU), cryotherapies and photodynamic therapies, but the role of 
these alternatives is so far investigational (Mottet et al., 2018). Therefore, a reliable 
and sensitive imaging modality for adequate identification of each significant cancer 
foci is essential for the further development of these methods (Mouraviev et al., 2011). 
Contemporary ultrasound based applications do not yet meet the accuracy demands 
of focal therapies (Smeenge et al., 2012). Thus, developing prostate MRI seems to be 
a considerable basis for pre/intraoperative imaging in these new focal therapies. 
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2.2 Contemporary diagnostic protocol of prostate 
cancer 
2.2.1 Guidelines for primary diagnostics and risk 
stratification 
Recommendations of PCa diagnostics vary only minimally between the leading 
guidelines. In Finland, most urologists adhere to the EAU guidelines, which is the one 
discussed below in this chapter (Mottet et al., 2018). 
Suspicion of a PCa usually arises from an elevated PSA level or abnormal DRE. 
Sometimes, the histological diagnosis could be obtained incidentally by prostate 
surgery, like simple prostatectomy or TURP. However, according to the EAU 
guidelines, TURP should not be used as a diagnostic tool in PCa detection, even if it 
was formerly used for diagnostic purposes. 
According to the EAU guidelines, a suspicious finding in DRE or an elevated PSA 
level is an indication for prostate biopsies with certain considerations. An elevated 
PSA level should be repeated with a new sample prior the biopsy decision due to 
interfering factors. The guidelines give no cut-off value for PSA level suspicious to 
CSPCa. However, if the PSA level is between 2–10 ng/ml, in asymptomatic men with 
a normal DRE finding, the guidelines recommend offering further risk assessment to 
avoid unnecessary biopsies. As tools for the risk assessment, the guidelines 
recommend using a risk calculator, imaging or an additional serum or urine-based test 
(prostate cancer gene 3 [PCA3] marker, SelectMDX, Mi Prostate score, ExoDX, and 
prostate health index [PHI] and 4Kscore). The guidelines outline that PSA dynamics 
and doubling time give no additional information in primary diagnostics compared to 
PSA alone, also the value of free PSA/PSA ratio is limited, and it should not be used 
if total PSA is over 10 ng/ml. 
The EAU guidelines discuss widely and extensively the multiparametric MRI 
(mpMRI) in PCa diagnostics. It concludes that mpMRI should be performed to biopsy 
naïve patients, however, the strength of evidence is weak. Nevertheless, due to lack 
of evidence, mpMRI should not be used in screening for PCa. When mpMRI is done, 
the guidelines recommend with support of a strong level of evidence that both 
systematic and targeted biopsies should be performed if a cancer-suspicious lesion is 
present. With a weak strength of evidence, the guidelines give an option to omit 
(systematic) biopsies based on shared decision making with the patient, if there is no 
suspicious lesion in mpMRI and a clinical suspicion of a PCa is low. After a cancer-
negative biopsy the guidelines recommend mpMRI before repeat biopsies and even if 
mpMRI is negative, systematic biopsies should be performed based on shared 
decision making, if clinical suspicion of PCa is high. The level of evidence is strong 
with the mentioned recommendations. In the re-biopsy setting, the guidelines give an 
option to take only mpMRI targeted biopsies with the support of weak strength of 
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evidence. Finally, the guidelines outline that only a systematic biopsy is an acceptable 
approach, if mpMRI is unavailable. 
According to the EAU guidelines, after cancer-negative biopsies, repeat biopsies 
are indicated if the PSA level is rising or persistently elevated, or there is a suspicious 
finding in DRE. Also repeat biopsies should be performed, if there was atypical small 
acinar proliferation, extensive high grade intraepithelial neoplasia (HGPIN), a few 
atypical glands immediately adjacent to high-grade prostatic intraepithelial neoplasia 
or IDC-P as a solitary finding in prior biopsies. Also, a positive finding in mpMRI 
(performed with the prior biopsies) is a repeat biopsy indication. In men with an 
elevated risk for PCa and prior cancer negative biopsies, the guidelines recommend 
considering additional serum, urine and tissue-based tests for selecting men to repeat 
biopsies. Saturation biopsies (>20 biopsies taken via transperineal approach) may be 
performed as repeat biopsies. 
According to the EAU guidelines, prostate biopsies should be taken with TRUS 
guidance and via transrectal or perineal approach. Local anesthesia should be used. 
When taking systematic (baseline) biopsies, at least eight biopsy cores from the 
peripheral gland should be taken if prostate size is about 30 cc and 10–12 biopsy cores 
should be taken in larger prostates. Seminal vesicle biopsies are recommended if it 
has a decisive impact on treatment. Transitional zone biopsies should be limited to 
repeat biopsies. Prior prostate biopsies and oral or intravenous antibiotic prophylaxis 
is recommended by the guidelines. In transrectal ultrasound guided prostate biopsies 
(TRUS-Bx), ciprofloxacin and in transperineal biopsies, single dose of cephazolin are 
recommended antibiotic regimens. To risk patients, TRUS biopsies with prior rectal 
swab culture or targeted antibiotic prophylaxis should be offered. Rectal disinfection 
with povidone-iodine may be considered. 
2.2.2 Laboratory tests and clinical examination 
The PSA is the most widely used biomarker in PCa diagnostics. In clinical urology, it 
was introduced in the 1980s to be an useful marker in surveillance of radically treated 
PCa (Kuriyama et al., 1981; Stamey et al., 1987). The PSA is a member of the 
kallikrein gene family (also known as human kallikrein peptidase 3 [hK3]). It is 
practically exclusively produced in the prostate luminal epithelial cells and it is in 
high concentrations secreted to the seminal fluid where its function is to balance 
coagulation (Wein et al., 2016). It is essential that PSA is an organ-, not a cancer-
specific biomarker (Wein et al., 2016). On a per cell basis, PSA expression is similar 
between benign and malignant prostate cells; however, elevated serum PSA levels are 
probably due to disruption of cellular architecture within the prostate gland (Wein et 
al., 2016). Expression of PSA is strongly influenced by androgens, and the PSA level 
is also affected by benign conditions and medications, especially advanced age, 
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prostate volume, BPH, prostatitis and 5-alphareductase (5ARI) medication (Stamey 
et al., 2004; Wein et al., 2016). 
Although PSA is an excellent tool for the surveillance of radically treated PCa, it 
is a poor marker in diagnostics of PCa regardless its wide usage for diagnostic 
purposes (Brockman et al., 2015; Thompson et al., 2005). Formerly, prostate biopsies 
were recommended for men with normal DRE if the PSA value was over 4 ng/ml, i.e. 
a PSA level below the value 4 ng/ml was considered as normal (Catalona et al., 1994). 
In the landmark study of Thompson et al., the rate of PCas below the level of 4 ng/ml 
were 15% in a surveillance period of seven years, and no threshold value ruling out 
CSPCa were obtained (Thompson et al., 2004). However, a moderate correlation with 
an increasing PSA level and more aggressive PCa histology among men with PSA 
levels less than 4 ng/ml were presented in the study (Thompson et al., 2004). In 
another study with a large cohort of PSA screened men, the area under the receiver 
operating characteristic curve (AUC) for PSA discriminating any PCa to benign 
pathology was found to be 0.678 and with significant vs. benign or insPCa (Gleason 
score < 7), 0.782 (Thompson et al., 2005). Also, PSA velocity in PCa diagnostics has 
been under intensive research. However, the results are controversial and there is no 
convincing evidence that PSA velocity has an additional value to PSA level alone in 
PCa diagnostics (Loughlin, 2014). As a conclusion, when using PSA as a diagnostics 
tool for PCa, it should be taken into account in addition to the mentioned benign 
conditions that elevates PSA level, that there is no threshold value for ruling out PCa, 
and the probability of PCa rises with elevating PSA levels (Stamey et al., 2004; 
Thompson et al., 2005; Thompson et al., 2004). Thus, in low PSA levels, additional 
parameters are needed to an adequate biopsy decision. 
The prostate specific antigen in PCa screening has been widely used, however its 
use for the purpose remained a very controversial topic (Loeb, 2014). The major issue 
in PSA screening is a high false positive rate, which drives to patient anxiety, 
unnecessary biopsies, and thus unnecessary biopsy related complications in addition 
to unnecessary diagnoses of insPCas. The Cochrane systematic review from 2013 
concludes that among studies with 7–20 years’ follow-up, there were no statistically 
significant differences in PCa-specific or overall mortality in men randomized to the 
screening and control groups, however overall PCa incidence was significantly higher 
in PSA screened men (risk ratio: 1.3; 95% CI: 1.02–1.65) and in the screening cohort, 
diagnosed PCas more commonly localized (risk ratio: 0.80, 95% CI: 0.73–0.87) (Ilic 
et al., 2013). In 2014, results of a 13-year follow up in The European Randomized 
Study of Screening for Prostate Cancer were published: in the study, a lower risk for 
PCa specific mortality was noted in the screened men, but there was no significant 
difference in overall mortality (Schröder et al., 2014). In addition, the incidence of 
PCa was 1.57-fold higher in the screening arm (Schröder et al., 2014). Similar results 
of PSA screening with a decrease in PCa specific mortality and no significant 
difference in overall mortality was seen in the Swedish Gothenburg randomized 
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population-based prostate cancer screening trial, where results of PSA screening were 
investigated in a 17-year study period (Carlsson et al., 2017). In the trial, the number 
needed to invite PSA screening and the number of PCas needed to diagnose to prevent 
one PCa death were 176 and 16, respectively (Carlsson et al., 2017). 
The European Association of Urology recommends an individualized risk-
adapted strategy for early detection to well-informed men with a good performance 
status and a life-expectancy of at least ten to fifteen years, thus systematical PSA 
screening to all men is not recommended (Mottet et al., 2018). Although many 
prospective high-volume studies have been published, PSA screening is still under 
investigation. 
There is no significant role for PSA density (PSA divided with prostate volume) 
as an individual marker in early detection of PCa according to the EAU and National 
Institute of Health and Care Excellence (NICE) guidelines (Mottet et al., 2018; NICE, 
2019). However, in the recent studies, PSA density seems to be a better predictor for 
CSPCa than the PSA level alone, especially in higher PSA levels and in repeat biopsy 
setting (Jue et al., 2017; Nordström et al., 2017). According to the studies, PSA density 
should be taken as an additional component for prostate biopsy decision-making, 
when estimating an individual risk for a CSPCa. However, as a PSA derivative, there 
is no threshold value in ruling out CSPCa. 
Within serum, PSA circulates bound to proteases and in unbound form (free PSA) 
and the lower ratio of free PSA and PSA is detectable in men with a PCa (Wein et al., 
2016). The usage of free PSA/PSA ratio is useful in PSA levels lower than 10 ng/ml, 
due to the rising positive predictive value (PPV) of total PSA in levels more than 10 
ng/ml (Wein et al., 2016). A recent meta-analysis presents poor outcomes of free 
PSA/PSA ratio in PCa diagnostics: pooled sensitivity and specificity were 0.70 and 
0.58, respectively, when total PSA was between 4–10 ng/ml (Huang et al., 2018). 
According to the EAU guidelines, the free PSA ratio has limited clinical value in the 
light of novel serum tests (Mottet et al., 2018). 
Feasibility of PSA kinetics (velocity and doubling time) have been studied aiming 
to increase PSA sensitivity in primary diagnostics of PCa, and its usage has been 
recommended in several guidelines (Carter et al., 2007; Loughlin, 2014). However, 
its feasibility has been questioned in recent studies (Loughlin, 2014). It seems that the 
additional value given by PSA velocity to increase sensitivity of PSA is minimal or 
none, and its usage is not recommended by contemporary EAU guidelines (D'Amico, 
Whittington, Malkowicz, Schultz, Kaplan, et al., 1998; Mottet et al., 2018). 
The EAU guidelines mention several commercial diagnostic tests listed below that 
could be used as a part of individual risk assessment when DRE is normal and PSA is 
between 2–10ng/ml (Mottet et al., 2018). Prostate cancer gene 3 and SelectMDX are 
urine-based microRNA markers. Prostate cancer gene 3 is shown to outperform PSA 
testing predicting PCa in subsequent biopsy, however they performed similarly in 
predicting high-grade PCas (Wein et al., 2016). SelectMDX measuring HOXC6 and 
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DLX1 mRNA levels, which were shown to be good predictors for the detection of 
high-grade PCa (Van Neste et al., 2016). The Michigan Prostate score is based on a 
urine test and it combines information from transmembrane proteinase TMPRSS2 and 
ERG-gene fusion and PCA3. TMPRSS2:ERG fusion which is present in at least 50% 
of screened PCas. The ExoDX measures exomes secreted by PCa cells from urine in 
which ERG and PCA3 is analyzed resulting in a good NPV for high grade PCa 
(Donovan et al., 2015). The prostate health index and 4Kscore are serum tests using 
kallikreins expressed from the prostate as a part of a multifactorial score, and various 
combinations of these kallikreins outperformed PSA and free PSA/PSA ratio in the 
detection of PCa and are additionally closely correlated with an increasing Gleason 
score (Wein et al., 2016). 
A clinical examination in the context of PCa diagnostics means DRE and TRUS. 
A local extent of PCa can also be estimated with MRI, which is discussed later (see 
chapter 2.3. MRI in primary diagnostics of prostate cancer). Distant spreading of PCa 
is routinely evaluated with bone scan and computer tomography (CT) in patients with 
increased risk of non-localized disease (Mottet et al., 2018). According to the 
guidelines, distant spreading should be evaluated from men in the intermediate risk 
group (see Table 3) with GGG ≥3 (Mottet et al., 2018). In addition, various 
applications of positron emission tomography (PET) could be used in staging of PCa, 
however the clinical significance of PET findings still remain unclear (Mottet et al., 
2018). However, PET is not routinely used to evaluate the local extent of PCa in the 
primary diagnostics. 
Digital rectal examination has relatively poor value as an individual test in PCa 
diagnostics: In the recent meta-analysis, DRE performed by a primary care physician 
had a sensitivity of 0.59 and specificity of 0.51 (Naji et al., 2018). However, DRE has 
limited complementary value in combination with PSA in an early detection of PCa, 
because PSA and DRE not necessarily detect the same cancers (Catalona et al., 1994; 
Wein et al., 2016). 
Transrectal ultrasound has been used in PCa diagnostics from the 1980s. 
Ultrasound guided biopsies have been the gold standard in PCa diagnostics for the last 
decades. However, traditional grayscale ultrasound has relatively poor value in 
visualizing PCa lesions, and according to the EAU guidelines, biopsies targeted to 
lesions visible in traditional ultrasound cannot replace systematic biopsies (Mottet et 
al., 2018). According to the consensus meeting concerning the role of ultrasound in 
PCa focal therapies, conventional ultrasound without biopsy is not suitable for 
diagnosing and staging PCa and it should be used solely for identifying the location 
of the prostate, directing biopsies and assessing gland volume, as well as anatomical 
variations (Smeenge et al., 2012). 
Onur et al. presented with the prospectively collected study cohort in the 1990, 
that in biopsies from hypoechogenic i.e. cancer suspicious areas or isoechogenic areas 
in TRUS from any location (base, middle, apex, transitional zone) of prostate, have 
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no significant difference in cancer detection rate (Onur et al., 2004). In addition, 
prostates with hypoechogenic lesions did not have significantly more PCas than 
prostates without them (Onur et al., 2004). However, prostate size or the Gleason 
score of cancers detected were not defined in the study. In a more recent study from 
the early 2000s, Toi et al., presented in a large prospective series of men quite opposite 
results: in prostates with a suspicious lesion visible in TRUS, a PCa was detected 
almost twice as likely than when there were no visible lesions and 83.8% had PCa 
detected in a biopsy core taken from the visible lesion (Toi et al., 2007). In addition, 
the TRUS finding is also correlated with the tumor grade; a Gleason score of ≥7 was 
found twice as frequently in the TRUS positive group as in the TRUS negative group 
(Toi et al., 2007). Aforementioned differences between the groups were all significant 
(Toi et al., 2007). An obvious explanation for the difference in results seems to be the 
evolution of ultrasound technique in a course of time. 
The European Association of Urology guidelines do not recommend using TRUS 
for local staging of PCa (Mottet et al., 2018). According to the study of Hamper et al. 
from the 1980s, the outcomes in evaluating extraprostatic extension with ultrasound 
is moderate (Hamper et al., 1991). It is worth mentioning that the cancer detection rate 
was quite good in the study; a PCa was detected in 76% of hypoechogenic lesions, 
however hypoechogenic lesions detected without a cancer were not reported (Hamper 
et al., 1991). In the study, a positive predictive value (PPV) for capsular penetration 
was 80% and a negative predictive value (NPV) was 85% while the ultrasound 
became more accurate with increasing penetration depth (Hamper et al., 1991). 
New interesting applications of ultrasound technology, e.g. ultrasound 
elastography and contrast-exchanged ultrasound, are emerging in PCa diagnostics 
with a promising results (Sarkar & Das, 2016). However, their role in PCa diagnostics 
or staging is not yet defined by the guidelines (Mottet et al., 2018). 
2.2.3 Prostate biopsies 
2.2.3.1 Procedures and outcomes 
After a suspicion of PCa has emerged, systematic prostate biopsies using an 18 gauge 
needle gun and TRUS guidance with or without ultrasound/MRI/DRE lesion-targeted 
biopsies remain to be the cornerstones of PCa diagnostics, especially in biopsy naïve 
patients (Mottet et al., 2018). According to the guidelines, depending on prostate size, 
8–12 biopsy cores are taken from the prostate systematically from the template 
distributed regions (Mottet et al., 2018; NICE, 2019). An increasing core number over 
12 is not more conclusive in diagnostics; however, additional targeted biopsies from 
suspicious lesions are acceptable to take (Mottet et al., 2018; Shariat & Roehrborn, 
2008). Saturation biopsies (i.e. > 12 systematic biopsy cores) increase the detection 
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rates of both CSPCa and insPCa, thus as a procedure demanding additional anesthetic 
requirements, it could be more useful in a repeat biopsy setting (Li et al., 2014; Walz 
et al., 2006; Wein et al., 2016). 
Commonly, prostate biopsies can be taken via the transperineal or transrectal 
route. In the transrectal biopsy procedure, biopsy needles penetrate rectal mucosa 
whereas in the transperineal biopsy procedure, they penetrate the sterilized perineum. 
Theoretically, the transperineal biopsy procedure should then be more sterile. 
Anatomically, transperineal prostate biopsies could also be the better approach in 
biopsing anterior and apical lesions and, in addition, the longitudinal orientation could 
be more efficient in biopsing the peripheral zone (Eldred-Evans et al., 2016; Wein et 
al., 2016). Obviously, the transperineal approach is the only way to perform prostate 
biopsies in patients with no access to the rectum. However, in the recent meta-
analysis, the approaches have no significant differences in cancer detection and 
complication rates in systematic biopsies (Xue et al., 2017). The TRUS-Bx procedure 
is performed using a local infiltration anesthesia to the periprosthetic region, while the 
transperineal procedure requires at least an additional infiltration anesthesia to 
perineal skin and subcutis (Wein et al., 2016). These requirements of anesthesia and 
sterilized conditions make transperineal biopsies less practical in outpatient use 
comparing to the transrectal approach. 
Taking into account the central role of systematic prostate biopsies in the 
traditional PCa diagnostics, their sensitivity in diagnostics of CSPCa is low. In a study 
of Epstein et al., authors investigated a large series of prostatectomy specimens, in 
which the Gleason scores from 5–6 were upgraded in 36% of cases and if tertiary 
patterns were ignored, 25% of the whole cohort were upgraded (Epstein et al., 2012). 
In the autopsy study of Haas et al., an NPV of traditional 12-core biopsy protocol in 
excised prostates was 80% for CSPCa (Haas et al., 2007). In a recent study of Ahdoot 
et al., the Gleason score was upgraded to CSPCa from systematic biopsies in 30.2% 
of cases in a series of 404 prostatectomy specimens (Ahdoot et al., 2020). 
An alternative to systematic biopsies is template mapping biopsies, in which the 
prostate gland is transperineally saturated with biopsy cores using a grid of e.g. 5 mm, 
which theoretically cannot miss (spherical) lesions larger than 5 mm. In a study of 
Crawford et al., in 25 men, transperineal mapping biopsies from prostates with a 5mm 
grid with mean 49 cores (27–110) per patient, were compared to the pathology of 
whole mount prostatectomy specimen (Crawford et al., 2013). In the study, 18 of 64 
lesions diagnosed in the prostatectomy specimen were missed by transperineal 
mapping prostate biopsies, but a CSPCa was in only one missed lesion (Crawford et 
al., 2013). In the study, CSPCa was defined as lesions ≥ 0.5 cm3 or Gleason score ≥ 7 
(Crawford et al., 2013). However, the prostate with the missed CSPCa lesion has an 
additional CSPCa focus diagnosed by the study biopsies (Crawford et al., 2013). 
Marra et al. analyzed biopsy results and prostatectomy specimens from 204 
retrospectively collected men, which underwent saturation template mapping biopsies 
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with a 5mm grid with a mean of 30 biopsies per patient and subsequent radical 
prostatectomy (Marra et al., 2017). In the study, the PCa histology in 12.7% of patients 
was upgraded, and 11.8% were downgraded from prostate biopsies in an analysis of 
prostatectomy specimen (Marra et al., 2017). As a conclusion, for now, transperineal 
template mapping biopsies are quite a demanding alternative for TRUS-Bx in primary 
diagnostics of a PCa. In addition, the limitations in sensitivity and specificity should 
be noted when used as a reference in studies concerning targeted prostate biopsies. 
2.2.3.2 Antibiotic prophylaxis 
The EAU guidelines recommend an use of antibiotic prophylaxis in TRUS-Bx and 
transperineal prostate biopsies (Mottet et al., 2018). In the TRUS-Bx,  
fluoroquinolones is recommended as an antibiotic regimen, while in transperineal 
biopsies only a single dose of intravenous cephazolin is recommended (Mottet et al., 
2018). However, the guidelines do not give recommendations for a dose or timing for 
the prophylaxis (Mottet et al., 2018).  
As an additional prophylactic intervention, the EAU guidelines now recommend 
to consider a rectal disinfection with povidone-iodine prior biopsies (Mottet et al., 
2018). According to the studies, it is simple and affordable, not associated with the 
selection of resistant bacteria and seems to reduce infectious complications after 
transrectal prostate biopsies (Pilatz et al., 2019; Roberts et al., 2017).  
In a Cochrane review from 2011, the effectiveness of antibiotic prophylaxis in 
transrectal prostate biopsies was evaluated (Zani et al., 2011). In the analysis, the 
authors presented that in placebo/no treatment controlled trials, antibiotic prophylaxis 
was significantly more effective against infectious complications classified as 
bacteriuria, urinary tract infection and hospitalization (Zani et al., 2011). Moreover, 
analyzing studies that directly compared different antibiotics, there was no difference 
between fluoroquinolones and other classes of antibiotics (Zani et al., 2011). In 
addition, using a long course of antibiotics or multiple antibiotic regimens in 
prophylaxis had significant reducing effect to bacteriuria, but not for other measured 
variables (Zani et al., 2011). Most of the studies in the aforementioned review were 
published 20 years ago, which should be taken into account in applying the results to 
today’s practice in an evolving bacterial resistance environment (CDDEP, 2019). 
Recently, infectious complications of transrectal prostate biopsies have increased, 
and it is suspected to arise from an increasing fluoroquinolone resistance rate of the 
most common pathogen causing biopsy related infections, Escherichia coli (E. coli) 
(See chapter: 2.2.3.3 Biopsy complications). Therefore, numerous alternative and 
additional antibiotics to fluoroquinolones in addition to targeting antibiotic 
prophylaxis have been investigated, aiming to reduce the complication rate (Loeb et 
al., 2013). In a meta-analysis of Roberts et al., fosfomycin significantly outperformed 
fluoroquinolones in reducing post-TRUS-Bx complications when comparing the rates 
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of overall infectious complications and infectious complications caused by 
fluoroquinolone resistant organisms (Roberts et al., 2018). However, in the study, 
there was no significant difference in the rate of infectious complications caused by 
fluoroquinolone sensitive organims (Roberts et al., 2018). As a conclusion, while 
fosfomycin is relatively safe, and have favourable pharmacological features for use as 
TRUS-Bx prophylaxis, it is promising in reducing infectious complications after 
TRUS-Bx (Noreikaite et al., 2018; Roberts et al., 2018). In addition, targeted 
antibiotic prophylaxis might have an effect on reducing complications, however the 
influence on the complication rate was minor and high-quality evidence is still 
missing (Pilatz et al., 2019; Scott et al., 2018).  
Fluoroquinolone resistance and its adverse effects have recently been under 
intensive public discussion. In March 2019, the European Commission has banned 
fluoroquinolones as a prophylaxis in urological procedures including TRUS-Bx 
(Bonkat et al., 2019). At the moment (January 2020), EAU guidelines are not yet 
adapted to this regulation; however, possible alternatives might be fosfomycin or a 
rectal swab culture targeted prophylaxis, as well as the change to transperineal 
prostate biopsy (Bonkat et al., 2019). 
2.2.3.3 Biopsy complications 
In a systematic review by Loeb et al., complications of TRUS-Bx were primarily 
investigated (Loeb et al., 2013). In this systematic review, the frequency of infection 
varies among studies, with most studies reporting infectious complications requiring 
hospitalization in 0–6.3% of cases (Loeb et al., 2013). Also serious infectious 
complications occur: Incidence of sepsis and bacteremia varies among studies 
between 0.62% and 3.06% (de Jesus et al., 2006; Pinkhasov et al., 2012; Simsir et al., 
2010; Steensels et al., 2012; Zaytoun et al., 2011). Lahdensuo et al. reported in their 
retrospective study cohort a mean bacteremia rate of 0.7% in patients after TRUS-Bx 
in southern Finland (Lahdensuo et al., 2016). Carmignati et al. presented, in a 
prospective, multicenter study, urosepsis in 10/447 (2.2%) patients after TRUS-Bx 
(Carmignani et al., 2012).  
There is also a significant number of non-infectious biopsy complications. In the 
systematic review of Loeb et al., the rate of hematuria varies between 10–84%, 
however significant bleeding requiring hospitalization occurs in less than 1% of cases 
(Loeb et al., 2013). Rate of rectal bleeding were 1.3–45% and urinary retention occurs 
in 0.2–1.7% of cases (Loeb et al., 2013).  
In the aforementioned systematic review of Loeb et al., an additional analysis was 
made concerning complications of transperineal biopsies: In the analysis, the rate of 
urinary tract infections varies between 0–1.6%, and the rate of prolonged or severe 
hematuria occurs in 0–5.2% (Loeb et al., 2013). Urinary retention was reported in 1.6–
8.8% of cases (Loeb et al., 2013). There is no clear evidence supporting the hypothesis 
Review of the literature 
 35 
that transperineal prostate biopsies cause less infectious complications compared to 
the transrectal approach (Loeb et al., 2013; Pilatz et al., 2019). However, urinary 
retention might be more prevalent after transperineal biopsies (Loeb et al., 2013; 
Moran et al., 2006). 
An increased number of biopsy cores does not seem to cause more infectious 
biopsy complications, however the influence on bleeding complications is 
controversial (Loeb et al., 2013; Pilatz et al., 2019). 
The current EAU guidelines do not recommend interrupting anticoagulation 
antiplatelet therapy prior to prostate biopsies (Mottet et al., 2018). According to a 
review of Culkin et al., an uninterrupted use of aspirin does not increase the risk of 
moderate/severe hematuria or rectal bleeding after TRUS guided biopsies (Culkin et 
al., 2014). In the study of Ihezue et al., there were no significant differences in the rate 
of rectal bleeding after TRUS guided prostate biopsies between a patient group using 
warfarin medication and a control group (Ihezue et al., 2005). In the study, hematuria 
was significantly more common in the warfarin group; however, there were no 
significant differences in the severity of bleeding complications between the groups 
(Ihezue et al., 2005). As a conclusion, severe bleeding complications after prostate 
biopsies are rare and their prevalence does not seem to depend on 
anticoagulation/antiplatelet therapy; however, risks following interruption of 
anticoagulation/antiplatelet therapy could be more harmful. 
There is a worrying trend of increasing infectious complications after prostate 
biopsies in recent years, however a similar trend is not seen in other types of biopsy 
complications (Borghesi et al., 2016; Carignan et al., 2012; Nam et al., 2013). In a 
retrospective registry study of 75 000 biopsied men, hospital admission rates due to 
infection after prostate biopsies from 1996 to 2005 have increased from 0.6% to 3.6% 
(Nam et al., 2013). According to the mentioned study, the mortality rate during 30 
days after prostate biopsies was 0.09%, however there was no similar increasing trend 
in the mortality rate as was in infectious complications (Nam et al., 2013). In a 
retrospective registry study conducted in Finland, bacteremic complications after 
prostate biopsies have increased from 0.5% in 2005 to 1.2% in 2012 and 53% were 
caused by a fluoroquinolone resistant organism (Lahdensuo et al., 2016). Feliciano et. 
al presented similar results: The incidence of infectious complications after TRUS-Bx 
were three times higher and specifically infectious complications caused by 
fluoroquinolone resistant organisms were also 3.3 to 4.3 times higher in 2006 
compared to the incidence in 2004 and 2005 (Feliciano et al., 2008). In addition, post-
biopsy urine and blood cultures of 79% of patients with infectious complications 
included a fluoroquinolone resistant organism (Feliciano et al., 2008). It has been a 
widely accepted hypothesis that the increasing rate of infectious complications after 
TRUS-Bx arises from a globally increasing fluoroquinolone resistance rate of E. coli 
strains (Borghesi et al., 2016; Loeb et al., 2013; Wagenlehner et al., 2013). 
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In determining an ability of fluoroquinolone resistant organisms to cause post-
TRUS-Bx infections, it might not be a fruitful approach to dichotomize pathogens as 
resistant or susceptible to fluoroquinolones. In the study of Kalalahti et al., also a 
moderately decreased fluoroquinolone susceptibility of an organism seems to be 
associated with higher infectious TRUS-Bx complication rates (Kalalahti et al., 2018). 
In an international prospective multicenter study, no significant risk factors for 
infectious complications emerged after prostate biopsies, which were mainly 
performed by the transrectal approach (Wagenlehner et al., 2013). In a prospective 
study of Steensels et al., rectal cultures from patients having TRUS-Bx were 
investigated, and fluoroquinolone resistant E. coli seems to be a significant risk factor 
for infectious biopsy complications (Steensels et al., 2012). In a systematic review 
investigating risk factors for infectious complications after TRUS-Bx, all significant 
risk factors were presumably associated with an increased risk of antibiotic resistant 
strains (urogenital infection, antibiotic use, international travel, hospital exposure, 
bacteriuria, previous TRUS-Bx, and resistance of fecal flora to antibiotic prophylaxis) 
(Roberts et al., 2017). However, also a higher comorbidity has been associated with a 
significantly increased risk of hospitalization after TRUS-Bx (Carignan et al., 2012; 
Roberts et al., 2017). 
2.2.3.4 Emerging antibiotic resistance of E. coli 
Escherichia coli as a concept consists of a wide variety of bacterial strains with 
varying virulence potential (Vaara et al., 2010). It is a gram-negative, aerobic coliform 
and a main aerobic pathogen of the human bowel (Vaara et al., 2010). It is the most 
common pathogen causing infections after prostate biopsies and also the most 
common fluoroquinolone resistant pathogen: In a series of 63 men admitted to 
hospital due to an infection after prostate biopsies, E. coli was a predominant organism 
in 84% of urine and 91% of blood cultures (Loeb et al., 2012). In a prospective study 
of Taylor et al., the rectal flora of 865 patients having TRUS-Bx during 2009–2011 
were investigated (Taylor et al., 2013). In the study, fluoroquinolone resistant gram‐
negative coliforms were detected in 19% of men and the rate of E. coli in these gram-
negative and fluoroquinolone resistant strains was 90% (Taylor et al., 2013). There is 
an worldwide increase in the fluoroquinolone resistance of bacterial strains, including 
E. coli, and it has a significant clinical relevance to PCa diagnostics, because 
fluoroquinolones are still recommended as an antibiotic prophylaxis prior TRUS-Bx 
(See chapter: 2.2.3.3 Biopsy complications) (CDDEP, 2019; Mottet et al., 2018).  
Additionally, E. coli is the most common pathogen producing extended spectrum 
beta lactamases (ESBL), and its prevalence is also increasing worldwide (Ben-Ami et 
al., 2009). Extended spectrum beta lactamases are a heterogeneous family of 
commonly plasmid mediated enzymes that inactivate and confer resistance to most 
beta-lactam antibiotics, including penicillins and cephalosporins (Brolund & 
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Sandegren, 2016; Vaara et al., 2010). A clinical relevance of ESBL producing strains 
in PCa diagnostics is that cephalosporins are commonly used as a first line parenteral 
antimicrobial therapy in community-acquired infections in emergency medicine, 
including men’s urinary tract infections. In the aforementioned prospective study of 
Taylor et al., 4.6% of men having prostate biopsies harbored an ESBL producing 
strain in their rectal bacterial flora (Taylor et al., 2013). In addition, ESBL producing 
pathogens show greater resistance to fluoroquinolones than the average; over 70% of 
ESBL strains were also fluoroquinolone resistant in an international multi-
institutional study (Ben-Ami et al., 2009).  
Colonization with resistant E. coli strains mainly occurs by indigestion and the 
resistant strains are suspected to arise especially from a wide and off-label usage of 
antibiotics in food animals (Collignon, 2009). However, the antibiotic usage of an 
individual could also influence the colonization of resistant organisms: In the registry 
study of Kim et al., an inpatient use of fluoroquinolones, beta-lactams/beta-lactamase 
inhibitors and carbapenems significantly increased E. coli strains’ resistance to 
fluoroquinolones in various isolates (Kim et al., 2018). In addition, carbapenem and 
fluoroquinolone usage increased resistance of E. coli to 3rd-generation cephalosporins 
(3CEF) (Kim et al., 2018). 
In the previously mentioned prospective study of Taylor et al., risk factors for 
carriage of a ciprofloxacin resistant strain in men undergoing prostate biopsies were 
also analyzed (Taylor et al., 2013). In the study, 19% of men were found to have 
ciprofloxacin resistant gram-negative organism in the rectal flora and in a multivariate 
analysis, a heart valve replacement and ciprofloxacin use within three months were 
the only significant risk factors for the carriage of the organism (Taylor et al., 2013). 
Additionally, infectious complications were observed in the study: an infectious 
complication occurred in 3.6% of the patient population and 48% of these patients 
grew ciprofloxacin‐resistant organisms on their pre‐biopsy rectal swab culture, while 
fluoroquinolone resistant gram‐negative coliforms were detected in 19% of the whole 
study cohort (Taylor et al., 2013). It should be mentioned that diabetes and suppressed 
immunity were not significant risk factors for fluoroquinolone resistance in the study 
(Taylor et al., 2013). Mulder et al. studied risk factors for fluoroquinolone resistance 
in patients having community acquired urinary tract infections (Mulder et al., 2017). 
In the study, the rate of ciprofloxacin resistant E. coli were 10.2% and in a multivariate 
analysis, higher age and recent fluoroquinolone prescriptions were detected as risk 
factors for ciprofloxacin resistance, while no association between fluoroquinolone use 
more than one year before the culture and ciprofloxacin resistance could be 
demonstrated (Mulder et al., 2017). However, the study population consisted mainly 
of women (Mulder et al., 2017). 
Ben-Ami et al. reviewed the risk factors for community acquired infection due to 
an ESBL producing organism (Ben-Ami et al., 2009). In the study, the most common 
ESBL producing pathogen was E. coli, which occurs in 87.6% of the analyzed patient 
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specific isolates and the rate of ESBL producing strains among the E. coli isolates was 
33.6% (Ben-Ami et al., 2009). In a multivariate analysis, statistically significant 
predictors for infection due to ESBL-producing enterobacteriaceae were age ≥ 65 
years, recent use of any antibiotic, recent hospitalization, residence in a long-term care 
facility, and male sex (Ben-Ami et al., 2009). 
An interesting study about colonization of antibiotic resistant E. coli strains was 
carried out by Kennedy et al. with volunteers traveling internationally (Kennedy & 
Collignon, 2010). In the study, pre-travel and post-travel incidence of ciprofloxacin 
resistant E. coli were 3.9% and 33.3%, respectively and pre-travel and post-travel 
incidence of 3CEF resistant E. coli (mostly ESBL producing) strains were 2.0% and 
25.5%, respectively (Kennedy & Collignon, 2010). The differences were all 
significant. Study patients with resistant E. coli were more likely to have developed 
gastroenteritis or have taken antibiotics whilst traveling (Kennedy & Collignon, 
2010). Over a half of the patients had gentamicin, ciprofloxacin and/or 3CEF resistant 
E. coli after traveling in Asia (excluding Japan), South America, Middle East, Africa 
or India (Kennedy & Collignon, 2010). The majority of study patients cleared all 
ciprofloxacin and 3CEF resistant E. coli  within two months and clearance of 3CEF 
resistant strains was the most rapid; however, at least 18% of those returning with 
ciprofloxacin/3CEF resistant strains remained persistently colonized at six months 
post-travel (Kennedy & Collignon, 2010).  
Similar results were presented by Kantele et al. in a study investigating risk factors 
for ESBL colonization within Finnish volunteers traveling from outside  the Nordic 
countries (Kantele et al., 2015). In the study, 21% of travelers were colonized by 
ESBL producing strain while in a multivariate analysis, significant risk factors for the 
colonization were travels to sub-Saharan Africa, tourist diarrhea, having an antibiotic 
use for tourist diarrhea and having meals with the locals (Kantele et al., 2015). 
2.3 MRI in primary diagnostics of prostate cancer 
2.3.1 Basics of prostate MRI sequences and reporting 
systems 
Prostate MRI is multiparametric, i.e. includes several sequences, including anatomical 
(T1 and T2 weighted [T2W] imaging) and functional (diffusion weighted imaging 
[DWI], dynamic contrast exchanged [DCE] imaging and MRI spectroscopy) 
sequences (Sarkar & Das, 2016). The gold standard in prostate MRI imaging is 
mpMRI, including T2W imaging, DWI and DCE imaging sequences (Mottet et al., 
2018; NICE, 2019). 
T2 weighted imaging is an anatomical imaging sequence, with excellent soft tissue 
contrast and depiction of the zonal anatomy of the prostate, thus it is the most practical 
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sequence to identify defects in the zonal anatomy i.e. extracapsular extension by PCa 
cells (Sarkar & Das, 2016). In T2W imaging, the water-rich peripheral zone appears 
in bright, while PCa appears usually as a rounded or ill-defined low signal intensity 
lesion in the peripheral zone. Rarely BPH in the peripheral zone could give a false 
positive finding (Sarkar & Das, 2016; Wein et al., 2016). However, several other 
conditions mimic the PCa appearance as well (Sarkar & Das, 2016). The transitional 
zone appears relatively darker in T2W imaging where it is often harder to distinguish 
PCa from BPH (Sarkar & Das, 2016). T1 weighted images are obtained to determine, 
if hemorrhage is present in the prostate, which can give rise to a false positive 
interpretation in T2 weighted imaging (Wein et al., 2016). T2 weighted imaging has 
a high specificity, but low sensitivity to detect PCa, therefore multiparametric 
assessment is needed (Wein et al., 2016). 
Diffusion weighted imaging measures the diffusion of water molecules in the 
magnetic field (Brownian motion) in extracellular space, therefore a high cellular 
density, which is typical in PCa, makes contrast to images decreasing extracellular 
space (Sarkar & Das, 2016; Wein et al., 2016). In DWI, a duration and strength of the 
magnetic field, measured by b-values, can be changed and apparent diffusion 
coefficient (ADC) maps can be made for cancer detection (Sarkar & Das, 2016). The 
b-values present a threshold for detecting tissue restriction (Wein et al., 2016). 
Apparent diffusion coefficient values have been found to predict cancer 
aggressiveness (Sarkar & Das, 2016; Wein et al., 2016). 
Dynamic contrast enhanced imaging is a T1 weighted sequence using a contrast 
medium, typically gadolinium, which rapidly diffuses to the extracellular space 
(Sarkar & Das, 2016). The DCE made before, during and after intravenous injection 
of the contrast medium, and the increased tumor microvessel density and higher 
permeability make differences in the enhancement of tumor tissue (Sarkar & Das, 
2016). 
Magnetic resonance spectroscopic imaging is based on determining the cellular 
metabolite concentrations in the prostate tissue (Sarkar & Das, 2016). The cancerous 
tissue has lower levels of citrate and the levels of choline increase with higher cellular 
density, cell membrane turnover, and phospholipid metabolism during PCa and the 
choline-citrate ratio is measured by the sequence (Sarkar & Das, 2016). 
The most widely accepted reporting system for prostate MRI is the Prostate 
Imaging Reporting and Data System (PI-RADS), and the EAU guidelines recommend 
to adhere to PI-RADS guidelines in mpMRI interpretation (Mottet et al., 2018). The 
last update to the PI-RADS system was in 2019 to version 2.1 (Turkbey et al., 2019). 
The system is a five-tiered estimation of the probability of CSPCa, based on a 
combination of T2W, DWI and DCE MRI sequences, while DCE plays a minor role 
in determining PI-RADS (American College of Radiology®, 2019). Significant 
prostate cancer is defined in PI-RADS v2.1 scoring system by Gleason score ≥ 3+4, 
and/or tumor volume ≥ 0.5 cc, and/or tumor extraprostatic extension (American 
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College of Radiology®, 2019). PI-RADS score is given to every cancer-suspicious 
lesion in the prostate gland, based on a combination of mpMRI findings only and not 
incorporating any clinical factors (American College of Radiology®, 2019). 
Although, PI-RADS v2.1 does not include detailed recommendations for the 
management of suspicious lesions (American College of Radiology®, 2019). 
However, according to the PI-RADS v2.1, biopsy should be considered for PI-RADS 
4 or 5, but not for PI-RADS 1 or 2, while a decision to biopsy PI-RADS category 3 
lesion should be based on other factors than the mpMRI score, including the 
laboratory/clinical history and local preferences, expertise and standards of care 
(American College of Radiology®, 2019). 
PI-RADS version 2.1 assessment categories (American College of Radiology®, 
2019):  
• PI-RADS 1: very low (clinically significant cancer is highly unlikely to be 
present) 
• PI-RADS 2: low (clinically significant cancer is unlikely to be present) 
• PI-RADS 3: intermediate (the presence of clinically significant cancer is 
equivocal) 
• PI-RADS 4: high (clinically significant cancer is likely to be present) 
• PI-RADS 5: very high (clinically significant cancer is highly likely to be 
present) 
PI-RADS version 2.1 scoring is based only on the radiographic appearance of the 
lesion (American College of Radiology®, 2019). T2W and DWI lesional scores are 
reported in a scale of 1–5 and the contribution of sequence score to the final score is 
depending on the location of the lesion (American College of Radiology®, 2019). The 
dynamic contrast enhancement score is dichotomized, and its significance is in 
upgrading score 3 to 4 in peripheral zone lesions (American College of Radiology®, 
2019). Generally, a difference between PI-RADS version 2.1 scores 4 and 5 is 
depending only on a diameter (cutoff 1.5cm) or a definite extraprostatic 
extension/invasive behavior of the lesion (American College of Radiology®, 2019). 
Due to a multifocal nature of PCa, in the PI-RADS version 2.1 scoring, up to four 
lesions should be identified, and the lesion with the highest PI-RADS version 2.1 
score should be defined as an index lesion, or if there are several lesions with the same 
PI-RADS version 2.1 score, the lesion with extraprostatic extension, or secondarily, 
the largest lesion should be defined as the index lesion (American College of 
Radiology®, 2019). 
Another, less used alternative for PI-RADS scoring in prostate MRI reporting is 
the five-step tiered Likert scoring, in which suspicion categories for CSPCa are 
analogous with PI-RADS scoring. The Likert system varies between studies, and it is 
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more a general impression of the performing radiologist of the level of CSPCa 
suspicion, and it is not bound to any structured reporting system. The main differences 
of the Likert system comparing to the PI-RADS system in PCa diagnostics is an 
opportunity to patient based (contrary to lesion-based) analysis and combination of 
non-prespecified imaging, biochemical data and reader’s experience (Khoo et al., 
2019). According to the Khoo et al. prospective, multicenter study, the Likert scoring 
system is a valid alternative to PI-RADS system in experienced centers, with no 
significant differences in cancer detection rates (DR) of CSPCas or insPCas (Khoo et 
al., 2019).  
Rosenkranz et al. investigated in a retrospectively collected cohort an inter-reader 
reproducibility of mpMRI interpretation with PI-RADS (initial version) and Likert 
scoring systems among three radiologists with different grades of experience 
(Rosenkrantz et al., 2013). In the analysis, generally agreement between experienced 
readers in Likert and PI-RADS scoring system was strong (Rosenkrantz et al., 2013). 
However, in transition zone lesions, agreement was lower with both reporting systems 
(Rosenkrantz et al., 2013). Agreement between experienced and inexperienced 
readers was slightly better in Likert than in PI-RADS scoring system (Rosenkrantz et 
al., 2013).  
2.3.2 MRI in prostate cancer diagnostics 
Multiparametric MRI has now been adopted to EAU guidelines as a complementary 
part of initial PCa diagnostics, if available (Mottet et al., 2018). Formerly, mpMRI 
was recommended only after cancer negative biopsies in prevailing suspicion of PCa. 
The role of MRI in the guidelines is handled in more detail in chapter 2.2.1: Guidelines 
for primary diagnostics and risk stratification.  
Recently, high quality prospective (Table 4) studies concerning the sensitivity of 
mpMRI in diagnostics of PCa have resulted quite unanimously in its good sensitivity 
to CSPCa in addition to its tendency to discriminate insPCas as described in more 
detail below. 
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Table 4.  Details of prospective studies concerning mpMRI in PCa diagnostics. 
study 
name author year n 
reference 
standard 
CSPCa 
definition (in 
current 
comparison) 
definition for 
a CSPCa 
suspicious 
lesion 
PROMIS Ahmed et al. 2017 576 transperineal 
template 
mapping 
biopsies 
Gleason ≥ 7 Likert score 
3–5 
PRECISION Kasivisvanathan 
et al. 
2018 500 systematic 
transrectal 
biopsies 
Gleason ≥ 7 PI-RADS 
version 2 
score 3–5 
4M Van der Leest  et 
al. 
2019 626 systematic 
transrectal 
biopsies 
Gleason ≥ 7 PI-RADS 
version 2 
score 3–5 
MRI-FIRST Rouvière et al. 2019 275 systematic 
transrectal 
biopsies 
Gleason ≥ 7 Likert score 
3–5 
 
In a multicenter PROMIS trial, mpMRI targeted and TRUS guided systematic biopsy 
results were compared against transperineal template mapping biopsies (Ahmed et al., 
2017). In the study, NPV of mpMRI and TRUS guided systematic biopsies in ruling 
out CSPCa were 76% and 63% (p<0.0001), respectively, while a prevalence of CSPCa 
was 53% (Ahmed et al., 2017). 
In an international, multicenter, randomized, controlled PRECISION trial, a 
cohort of men with prebiopsy mpMRI was compared to a cohort of men having a 
traditional diagnostics with only systematic prostate biopsies (Kasivisvanathan et al., 
2018). In the mpMRI cohort, only lesion targeted biopsies from lesions suspicious to 
a CSPCa in mpMRI, if present, were taken without performing additional systematic 
biopsies (Kasivisvanathan et al., 2018). In the MRI cohort, CSPCa were diagnosed in 
38% of men, and in 26% of men in the systematic biopsy cohort (p=0.005) 
(Kasivisvanathan et al., 2018). In addition, fewer insPCas were diagnosed in the MRI 
cohort (9% vs. 22%; p<0.001) and the percentage of PCa in biopsy cores was higher 
in the MRI group (Kasivisvanathan et al., 2018). 
In a multicenter 4M trial, prebiopsy mpMRI were performed and systematic 
biopsies were taken from all patients (van der Leest et al., 2019). Additional in-bore 
mpMRI targeted biopsies were taken, if suspicious lesions were present in the mpMRI 
(van der Leest et al., 2019). In the study, there were no statistically significant 
differences in detection rates of CSPCa in systematic biopsies and MRI-targeted 
biopsies while the prevalence of CSPCa was 32% in combined biopsies (van der Leest 
et al., 2019). Additionally, there were no significant differences in Gleason ≥ 4+3 
prevalence in MRI targeted biopsies comparing to the systematic biopsies, while the 
prevalence of Gleason ≥ 4+3 PCa in combined biopsies was 15% (van der Leest et al., 
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2019). However, the rate of insPCa was significantly lower in MRI targeted biopsies 
than in systematic biopsies (14.1% vs. 24.8%; p<0.0001) (van der Leest et al., 2019). 
Finally, in a multi-institutional MRI-FIRST study, systematic biopsies were 
performed to all patients and additional targeted biopsies were taken if cancer-
suspicious lesions were present in mpMRI (Rouvière et al., 2019). In the analysis, 
there was no significant difference in the prevalence of CSPCa in MRI guided biopsies 
(29.9%) comparing to systematic biopsies (32.3%), while the prevalence of CSPCa in 
combined biopsies was 37% (Rouvière et al., 2019). However, MRI biopsies missed 
5.2% of CSPCas detected in systematic biopsies, and conversely, systematic biopsies 
missed 7.6% of CSPCas detected in MRI-targeted biopsies (Rouvière et al., 2019). 
Interestingly, the prevalence of Gleason ≥ 4+3 PCas was significantly higher in the 
target biopsies comparing to systematic biopsies, and added value of targeted biopsies 
to the systematic biopsies in detection of Gleason ≥ 4+3 PCa was 6.0% (p=0.0095), 
while the prevalence of Gleason ≥ 4+3 PCas was 21.1% in the combined biopsies 
(Rouvière et al., 2019). 
Two of the mentioned studies provided prevalence of CSPCas and insPCas in MRI 
targeted biopsies in various MRI suspicion scores, which are presented in Table 5. 
Table 5.  Prevalence of CSPCa (Gleason ≥ 7) and insPCa in MRI targeted biopsies in relation to 
mpMRI score in the prospective 4M and MRI-FIRST studies (Rouvière et al., 2019; van 
der Leest et al., 2019). Rate of insPCas in systematic biopsies in men with MRI suspicion 
level of 1-2 were 20% in 4M trial and 31% in MRI-FIRST trial, while definition of insPCa 
were Gleason score 3+3 in 4M trial, and Gleason score 3+3 with maximum cancer core 
length < 6 mm in MRI-FIRST trial (Rouvière et al., 2019; van der Leest et al., 2019). 
mpMRI score 
mpMRI targeted biopsies 
4M MRI-FIRST 
CSPCa % insPCa % CSPCa % insPCa % 
3 18 18 12 5 
4 40 32 31 15 
5 70 26 77 0 
 
Ahdoot et al. compared mpMRI targeted and systematic biopsy results in a large 
cohort of men (n=2103) having detectable lesions in mpMRI (Ahdoot et al., 2020). In 
the study, additional GGG ≥ 2 PCas were diagnosed with mpMRI targeted biopsies in 
12.7% of men comparing to only systematic biopsies, while systematic biopsies 
diagnosed additional GGG ≥ 2 PCas in 5.8% of men, comparing to only mpMRI 
targeted biopsies (Ahdoot et al., 2020). Additionally, new insPCas (GGG 1) were 
diagnosed in 3.5% of men with mpMRI targeted biopsies and 7.8% of men with 
systematic biopsies (Ahdoot et al., 2020). All the differences were statistically 
significant. The overall prevalences of PCa and CSPCa in the study biopsies were 
62.4% and 43.7%, respectively (Ahdoot et al., 2020). 
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In a meta-analysis of 48 included studies, Moldovan et al. investigated NPV of 
mpMRI in ruling out CSPCa (Moldovan et al., 2017). In the study, the median NPV 
for CSPCa was 88.1% while significant cancer prevalence median was 32.9% 
(Moldovan et al., 2017). The meta-analysis presented the commonly known fact, that 
when cancer prevalence decreases, NPV increases: in the analysis, when overall PCa 
prevalence was 50%, mpMRIs NPV and PPV was 0.76 and 0.64, while PCa 
prevalence was 30%, NPV and PPV was 0.88 and 0.43 in detection on CSPCa, 
respectively (Moldovan et al., 2017). However, there was great variation in the 
definitions of CSPCa in addition to the study protocol and reference standards 
(Moldovan et al., 2017). 
In a meta-analysis by Kasivisvanathan et al., DRs of MRI-guided biopsies to 
TRUS-guided systematic biopsies were compared (Kasivisvanathan et al., 2019). In 
the paired data cohort of 56 studies, the DR of Gleason ≥ 3+4 PCa was 1.09 (p=0.018) 
which favors slightly, but statistically significantly MRI-guided biopsies in 
sensitivity; however, the DR increases with a stricter definition of CSPCa 
(Kasivisvanathan et al., 2019). More evident results were seen in DRs of insPCa 
defined as Gleason 3+3: in the analysis of 46 paired data cohorts, DR for insPCa was 
0.74 (p<0.0001) favoring MRI-targeted biopsies (Kasivisvanathan et al., 2019). The 
proportion of men with CSPCa missed by MRI targeted biopsies, but detected by the 
addition of systematic biopsies in the analysis of 56 studies, was 13% (p<0.0001) 
(Kasivisvanathan et al., 2019). Similar results are seen in the mentioned study of 
Ahdoot et al., where in the analysis of 404 whole mount prostatectomy specimens, 
GGG was upgraded to ≥ 2 in 18.3% of MRI targeted biopsies and in 30.2% of 
systematic biopsies while only in 6.7% of combination biopsies a GGG was upgraded 
to ≥ 2 (Ahdoot et al., 2020). These results indicate that MRI targeted and systematic 
biopsies might diagnose different CSPCas, however, targeting errors should be also 
taken into account. 
In a Cochrane meta-analysis of Drost et al., the authors concluded that prostate 
MRI with or without targeted biopsies has the most favorable accuracy in CSPCa 
detection while the DR of insPCa is reduced (Drost et al., 2019). In the meta-analysis, 
a pooled analysis was made concerning the studies comparing MRI targeted biopsies 
to systematic biopsies using template-guided mapping biopsies as a reference standard 
in CSPCa (Gleason ≥ 7) detection (Drost et al., 2019). In the analysis, using a baseline 
prevalence of 30%, pooled sensitivity and specificity of MRI targeted biopsies were 
0.80 and 0.94, respectively, while sensitivity of systematic biopsies was 0.63 (Drost 
et al., 2019). 
MRI-targeted biopsies are commonly taken using the cognitive approach or MRI-
TRUS-fusion where the MRI-suspicious lesion in the prostate is marked by the 
radiologist and is visible real-time in TRUS. Also, biopsies can be taken in the MRI-
scanner (in-bore target biopsies). However, there is no evidence of significant 
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difference in CSPCa detection between the methods (Monda et al., 2018; Rouvière et 
al., 2019; Wegelin et al., 2019). 
As a conclusion, there is high-quality evidence about the mpMRI’s great 
sensitivity for CSPCa and tendency to discriminate insPCas, still standard biopsies 
find CSPCas that are not visible in mpMRI. However, the specificity measures should 
also be taken into account. As Table 5 clearly presents, even the highest suspicion 
level is not definitely a guarantee for CSPCa, and in the mentioned studies, PPV of 
mpMRI is low. Obviously, targeting errors should be considered. 
2.3.3 Biparametric MRI protocol 
Biparametric MRI (bpMRI) is performed without a contrast medium, thus it includes 
only T2W and DWI sequences. The benefits of the bpMRI protocol are a faster MRI 
scanning process, mainly due to the lack of need for intravenous access and also due 
to a shorter interpretation time. In addition, the use of gadolinium contrast medium in 
mpMRI and gadolinium deposits on the brain have been under discussion; however, 
there are no reliable data regarding its clinical or biological significance, if any 
(Gulani et al., 2017). In the study of Porter et al., time reserved for an mpMRI scan is 
45 min, and the average interpretation time is about 21 min (Porter et al., 2019). 
Correspondingly, the time reserved for bpMRI is 15 min and the average 
interpretation time is about 16 min (Porter et al., 2019). While the significance of DCE 
is under debate, bpMRI appears to be an attractive alternative to mpMRI due to its 
rapid and thus more cost-effective imaging protocol (Porter et al., 2019).  
According to the PI-RADS version 2.1, bpMRI and mpMRI have no difference in 
grading of transitional zone lesions, however peripheral zone lesions graded to PI-
RADS version 2.1 score 3 cannot be upgraded to 4 in bpMRI, which will impact the 
ratio of PI-RADS 3/4 (American College of Radiology®, 2019). While mpMRI is still 
the gold standard of prostate imaging, further research is needed to validate bpMRI’s 
position in diagnostics of PCa (American College of Radiology®, 2019). However, 
the PI-RADS steering committee recommends mpMRI over bpMRI in men with high 
and/or prevailing suspicion of CSPCa, after prostatic interventions or 5ARI therapy, 
or patients with hip implantation or other considerations that are expected to yield 
degraded DWI (American College of Radiology®, 2019). 
Biparametric MRI and mpMRI have been compared in various studies. Di Campli 
et al. retrospectively compared bpMRI and mpMRI (Di Campli et al., 2018). In the 
study (n=85), CSPCa was defined as Gleason ≥ 7 and its prevalence was 48%, while 
systematic biopsies (42/85) or a prostatectomy specimen (43/85) was used as a 
reference standard (Di Campli et al., 2018). There were no significant differences in 
AUC values between the mpMRI and bpMRI in diagnostics of CSPCa (Di Campli et 
al., 2018). Additionally bpMRI and mpMRI were compared among three radiologists 
with a different grade of experience using PI-RADS version 2 reporting system: In 
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the analysis, there were no significant differences within the imaging method used 
between AUC values of the most experienced reader comparing to the less 
experienced in the diagnostics of CSPCa (Gleason score ≥ 7) (Di Campli et al., 2018). 
In the study of Schimöller et al., 235 MRI scanned men were retrospectively 
included in the study, where in-bore biopsies of 200 lesions from 115 included men 
were analyzed (Schimmöller et al., 2014). In the analysis, AUC values for T2W+DWI 
and T2W+DWI+DCE in diagnostics of significant (Gleason ≥ 4+3) PCa in lesion 
level were 0.847 (95% CI 0.798–0.895) and 0.871 (95% CI 0.832–0.911), 
respectively, i.e. no statistically significant differences were detected between bpMRI 
and mpMRI methods (Schimmöller et al., 2014). Additionally, differences between 
the methods were also statistically insignificant when comparing the detection of 
transitional and peripheral zone lesions (Schimmöller et al., 2014). 
Biparametric MRI have also been investigated in a high-quality setting. In a 
prospective, single-institutional BIDOC study (n=1020), all included men underwent 
bpMRI and systematic TRUS-guided biopsies were taken (Boesen et al., 2018). 
Additional targeted TRUS-MRI-fusion guided biopsies were taken from men with 
PCa suspicious (modified PI-RADS version 2 score 3–5) lesions present in bpMRI 
(Boesen et al., 2018). In the study, standard biopsy strategy (all men, only systematic 
biopsies taken) were compared to the combined biopsy strategy (men with a 
suspicious lesion in MRI present and systematic+targeted biopsies taken) (Boesen et 
al., 2018). In the study, 70% of men had suspicious lesions present in MRI and thus 
combination biopsies were taken (Boesen et al., 2018). There were no statistically 
significant differences in the amount of CSPCa (Gleason ≥ 3+4) diagnosed in the 
patient subgroup with combined biopsies, comparing to standard biopsy results of a 
whole study cohort, while the total CSPCa prevalence was 47% (Boesen et al., 2018). 
Additionally, significantly less insPCas were diagnosed with combined biopsy 
strategy (relative difference -42%, 95% CI -53% to -28%) (Boesen et al., 2018). 
When a more strict definition for a CSPCa (Gleason ≥ 4+3) was used, significantly 
more CSPCas were diagnosed with the combined biopsy strategy cohort (relative 
difference 11%, 95% CI 0.6% to 21%) and significantly less insPCas were diagnosed 
(relative difference -40%, 95% CI -49% to -29%) (Boesen et al., 2018). The NPVs for 
CSPCa with the definitions of Gleason ≥ 3+4 and Gleason ≥ 4+3 of bpMRI targeted 
biopsies were 93% and 97%, respectively, when combined biopsies to all men were 
used as a reference standard (Boesen et al., 2018). 
2.3.4 Diagnostic performance of MRI combined with 
additional parameters 
Recommendations of the EAU guidelines for patient selection prior initial prostate 
biopsies are presented in more detail in Chapter 2.2.1: Guidelines for primary 
diagnostics and risk stratification. 
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Even the EAU guidelines recommend mpMRI prior initial biopsies when there is 
a suspicion of a CSPCa, considering the well-known issues in PCa diagnostics, 
including the lack of cut-off value for PSA in ruling out CSPCa, poor sensitivity of 
DRE in addition to the risk for biopsy complications and diagnosing insPCas, the 
question about relevant patient selection for prostate biopsies is still open. In 
summary, the question is: is there some objective way to omit systematic biopsies, 
when the level of suspicion in MRI is low or equivalent and conversely, is there some 
subgroup of patients, whose negative MRI is not excluding CSPCa in an acceptable 
probability? Additional clinical parameters provide an interesting approach to the 
mentioned issues. 
PSA density might be the most investigated additional parameter to be used in 
combination with MRI. In a large, prospectively collected cohort, Distler et al. 
investigated PSA density in combination of mpMRI in ruling out CSPCa (Gleason ≥ 
7) (Distler et al., 2017). In the study, there was statistically significant improvement 
in AUC values to PI-RADS scoring in a combination of PI-RADS + PSA density 
(AUC 0.752 vs. AUC 0.789) (Distler et al., 2017). Also NPV of negative mpMRI (PI-
RADS < 3) in ruling out CSPCa was analyzed in PSA density groups of <0.07 
ng/ml/ml, 0.07–0.15 ng/ml/ml and >0.15 ng/ml/ml: the NPV of whole cohort was 
79.4%, while it increased to 88.9% in PSA density group 0.07–0.15. However, the 
prevalence of CSPCa in the whole cohort was 43.4% and in the mentioned subgroup 
24% (Distler et al., 2017). 
Boesen et al. investigated using the previously described BIDOC dataset an 
optimal biopsy strategy to biopsies using PSA density and bpMRI score (Boesen et 
al., 2019). In a decision curve analysis (DCA), the best strategy was restricting 
biopsies to men with (modified) PI-RADS version 2 score of 4–5 or PSA density ≥ 
0.15 ng/ml/ml (Boesen et al., 2019). Using this strategy, NPV for CSPCa (Gleason ≥ 
7) was 0.96 and the strategy would reduce prostate biopsies by 41% missing a CSPCa 
in 5% of men (Boesen et al., 2019). 
In a study of Panebianco et al., large surveillance data was analyzed concerning 
patients with non-suspicious mpMRI (PI-RADS 1–2) (Panebianco et al., 2018). In 
biopsy naïve men, CSPCa diagnosis-free survival probability at 24 months was 95%, 
and the values remained unchanged at 48 months, while the median follow up time 
was 38 months (Panebianco et al., 2018). The statistically significant predictors for 
having CSPCa during the follow-up period were increasing PSA, PSA density and 
age, however, the previous biopsies did not increased the risk (Panebianco et al., 
2018). In the study, PCa was defined as insignificant if active surveillance criteria 
were fulfilled, or PCa was defined as low risk stage in the prostatectomy specimen 
(Panebianco et al., 2018). 
Thompson et al. prospectively investigated the NPV of mpMRI (PI-RADS < 3) in 
combination with PSA and DRE using transperineal mapping biopsies or radical 
prostatectomy specimen as a reference standard (Thompson et al., 2016). Significant 
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PCa was defined as Gleason score 7–10 with greater than 5% having Gleason grade 
4, 20% or more cores positive, or 7 mm or more PCa in any core, while the prevalence 
of CSPCa were 41.6% (Thompson et al., 2016). In the study (n=344), NPV of mpMRI 
for ruling out CSPCa were 92% in a whole cohort, while among a subgroup of men 
with prebiopsy PSA > 10.0 ng/ml or abnormal DRE, NPV of mpMRI was even 100%, 
while 11% of men would have been avoided biopsies without missing any CSPCa 
(Thompson et al., 2016). However, patients with normal DRE and a PSA less than 
10.0 ng/ml, the NPV of mpMRI were 90% in ruling out CSPCa (Thompson et al., 
2016). 
In the previously described MRI-FIRST study, the authors made an additional 
analysis to compare CSPCa detection rates of systematic and targeted biopsies in 
various clinical subgroups (Rouvière et al., 2019). In the analysis of clinical stage, 
PSA (cut-off 10 ng/ml), prostate volume (cut-off 50 ml), and cognitive/fusion 
guidance, no statistically significant difference in detection rates of CSPCa were 
found (Rouvière et al., 2019). 
As a conclusion, the prior studies give no unanimous answer, which patients could 
safely avoid biopsies after a negative MRI or in case of an equivalent MRI suspicion. 
However, PSA with its derivates seems to be the most promising approach. Again, 
the studies cited in this review quite coherently present that NPV decreases when 
prevalence increases. 
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3 Aims of the study 
Novel imaging methods are now changing diagnostics of PCa almost as radically as 
the invention of PSA did in the late 1980s. Also, analogously with the introduction of 
PSA, prostate MRI, especially in initial PCa diagnostics, is still seeking its position as 
a part of modern PCa diagnostics. Even though the recent studies have demonstrated 
very good NPV of prostate MRI in ruling out CSPCa and its trend to discriminate 
insPCas, initial PCa diagnostics based only on MRI targeted biopsies without 
systematic biopsies are not yet a viable practice and the question about patient 
selection for biopsies is still open. Considering the risk of biopsy complications, 
emerging antibiotic resistance and unnecessary and even harmful diagnoses of 
insignificant cancers, ideally the PCa diagnostics should shift towards the lesion-
based approach, thus reducing the need for unnecessary biopsies.  
This doctoral thesis consists of five studies (below: “Study I–V”). Specifically, 
the aims of the studies are to 
• survey the prevalence of TRUS-Bx complications, 
• survey the prevalence and risk factors for intestinal E. coli antibiotic 
resistance in men undergoing prostate biopsies, 
• validate the bpMRI score and PSA density combination strategy in 
selecting men for prostate biopsies, 
• investigate the impact of prebiopsy prostate bpMRI on the prevalence of 
CSPCa in an initial biopsy session, and 
• investigate the NPV of IMPROD bpMRI as a whole and in clinical 
subgroups. 
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4 Patients and methods 
4.1 Study population 
The study population for the five substudies of this doctoral thesis is from four 
prospective, registered trials conducted in Turku University Central Hospital (TYKS) 
between 2013–2017, investigating an IMPROD bpMRI protocol and IMPROD Likert 
scoring system in PCa diagnostics, as described more detail in Table 6 and below. In 
addition, a control cohort was retrospectively collected to Study IV.  
Table 6. Details of prospective studies used in this doctoral thesis. 
study Clinicaltrials.gov 
identifier 
n essential inclusion 
criterias 
essential exclusion criterias 
IMPROD NCT01864135 175 suspicion of a PCa 
based on PSA level of 
2.5–20 ng/ml or 
abnormal DRE 
previous prostate biopsies 
within 6 months, previous 
prostate surgery or previous 
PCa diagnosis 
MULTI-
IMPROD 
NCT02241122 364 suspicion of a PCa 
based on PSA level of 
2.5–20 ng/ml or 
abnormal DRE 
previous prostate biopsies 
within 6 months, previous 
prostate surgery or previous 
PCa diagnosis 
IMPROD2.0 NCT02844829 69 suspicion of a PCa 
based on PSA level of 
2.5–20 ng/ml or 
abnormal DRE 
previous prostate biopsies, 
previous prostate surgery or 
previous PCa diagnosis 
PROMANEG NCT02388126 257 suspicion of a PCa 
based on PSA level of 
2.5–20 ng/ml or 
abnormal DRE and/or 
previous negative 
prostate biopsies. Also 
patients in active 
surveillance of PCa 
were included. 
 
 
In a prospective, single center IMPROD trial, prebiopsy IMPROD bpMRI and 
IMPROD Likert scoring system in diagnostics of CSPCa were investigated. 
Systematic biopsies were performed on all the included patients. In addition, on men 
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with an IMPROD bpMRI Likert scored 3–5 lesion in IMPROD bpMRI, additional 
lesion-targeted biopsies were performed. 
A prospective, multicenter MULTI-IMPROD trial was conducted in four centers 
in Finland. The aim of the trial was to validate the results of the IMPROD trial in a 
multicenter setting. In the study, systematic biopsies were performed on all the 
included patients. In addition, on men with IMPROD bpMRI Likert score 3–5 lesions 
in IMPROD bpMRI, additional lesion-targeted biopsies were performed. The men 
included in the study filled in a detailed questionnaire form concerning their medical 
history, medication, smoking, recent traveling and recent antibiotic usage. In addition, 
in a prostate biopsy session, rectal swab samples were taken, and the samples were 
cultured in a microbiology laboratory to discover the antibiotic resistance profile of 
intestinal E. coli. 
In a prospective, single-center, IMPROD2.0 trial, prebiopsy IMPROD bpMRI and 
IMPROD bpMRI Likert scoring system in diagnostics of CSPCa was investigated. 
Systematic biopsies were performed on the all included patients. In addition, on men 
with an IMPROD bpMRI Likert scored 3–5 lesion in IMPROD bpMRI, additional 
lesion-targeted biopsies were performed. 
In a prospective, single-center, PROMANEG trial, prebiopsy IMPROD bpMRI 
and IMPROD bpMRI Likert scoring system were investigated in diagnostics and also 
in active surveillance of PCa. According to the study protocol, systematic biopsies 
were performed on all the included patients. In addition, from men with an IMPROD 
bpMRI Likert score 3–5 lesion in IMPROD bpMRI, MRI-targeted biopsies were 
taken. 
The population of Study I and Study II is based on the MULTI-IMPROD trial. 
Study III is based on the population of both the IMPROD and MULTI-IMPROD 
trials. In Study I and in a risk factor analysis of Study II, only patients with a full 
data available (questionnaire form and cultured rectal swab sample) were included. 
Study IV is based on a population of all the previously described four studies. 
However, patients with prior PCa diagnosis or prior prostate biopsies were 
excluded. In addition, a control cohort was retrospectively collected for the study 
from a patient registry using a prostate biopsy laboratory code and PSA level under 
20 ng/ml as a criteria in a search algorithm, aiming to collect comparable patients 
who had initial prostate biopsies taken in TYKS between 2010–2013, i.e. prior the 
clinical use of prostate MRI. Study V is also based on the population of all the 
described four studies. However, patients with a prior PCa diagnosis were 
excluded. 
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4.2 Study methods 
4.2.1 MRI protocol and reporting system 
In all four MRI studies, the IMPROD bpMRI protocol and IMPROD bpMRI Likert 
scoring system was used, which has been developed in TYKS since 2013. The 
IMPROD bpMRI protocol and IMPROD Likert bpMRI reporting system are public 
and freely available on the study server. 
IMPROD bpMRI was performed using body array coils (no endorectal coil) and 
3 Tesla MRI scanners in Turku (Verio, Siemens), Tampere (Skyra, Siemens), Helsinki 
(Skyra, Siemens), while a 1.5T (Aera, Siemens) MRI scanner was used in Pori. The 
imaging consisted of T2W acquisitions in axial and sagittal planes, three separate 
DWI and corresponding calculated ADC maps fitted using mono-exponential fit. 
Dynamic contrast enhanced imaging was not performed, thus an intravenous contrast 
agent was not used. Diffusion weighted imaging datasets were collected in three 
separate acquisitions: 1) b-values 0,100,200,300,500 s/mm2; 2) b values 0, 1500 
s/mm2; 3) values 0, 2000 s/mm2. The imaging protocol was carefully optimized to 
allow comparable image quality at 1.5T and at 3T. The overall imaging time using 3T 
scanners was 13–17 minutes including shimming and calibration while the 
corresponding time at 1.5T was about 3 minutes longer. Only routinely available 
magnetic resonance acquisition and post-processing methods were used. Patients have 
a rectal enema prior the MRI scan. 
All imaging data sets were reported using a five-step tiered IMPROD bpMRI 
Likert scoring system by a local radiologist and confirmed centrally by one designated 
central reader with six years of experience in prostate MRI in the beginning of the 
first IMPROD trial, to guarantee reporting integrity before each biopsy procedure. 
IMPROD bpMRI Likert scoring system is very similar to PI-RADS version 2.1, 
however the final IMPROD bpMRI Likert score is not based on an arithmetical 
combination of ratings for each method (T2W, DWI), but the “overall impression 
score” of a lesion to be a significant cancer or not. IMPROD bpMRI Likert scoring 
system does not include additional clinical data. 
The central reader was unaware of all clinical data. In all the studies, the prostate 
volume was primarily estimated with TRUS. The cognitive biopsy targeting method 
was mainly used in all the studies, with the exception of one center in the MULTI-
IMPROD trial, where MRI-TRUS fusion was used (n=58). The prostate volume was 
estimated using TRUS with the exception of 17 cases, where MRI based volume 
estimation was used due TRUS based prostate volume estimation was not reported. 
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4.2.2 Antibiotic susceptibility testing 
During the TRUS-Bx procedure in MULTI-IMPROD trial, fecal samples were 
collected with sterile rectal swab (Copan floq swab). Fecal swabs were sent to the 
Medical microbiology laboratory for culturing. The samples were directly cultured on 
a CHROMagar™ Orientation plate. A ciprofloxacin disc (Oxoid, 5 µg) was added on 
top of the plate to select the patient’s most resistant bacteria. The plates were 
incubated over night at +35 °C. The following day, the most resistant E. coli strain 
was selected for pure culture, i.e. a pink or dark rose colony nearest to the 
ciprofloxacin disc. Antimicrobial susceptibility testing of E. coli isolates was 
performed with the disc diffusion method using Oxoid susceptibility discs (Thermo 
Scientific, Helsinki, Finland). Susceptibility was tested against ampicillin (10µg), 
amoxicillin-clavulanic acid (30µg), mecillinam (10µg), cefoxitin (30µg), cefotaxime 
(5µg), ceftazidime (10µg), meropenem (10µg), ciprofloxacin (5µg), gentamicin 
(10µg), nitrofurantoin (100µg), trimethoprim (5µg) and trimethoprim-
sulphamethoxazole (25µg) on Mueller-Hinton agar (Oxoid, Thermo Scientific, 
Helsinki, Finland) plates according to EUCAST criteria (The European Committee on 
Antimicrobial Susceptibility Testing, 2017). Ciprofloxacin-resistant strains 
(inhibition zone <24 mm) were re-tested and resistance to fluoroquinolones was 
confirmed with nalidixic acid (30µg), levofloxacin (5µg) and pefloxacin (5µg) discs.  
Isolates showing reduced susceptibility to cefotaxime and ceftazidime (inhibition 
zone <21 mm and <22 mm, respectively) were tested for ESBL production with the 
combination disc test (Rosco ESBL and AmpC confirmation Kit, Rosco, Denmark). 
Bacterial strains were incubated with cefotaxime and cefotaxime-clavulanic acid as 
well as ceftazidime and ceftazidime-clavulanic acid discs. If the inhibition zone 
around the antimicrobial disc with clavulanic acid was ≥5 mm greater than the 
inhibition zone around the antimicrobial disc without clavulanic acid, the strain was 
determined to be an ESBL producer. In this study, E. coli strains with 3CEF resistance 
were used instead of ESBL production in all analysis. 
Before collecting the rectal swab samples and a TRUS-Bx procedure, antibiotic 
prophylaxis was administered according to the guidelines of each research center. 
EUCAST guidelines for determining antimicrobial susceptibility are updated 
annually. In the risk factor analysis, the most recent EUCAST 2017 clinical 
breakpoint criteria was used (The European Committee on Antimicrobial 
Susceptibility Testing, 2017). As the criteria for defining fluoroquinolone resistant E. 
coli strains changed remarkably in the latest EUCAST update, we analyzed 
fluoroquinoloneresistance rates in E. coli strains also according to the prior EUCAST 
criteria (The European Committee on Antimicrobial Susceptibility Testing, 2016). 
The definition of 3CEF resistance of E. coli did not change during the study period. 
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4.2.3 Methods of the individual studies 
Study I 
In the study, we aimed at prospectively investigating the prevalence and risk factors 
for biopsy complications in men undergoing TRUS-Bx. After an MRI scan, the 
included men underwent TRUS guided systematic biopsies in addition to 2–4 lesion-
targeted biopsies, if suspicious lesions were present in the MRI. During the biopsy 
session, patients had antibiotic prophylaxis according to the local guidelines, and it 
was prospectively registered in detail. After a follow-up period of 30 days, 
complications following the TRUS-Bx were collected from medical records and 
analyzed with the data from the questionnaire form and determined antibiotic 
resistance profile of E. coli in the rectal swab sample. Rectal bleeding, urinary 
infections, hematuria, and other urinary symptoms leading to an emergency 
department visit, were registered as biopsy related complications. The prevalence of 
complications was analyzed in clinical subgroups of prostate volume, age, diabetes 
and anticoagulation/antiplatelet therapy, which was selected on the basis of a clinical 
experience and prior studies. 
Study II 
In the study, we aimed to prospectively determine the prevalence and risk factors for 
antibiotic resistance of intestinal E. coli in men undergoing TRUS-Bx. During a 
biopsy session, rectal swab samples were taken and cultured in a microbiology 
laboratory to determine the antibiotic resistance profile of E. coli. In the study, we 
analyzed resistance for fluoroquinolones and 3CEF resistance, as well as the ESBL 
production of the E. coli stains. Fluoroquinolone susceptibility was reported in 
categories ”susceptible”, ”intermediate susceptible” and ”resistant” using the criteria 
of The European Committee on Antimicrobial Susceptibility Testing from 2017 and 
additional analyses were made using the mentioned criteria valid to 2016, due to 
remarkable changes of the fluoroquinolone susceptibility criteria in the time of the 
manuscript publication (The European Committee on Antimicrobial Susceptibility 
Testing, 2016, 2017). In the risk factor analysis, we used the data from the 
questionnaire form and medical records, and analyzed with the determined antibiotic 
resistance profile of E. coli.  
The patients without E. coli growth in the rectal swab sample were analyzed as 
fluoroquinolone susceptible in the risk factor analysis. E. coli strains as well as 
fluoroquinolone resistant and intermediate resistant E. coli strains were analyzed 
together as one variant. 
The risk factor categories were selected on the basis of earlier studies and clinical 
experience. The risk factor categories were international traveling during the last year, 
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being a current smoker or quitted smoking during the last two years, antibiotic therapy 
during the last year, diabetes, and age. The majority of the patients did not recall the 
specific name of the antibiotic used. As the study consent did not allow us to review 
study patients’ antimicrobial prescriptions, the data on antimicrobial usage was based 
on the patients’ recollections of their previous antimicrobial courses. Therefore, the 
previous use of antibiotics was analyzed as a whole, without dividing into different 
antibiotic classes. 
Study III 
In the study, we aimed at validating the optimal method combination strategy of PSA 
density and bpMRI score for selecting men to prostate biopsies, which was presented 
by Boensen et al. (Boesen et al., 2019). In this retrospective external validation study, 
we used our prospectively collected data and performed similar statistical analyses as 
in the validated study, which are described in more detail in chapter 4.3: Statistical 
analysis. In the study, CSPCa were defined as Gleason score ≥ 7 in any biopsy core 
(standard or targeted) taken. The prostate volume was estimated using TRUS, with 
the exception of 17 cases where MRI based volume estimation was used due TRUS 
based prostate volume estimation was not reported. 
Study IV 
In the study, we analyzed the rate of CSPCa from biopsies taken in an initial biopsy 
session among men undergoing prebiopsy prostate MRI and systematic prostate 
biopsies with additional lesion-targeted biopsies. Using follow-up data, we also 
investigated the delay and number of biopsy sessions performed for diagnosis of 
CSPCa. With a retrospectively collected control cohort of men, whose initial biopsies 
were taken prior to clinical use of prostate MRI, we determined the clinical 
significance of prostate MRI in the PCa diagnostics comparing it to the traditional 
diagnostic protocol. In the study, CSPCa was defined as Gleason score ≥ 7 in any 
individual biopsy core taken, combining targeted and systematic biopsies.  
Study V 
In the study, we aimed at determining in a prospectively collected cohort, an NPV 
of IMPROD bpMRI and IMPROD Likert scoring system in ruling out CSPCa. In an 
additional analysis, we investigated NPV of IMPROD bpMRI in various clinical 
subgroups. We also analyzed other performance measures of IMPROD bpMRI in 
CSPCa diagnostics in addition to AUC values for IMPROD Likert scoring system as 
presented in more detail in chapter 4.3 Statistical analysis. In the study, CSPCa was 
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defined as Gleason score ≥ 7 in any individual biopsy core taken, combining targeted 
and standard biopsies. 
4.3 Statistical analysis 
Study I 
Patient characteristics were summarized using descriptive statistics. Prevalence of 
complications during the follow up period were analyzed as a whole and divided to 
subclasses of infectious complications, rectal bleeding, hematuria, and urinary 
retention. Due to the low amount of biopsy-related complications, a further risk factor 
analysis was not made. Antibiotic susceptibility of E. coli was reported as prevalence 
rates. 
Study II 
Patient characteristics were summarized using descriptive statistics. Prevalence of E. 
coli growth, its fluoroquinolone and 3CEF resistance in patient level, were described 
in total and dividing to individual results from the included study centers. Also, the 
prevalence of ESBL producing strains was reported. 
Risk factors for having a fluoroquinolone or 3CEF resistant E. coli strain were 
analyzed using odds ratios (OR) with 95% CIs derived from univariate and 
multivariate logistic regression analysis. Statistical significance was defined as 
p<0.05. Binary variables in the risk factor analysis were international traveling during 
the last year, being a current smoker or quitted smoking during the last two years, 
antibiotic therapy during the last year and diabetes, and a continuous variable was age. 
The statistical analyses were made with IBM SPSS Statistics for Windows, Version 
22.0 (IBM Corp. Released 2013. Armonk, NY). 
Study III 
Patient characteristics were grouped according to the biopsy results and summarized 
using descriptive statistics. The Wilcoxon rank-sum test was used to compare no 
PCa/insPCa against CSPCa for continuous variables. The chi-squared test for 
homogeneity was used to assess the difference between no PCa/insPCa and CSPCa 
within the same PSA density groups as defined in the validated study. The 
combination of IMPROD bpMRI Likert score with PSA density thresholds was 
evaluated using a chi-squared test to determine the effect of PSA density as predictive 
value within each IMPROD bpMRI Likert score group. 
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The sensitivity, specificity, PPV, NPV and Youden’s J index (sensitivity + 
specificity - 1) were calculated to evaluate various IMPROD bpMRI Likert score and 
PSA density thresholds for detecting and ruling out CSPCa. Furthermore, net benefit 
analysis for biopsy strategies that combined IMPROD bpMRI Likert score with PSA 
density thresholds was performed to compare the benefit of detecting CSPCa against 
the risk of unnecessary biopsies. A DCA for all proposed biopsy strategies was carried 
out using thresholds’ probabilities ranging from 0% to 25% (Vickers et al., 2016). 
Statistical analysis was conducted using R v. 3.4.3 software (R Foundation for 
Statistical Computing, Vienna, Austria). Results with a two-sided p<0.05 was 
considered statistically significant. 
Study IV 
Patient baseline characteristics and follow up times were summarized separately in 
the both study cohorts (MRI group and non-MRI group) using descriptive statistics 
and the significance of differences between the study groups was calculated using 
Pearson’s chi-square test for nominal variables and with an independent samples T-
test for continuous variables. Descriptive statistics and Pearson’s chi-square test were 
also used to compare the study group’s initial biopsy results and biopsy/prostatectomy 
results during the follow up. All the pathology results were divided using GGGs. 
Delay to CSPCa diagnosis during the follow-up was presented using a Kaplan-
Meier graph, restricting it to the data of the first two years due to a significant 
difference in length of follow-up periods between the study groups. Statistical 
significance was defined as p<0.05 in all analyses. All the statistical analysis was 
made with SPSS version 24 for Windows (IBM Corp., Armonk, N.Y., USA). 
Study V 
Patient characteristics were summarized using descriptive statistics. Prevalence of 
PCa and CSPCa were also summarized using descriptive statistics, and an AUC value 
for IMPROD bpMRI Likert scoring system was determined for the whole study cohort 
and additionally for subcohorts of the four included studies. Performance measures 
(NPV, PPV, specificity, sensitivity) of IMPROD bpMRI for CSPCa were determined 
in suspicion levels of IMPROD bpMRI Likert 3–5 and IMPROD bpMRI Likert 4–5 
for the whole study cohort and additionally for subcohorts of the four included studies. 
The study population was divided to subgroups of PSA level, PSA density, 
prostate volume, free PSA/PSA ratio, age, history of previous biopsies, and 5ARI 
medication. The dichotomizing cut-off values for continuous variables were 
determined by mean value of the study cohort in age and free PSA/PSA ratio. In PSA, 
prostate volume and PSA density, the most dichotomizing cut-off values were 
determined by dividing the patients in value groups and analyzing the NPV in a 
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suspicion level of IMPROD Likert 4–5 separately in the different groups. The 
performance measures of IMPROD bpMRI for CSPCa were determined in all the 
subgroups separately in suspicion levels of IMPROD Likert 3–5 and IMPROD Likert 
4–5. Statistical significance was defined as p<0.05. 
The data analyses were performed using JMP Pro version 13 for Windows (SAS 
Institute Inc., Cary, N.C., USA) in exception of the ROC analysis which was made 
using SPSS version 24 for Windows (IBM Corp., Armonk, N.Y., USA). The 
performance measures were determined with IVD performance add-in v12.0 for JMP. 
4.4 Ethics 
All the four included prospective studies were conducted in compliance with the 
current revision of the Declaration of Helsinki guiding physicians and medical 
research involving human subjects (64th World Medical Association General 
Assembly, Fortaleza, Brazil, 2013). Prior to commencement of each of the studies, 
the study protocol, the patient information sheet and the informed consent form were 
approved by the ethics committee of the Hospital District of Southwest Finland. 
Patient data from the patient registry for the control cohort of Study III were collected 
with a permission of the Hospital District of Southwest Finland. 
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5 Results 
5.1 Study I 
In Study I, we aimed at surveying the prevalence of TRUS-Bx complications. In total, 
359 patients were recruited to the study. However, 294 biopsied patients with a 
cultured microbiological sample and full data available were included in the final 
analysis (Figure 3). Table 7 presents the characteristics of the study cohort. 
Figure 3.  Flowchart of the patient inclusion to the final analysis. 
 
Table 7.  Study patient characteristics. 
 
Included (294) 
age, mean (range) 64 (29–82) years 
PSA, mean (range) 7.6 (1.4–30.0) ng/ml 
prostate weight, mean (range) 45 (14–131) g 
5ARI medication (%) 30 (10%) 
alpha blocker therapy (%) 38 (13%) 
diabetes (%) 34 (12%) 
anticoagulation/antiplatelet therapy (%) 52 (18%) 
 
 
 
 
 
 
 
 
 
 
 
359 patients recruited 
to the study 
 
294 patients were 
included in the final 
analysis 
 
338 patients 
 
307 patients 
 
21 was not biopsied due to 
inclusion/exclusion criteria or 
the patients refused from the 
biopsies 
 31 were excluded due to 
missing questionnaire form 
 
13 patients were excluded due 
to missing microbiological 
sample 
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All biopsy-related complications leading to physical contact to a health care unit that 
occurred during the 30-day follow-up period are listed in Table 8. The total rate of 
complications was 4.1% (12/294). 
No septic or other infectious complications requiring hospitalization followed the 
TRUS guided biopsies during the follow-up period. Only two minor urinary tract 
infections occurred, and they were treated with per oral antibiotics in an outpatient 
setting. Both patients received fluoroquinolone-based prophylaxis prior to biopsies. 
One of them had an E. coli strain with reduced fluoroquinolone susceptibility in the 
pre-biopsy rectal swab culture. 
Significant hematuria occurred in seven study patients and rectal bleeding in one 
study patient. Two out of 52 patients with anticoagulation/antiplatelet medication 
(3.8%) had a bleeding complication. The rate of bleeding without 
anticoagulation/antiplatelet use was 2.5% (6/242).  
Three patients experienced an urinary retention. One study patient visited an 
emergency department due to urinary discomfort symptoms but without a diagnosed 
infection or a urinary retention. No mortality during the follow-up period was 
observed. Only one patient was hospitalized during the follow-up period (hematuria 
complication). 
Table 8. Complications related to prostate biopsies leading to a visit to a health care unit within 30 
days follow-up period after a TRUS-Bx. There was no mortality and only one patient was 
hospitalized during the follow-up period (hematuria complication). 
 total (% of study population) 
any complication 12/294 (4.1%)1 
infection 2/294 (0.7%) 
rectal bleeding 1/294 (0.3%) 
urinary retention 3/294 (1.0%) 
hematuria 7/294 (2.4%) 
1 One patient had both hematuria and urinary retention.  
The antibiotic prophylaxis given to the patients was based on guidelines of each 
institution and is summarized in Table 9. Fluoroquinolone based antibiotic 
(ciprofloxacin or levofloxacin) was the most common prophylactic antibiotic and it 
was administered to 97% (284/294) of the patients. Ten patients had fosfomycin and 
one patient had fosfomycin + ciprofloxacin as a prophylactic antibiotic. Antibiotic 
prophylaxis was compared with the results of the cultured E. coli fluoroquinolone and 
fosfomycin susceptibility profiles of the rectal swab samples. From this point of view, 
only 89% (262/294) of the study patients got an effective antibiotic prophylaxis 
against their intestinal E. coli pathogens. Interestingly, all patients who had 
fosfomycin as an antibiotic prophylaxis had either fosfomycin susceptible E. coli or 
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no E. coli growth in the rectal swab sample. The rate of fluoroquinolone resistant E. 
coli strains in patients with fosfomycin as an antibiotic prophylaxis was 36% (4/11). 
Table 9. Antibiotic prophylaxis given to the study patients. Antibiotic prophylaxis was administered 
according to the guidelines of each center.  
  mean time No E. coli growth or 
cultured E. coli strain in 
rectal swab sample 
susceptible to given 
prophylactic antibiotic (%)   n 
before 
biopsies 
after 
biopsies 
levofloxacin 500 mg 1x1 3 32 min   3 / 3 (100%) 
levofloxacin 500 mg 1x2 121 34 min 11 h 22 min 103 / 121 (85%) 
ciprofloxacin 500 mg 1x1 109 1 h 12 min   102 / 109 (94%) 
ciprofloxacin 500 mg 1x2 2 1 h 45 min 7 h 45 min 1 / 2 (50%) 
ciprofloxacin 750 mg 1x1 46 1 h 0 min   40 / 46 (87%) 
ciprofloxacin 750 mg 1x2 1 5h 30 min 6 h 0 min 1 / 1 (100%) 
fosfomycin 3000 mg 1x1 10 2 h 0 min   10 / 10 (100%) 
other1 2     2 / 2 (100%) 
average  57 min 11 h 4 min 262 / 294 (89%) 
1 Other prophylactic antibiotic prophylaxis was fosfomycin 3000 mg + ciprofloxacin 500 mg one hour 
before biopsies and in another patient levofloxacin 500 mg 2 h 10 min before and 9 h 50 min after 
biopsies + additional levofloxacin 250 mg daily five days after biopsies. 
The fluoroquinolone resistance rates in the patients’ pre-biopsy rectal swab samples 
are demonstrated in Table 10. According to The European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) 2017 criteria, 12% (36/294) of the 
study patients had a fluoroquinolone resistant E. coli strain and 6% (18/294) had a 
3CEF resistant E. coli strain (The European Committee on Antimicrobial 
Susceptibility Testing, 2017).  
Table 10. Antibiotic susceptibility profiles in study patients rectal swab culture. 
 n % 
E. coli growth in rectal swab sample 262 89% (262 / 294) 
no E. coli growth in rectal swab sample 32 9% (27 / 294) 
fluoroquinolone-resistant E. coli 36 12% (36 / 294)1 
fluoroquinolone-intermediate E. coli 9 3% (9 / 294) 
fluoroquinolone-susceptible E. coli 217 74% (217 / 294) 
E. coli resistant to 3rd generations cephalosporins 21 7% (18 / 294)1 
1 Patients with E. coli growth in rectal swab culture, 14% and 8% was resistant to fluoroquinolones 
and 3rd generations cephalosporins, respectively. 
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The risk factor analysis for biopsy complications is presented in Table 11. The 
patients having E. coli strain resistant to prophylactic antibiotics had no infectious or 
non-infectious complications. 
Table 11.  Risk factors for complications leading to a visit to a health care unit after a TRUS-Bx. 
Total 32/294 of patients (11%) had a E. coli strain resistant to given antibiotic prophylaxis 
in their intestinal bacterial flora. None of them had infectious or non-infectious 
complications leading to a visit to health care unit after biopsies. 
 n complication rate 
prostate weight over 40 g 128 7/128 (5.5%)1 
prostate weight 40 g or less 144 5/144 (3.5%)1 
age over 70 years 53 2/53 (3.8%) 
age 70 years or less 241 10/241 (4.1%) 
diabetes 34 2/34 (6.0%) 
no diabetes 260 10/260 (3.8%) 
anticoagulation/antiplatelet therapy 52 2/52 (3.8%) 
no anticoagulation/antiplatelet therapy 242 10/242 (4.1%) 
1) Prostate weight was measured in 272 of 294 patients. 
5.2 Study II 
In Study II, we aimed at surveying the prevalence and risk factors for intestinal E. coli 
antibiotic resistance in men undergoing prostate biopsies. The collection of patient 
data is demonstrated in Figure 4. A total of 359 patients from four study centers were 
recruited to the study. Microbiological samples were available from 317 patients. A 
total of 62 patients were excluded from the initial study population due to missing 
questionnaires or microbiological samples, i.e. 297 patients were included in the risk 
factor analysis to investigate underlying reasons for E. coli resistance. 
Figure 4. Flowchart of the patient inclusion to the final analysis. 
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Study patient characteristics are presented in Table 12. The mean age was 64 and the 
mean prostate size was 45 g. A total of 55% of the patients had travelled 
internationally during the preceding year. 
Table 12. Study patient characteristics. 
number of patients with the full data available 297 
age, mean (range) 64 (29–82) years 
PSA, mean (range) 7.6 (1.4–30) ng/ml 
prostate weight, mean (range) 45 (14–131) g 
diabetes, n (%) 35 (12) 
current smoker or quitted smoking during the last 2 years, n (%) 58 (20) 
international traveling during the last year, n (%) 163 (55) 
antibiotic therapy during the last year, n (%) 99 (33) 
 
The results of the rectal swab cultures are presented in Table 13. According to 
EUCAST 2017 criteria, the rates of fluoroquinolone and 3CEF resistant E. coli strains 
in patient level were 13% and 8%, respectively, whereas the rates of fluoroquinolone 
and 3CEF resistant strains among patients having E. coli strain were 14% and 8%, 
respectively (The European Committee on Antimicrobial Susceptibility Testing, 
2017). Patients having 3CEF resistant E. coli strain, 13/21 (62%) were ESBL-
producers and 21/24 (88%) were fluoroquinolone resistant. Differences in the 
fluoroquinolone resistance rates between patients from different study centers were 
notable in our study: Highest rates were in the Helsinki (18%) and lowest in the Pori 
(5%) study center.  
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Table 13. Results of cultured rectal swab samples antimicrobial susceptibility testing for E. coli 
strains in the study population. 
 
n E. coli growth  (%) 
no E. coli growth  
(%) 
3CEF resistant E. coli  
(%)3 
All 317 283 / 317 (89%) 34 / 317 (11%) 24 / 317 (8%)4,5 
Turku 130 122 / 130 (94%) 8 / 130 (6%) 12 / 130 (9%) 
Helsinki 56 48 / 56 (86%) 8 / 56 (14%) 6 / 56 (11%) 
Tampere 56 48 / 56 (86%) 8 / 56 (14%) 4 / 56 (7%) 
Pori 75 65 / 75 (87%) 10 / 75 (13%) 2 / 75 (3%)      
 EUCAST 2016  
 
fluoroquinolone 
resistant E. coli (%) 
fluoroquinolone 
intermediate 
susceptible E. coli (%) 
fluoroquinolone 
susceptible E. coli (%) 
All 22 / 317 (7%)2 9 / 317 (3%)2 286 / 317 (90%)2 
Turku 13 / 130 (10%) 2 / 130 (2%) 115 / 130 (88%) 
Helsinki 1 / 56 (2%) 6 / 56 (11%) 49 / 56 (88%) 
Tampere 5 / 56 (9%) 1 / 56 (2%) 50 / 56 (89%) 
Pori 3 / 75 (4%) 0 / 76 (0%) 72 / 75 (96%) 
     
 EUCAST 2017  
 
fluoroquinolone 
resistant E. coli (%) 
fluoroquinolone 
intermediate 
susceptible E. coli (%) 
fluoroquinolone 
susceptible E. coli (%) 
All 40 / 317 (13%)1 11 / 320 (3%)1 267 / 317 (84%)1 
Turku 20 / 130 (15%) 1 / 130 (1%) 109 / 130 (84%) 
Helsinki 10 / 56 (18%) 3 / 56 (5%) 43 / 56 (77%) 
Tampere 6 / 56 (11%) 2 / 56 (4%) 48 / 56 (85%) 
Pori 4 / 75 (5%) 4 / 75 (5%) 67 / 75 (89%) 
1) According to EUCAST 2017 criteria, the amount of fluoroquinolone resistance, fluoroquinolone 
intermediate susceptible, fluoroquinolone susceptible E. coli strains in patients having E. coli strain 
in their rectal swab sample was 40/283 (14%), 10/283 (4%), and 233/283 (82%), respectively. 
2) According to EUCAST 2016 criteria, the amount of fluoroquinolone resistance, fluoroquinolone 
intermediate susceptible, fluoroquinolone susceptible E. coli strains in patients having E. coli strain 
in their rectal swab sample was 22/283 (8%), 9/283 (3%), and 252/283 (89%), respectively. 
3) There were no changes in the EUCAST criteria defining 3CEF resistant E. coli in 2016/2017. 
4) According to EUCAST 2017 criteria, the amount of 3CEF resistant strain in patients having E. coli 
strain was 24/283 (8%).  
5) Of the 3CEF resistant E. coli strains, 21/24 (88%) were also fluoroquinolone resistant, and of the 
21 tested 3CEF resistant strains, 13 (62%) were ESBL-producers. 
The risk factor analysis for antibiotic resistance is presented in Table 14 and Table 
15. In univariate analysis, smoking, diabetes, recent use of antibiotics and age did not 
have statistically significant influence on the risk of having fluoroquinolone resistant 
E. coli strains. In univariate and multivariate analysis, unspecified international 
traveling during the preceding year significantly increased the risk of colonization 
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with the fluoroquinolone resistant E. coli strains, OR 3.592, p=0.001. Surprisingly, in 
multivariate analysis, recent (unspecified) antibiotic therapy during the preceding year 
reduced the risk of having the fluoroquinolone resistant E. coli strain, OR 0.442, 
p=0.035. None of the risk factors had significant influence on the 3CEF resistance 
rates in E. coli strains in univariate or multivariate analysis. Although no significant 
risk factors were found, we identified a trend of an increasing risk for 3CEF resistance 
E. coli strain in patients with international traveling and smoking history. 
The rate of patients having fluoroquinolone resistant E. coli strain in the rectal 
swab sample was compared to the patients’ traveling history during the preceding 
year. The results are presented in Figure 5. Traveling, especially to Asia or Japan, 
considerably increased the risk of a fluoroquinolone resistant E. coli strain in the rectal 
swab sample. 
 
  
Table 14. Analysis of risk factors for study patients having a E. coli strain with decreased susceptibility (resistant or intermediate susceptible) to 
fluoroquinolones. 
  
fluoroquinolone 
resistant or 
intermediate 
susceptible  
E. coli 
fluoroquinolone 
sensitive  
E. coli or no  
E. coli  
univariate analysis  
 
multivariate analysis  
O.R. 
95% CI 
p O.R. 
95% CI 
p Lower Upper Lower Upper 
international traveling during the 
last year, n (%) 36 (22) 127 (78) 
  3.170 1.544 6.507 0.002   3.592 1.704 7.571 0.001 
no international traveling during 
the last year, n (%) 11 (8%) 123 (92%)   reference   reference 
current smoker or quitted smoking 
during the last two years, n (%) 10 (17%) 48 (83%) 
  1.137 0.529 2.447 0.742   1.547 0.683 3.505 0.296 
non-smoker at least last two 
years, n (%) 37 (15%) 202 (85%)   reference   reference 
antibiotic therapy during the last 
year, n (%) 11 (11%) 88 (89%) 
  0.563 0.273 1.160 0.119   0.442 0.206 0.946 0.035 
no antibiotic therapy during the 
last year, n (%) 36 (18%) 162 (82%)   reference   reference 
diabetes, n (%) 6 (17%) 29 (83%)   1.115 0.436 2.855 0.820   1.549 0.570 4.209 0.391 
no diabetes, n (%) 41 (16%) 221 (84%)   reference   reference 
age, mean (SD) 63 (8) 64 (8)   0.982 0.945 1.021 0.366   0.982 0.941 1.026 0.425 
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Table 15.  Analysis of risk factors for study patients having a E. coli strain resistant to 3rd generations cephalosporins. 
 
3CEF resistant 
E. coli 
3CEF sensitive 
E. coli or no  
E. coli  
univariate analysis 
p  
multivariate analysis 
p O.R. 
95% CI 
O.R. 
95% CI 
Lower Upper Lower Upper 
international traveling during 
the last year, n (%) 14 (9) 149 (91)   2.228 0.778 6.377 0.135 
 2.330 0.789 6.879 0.126 
no international traveling during 
the last year, n (%) 5 (4) 129 (96)   reference   reference 
current smoker or quitted 
during the last two years, n (%) 5 (11) 53 (89)   1.553 0.532 4.528 0.420   1.754 0.582 5.291 0.318 
non-smoker at least last two 
years, n (%) 14 (6) 225 (94)   reference   reference 
antibiotic therapy during the 
last year, n (%) 6 (6) 93 (94)   1.013 0.371 2.765 0.980   0.911 0.324 2.560 0.860 
no antibiotic therapy during the 
last year, n (%) 13 (7) 185 (93)   reference   reference 
diabetes, n (%) 1 (3%) 34 (97)   0.385 0.050 2.989 0.362   0.473 0.059 3.804 0.481 
no diabetes, n (%) 18 (7) 244 (93)   reference   reference 
mean age (SD) 62,3 (7) 64,4 (8)   0.967 0.916 1.022 0.238   0.973 0.917 1.032 0.363 
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Figure 5. The rate of fluoroquinolone resistant (FQR) E. coli strains in our study patients rectal swab samples linked to international traveling during the 
preceding year. The size of the circle correlates with the number of patients with traveling history to the designated region. Reprinted with a 
permission. 
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5.3 Study III 
In Study III, we aimed at validating the bpMRI score and PSA density combination 
strategy in selecting men for prostate biopsies. In total, 499 men were included, 161 
patients from the IMPROD trial and 338 patients from the Multi-IMPROD trial. 
Baseline characteristics of the enrolled men are presented in Table 16. The median 
age was 65 years, median PSA was 7.1 ng/ml, median PSA density was 0.18 ng/ml/ml 
and median prostate volume was 39 ml. Based on the combination of standard and 
targeted biopsies, no PCa, insPCa, CSPCa was detected in 186 (37%), 84 (17%) and 
229 (46%) men, respectively. 
Table 16. Patient characteristics for men with benign prostate biopsy, insignificant (Gleason 3+3) 
prostate cancer, and significant prostate cancer (Gleason >3+3), respectively. 
 
 
Clinical Characteristics 
No  
PCa 
(n=186) 
Insignificant 
PCa 
(n=84) 
Significant 
PCa 
(n=229) 
 
 
p-value 
 
Total 
(n=499) 
Age (yr), median (IQR) 63 (58–67) 64 (59–68) 67 (62–71) <0.001 65 (59–69) 
PSA (ng/ml), median 
(IQR) 6.3 (4.6–8.6) 6.4 (5.3–8.6) 7.7 (6.2–10) <0.001 7.1 (5.4–9.3) 
Prostate volume, median 
(IQR) 44 (34–62) 37 (28–49) 35 (27–46) <0.001 39 (29–53) 
PSA density (ng/ml/ml), 
median (IQR) 
0.14  
(0.10–0.19) 
0.17  
(0.12–0.24) 
0.22  
(0.16–0.31) <0.001 
0.18  
(0.12–0.26) 
cTDRE category, n (%)      
cTx 127 (68) - 1 (1)  128 
cT1c 53 (28) 66 (79) 97 (42)  216 
cT2 - 5 (6) 18 (8)  23 
cT2a 5 (3) 4 (5) 35 (15)  44 
cT2b 1 (1) - 7 (3)  8 
cT2c - 8 (10) 44 (19)  52 
cT3 - 1 (1) 12 (5)  13 
cT3a - - 14 (6)  14 
cT4 - - 1 (1)  1 
PSA density group, n (%)      
1                 < 0.10 45 (24) 13 (16) 16 (7) <0.001 74 (15) 
2                  0.10 – 0.14 59 (32) 20 (24) 34 (15)  113 (23) 
3                  0.15 – 0.19 39 (21) 18 (21) 51 (22)  108 (22) 
4                  ≥ 0.20 43 (23) 33 (39) 128 (56)  204 (41) 
 
Prostatectomy was performed on 32% (161/499) of the included men, and Gleason 
score was upgraded in 24% (38/161) of the cases from the study biopsy results. In 
patients having IMPROD Likert scored 3 bpMRI finding, in a prostatectomy 
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specimen, Gleason score was upgraded in 21% (3/14) of men from the study biopsy 
results. 
Figure 6 presents a distribution of PCas within the IMPROD bpMRI Likert and 
PSA density groups. In men with an equivocal or high suspicion of PCa (IMPROD 
bpMRI Likert score 3–5), the amount of CSPCas rises with higher PSA density. 
Figure 6. Detection rates of prostate cancers divided to various risk groups. Distribution of PCas 
within PSA density groups and IMPROD bpMRI Likert score groups. Reprinted with a 
permission. 
 
Table 17 presents the performance measures for CSPCa detection at various 
thresholds of IMPROD bpMRI Likert scores and PSA density values. The NPVs for 
ruling out CSPCa in suspicion levels of IMPROD bpMRI Likert 3–5 and IMPROD 
bpMRI Likert 4–5 were 93% and 92%, respectively, while the corresponding PPVs 
were 57% and 72% respectively. The NPVs for PSA density of ≥ 0.20 ng/ml/ml and 
≥ 0.15 ng/ml/ml were 66% and 73% respectively, while the corresponding PPVs were 
63% and 57%, respectively. Youden’s J index values in patient groups with IMPROD 
bpMRI Likert scores 4–5 and 3–5 were 0.61 and 0.35, respectively. The highest 
Youden’s J index value in the PSA density groups were 0.29 in patients with PSA 
density ≥ 0.15. 
   
Table 17. Sensitivity, specificity and predictive values for CSPCa detection at various thresholds of bpMRI score and PSA density. 
Restricted 
Biopsies to 
Avoided  
biopsies, 
n (%) 
Missed 
significant 
PCa, n (%) 
Sensitivity 
(CI 95%) 
Specificity 
(CI 95%) 
PPV 
(CI 95%) 
NPV 
(CI 95%) 
Youden’s 
J index 
AUC  
(CI 95%) 
bpMRI Likert 
score, n (%)        
 
Likert ≥ 5,  
n=216 (43) 283 (57) 51 (22) 
0.78  
(0.72–0.83) 
0.86 
(0.81–0.90) 
0.82 
(0.77–0.87) 
0.82 
(0.77–0.86) 0.64 
0.82 
(0.79–0.85) 
Likert ≥ 4,  
n=296 (59) 203 (41) 17 (7) 
0.93 
(0.88–0.96) 
0.69 
(0.63–0.74) 
0.72 
(0.66–0.77) 
0.92 
(0.87–0.95) 0.61 
0.81 
(0.78–0.84) 
Likert ≥ 3,  
n=386 (77) 113 (29) 8 (3) 
0.97 
(0.93–0.98) 
0.39 
(0.33–0.45) 
0.57 
(0.52–0.62) 
0.93 
(0.87–0.97) 0.35 
0.68 
(0.65–0.71) 
PSA density,  
n (%)         
PSA density 
≥ 0.20, 
n=204 (41) 
295 (59) 101 (44) 0.56 (0.49–0.62) 
0.72 
(0.66–0.77) 
0.63 
(0.56–0.69) 
0.66 
(0.60–0.71) 0.28 
0.64 
(0.60–0.68) 
PSA density 
≥ 0.15, 
n=312 (63) 
187 (37) 50 (22) 0.78 (0.72–0.83) 
0.51 
(0.45–0.57) 
0.57 
(0.52–0.63) 
0.73 
(0.66–0.79) 0.29 
0.64  
(0.60–0.68) 
PSA density 
≥ 0.10, 
n=425 (85) 
74 (15) 16 (7) 0.93 (0.89–0.96) 
0.21 
(0.17–0.27) 
0.50 
(0.45–0.55) 
0.78 
(0.67–0.87) 0.14 
0.57  
(0.54–0.60) 
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Table 18 summarizes the effect of PSA density on predictive values for detecting and 
ruling out CSPCa in each IMPROD bpMRI Likert score group. In men with only 
IMPROD bpMRI Likert scored 3 lesion present (n=90), restricting biopsies within 
this group to men with PSA density ≥ 0.20 ng/ml/ml, 64 (71%, 64/90) men from the 
group would have avoided biopsies and five CSPCas would have been missed in the 
study biopsies. Restricting biopsies to men with IMPROD bpMRI Likert 4–5 lesion, 
17 (17/229, 7% of all CSPCas diagnosed in the study) CSPCas would have been 
missed, and with IMPROD bpMRI Likert 3–5 lesion, eight (8/229, 3% of all CSPCas 
diagnosed in the study) CSPCas would have been missed in the study biopsies. 
Table 18. Effect of PSA density on predictive values for detecting and ruling out significant prostate 
cancer (Gleason score ≥ 3+4) in each IMPROD bpMRI suspicion group. 
 
 
bpMRI 
Total Diagnostic evaluation 
Total n 
(%) 
Significant 
PCa n (%) 
PPV  
(CI 95%) 
NPV  
(CI 95%) 
 
p value* 
bpMRI Likert score 4–5 
and 
296 (59) 212 (93)    
PSA density ≥ 0.20 159 (54) 123 (58) 0.77 (0.70–0.84) 0.23 (0.16–0.30) 0.018 
PSA density < 0.20 137 (46) 89  (42) 0.65 (0.56–0.73) 0.35 (0.27–0.44)  
PSA density ≥ 0.15 226 (76) 171 (81) 0.76 (0.70–0.81) 0.24 (0.19–0.30) 0.006 
PSA density < 0.15 70 (24) 41 (19) 0.59 (0.46–0.70) 0.41 (0.30–0.54)  
PSA density ≥ 0.10 268 (91) 198 (93) 0.74 (0.68–0.79) 0.26 (0.21–0.32) 0.008 
PSA density < 0.10 28 (9) 14 (7) 0.50 (0.31–0.69) 0.50 (0.31–0.69)  
bpMRI Likert score 3 
and 
90 (18) 9 (4)    
PSA density ≥ 0.20 26 (29) 4 (44) 0.15 (0.04–0.35) 0.85 (0.65–0.96)  
PSA density < 0.20 64 (71) 5  (56) 0.08 (0.03–0.17) 0.92 (0.83–0.97)  
PSA density ≥ 0.15 45 (50) 5 (56) 0.11 (0.04–0.24) 0.89 (0.79–0.98)  
PSA density < 0.15 45 (50) 4 (44) 0.09 (0.02–0.21) 0.91 (0.76–0.96)  
PSA density ≥ 0.10 76 (84) 9 (100) 0.12 (0.06–0.21)  0.88 (0.79–0.94)  
PSA density < 0.10 14 (16) 0 (0) 0.0 (0.00–0.23) 1.0 (0.77–1.00)  
bpMRI Likert score 1–2 
and 
113 (23) 8 (3)    
PSA density ≥ 0.20 19 (17) 1 (13) 0.05 (0.00–0.26) 0.95 (0.74–1.00)  
PSA density < 0.20 94 (83) 7 (87) 0.07 (0.03–0.15) 0.93 (0.85–0.97)  
PSA density ≥ 0.15 41 (36) 3 (38) 0.07 (0.02–0.20) 0.93 (0.80–0.98)  
PSA density < 0.15 72 (64) 5 (63) 0.07 (0.02–0.15) 0.93 (0.85–0.98)  
PSA density ≥ 0.10 81 (72) 6 (75) 0.07 (0.03–0.15) 0.93 (0.85–0.97)  
PSA density < 0.10 32 (28) 2 (25) 0.06 (0.01–0.21) 0.94 (0.79–0.99)  
* Chi-squared test p value. 
According to the DCA of different biopsy strategies (Figure 7), the optimal biopsy 
strategy would be to restrict biopsies to men with IMPROD bpMRI Likert score 4–
5 lesion or IMPROD bpMRI Likert score 3 lesion with PSA density ≥ 0.20 ng/ml/cc. 
   
Figure 7. Decision curve analysis showing the net benefit of different biopsy strategies for detection of CSPCa across 0 to 25% threshold probabilities. 
Reprinted with a permission. 
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Table 20 presents combination strategies in various IMPROD bpMRI Likert score 
groups and PSA density thresholds. Using the optimal strategy based on the DCA, 
i.e. restricting biopsies to men with IMPROD bpMRI Likert scored 4–5 lesion or 
IMPROD bpMRI Likert scored 3 lesion with PSA density ≥ 0.20 ng/ml/ml, the 
strategy gives NPV of 93% and PPV of 67% in diagnostics of a CSPCa. Using this 
strategy, 35% (177/499) of men would have avoided biopsies and only 13 CSPCas 
would have been missed (13/229, 6% of all diagnosed CSPCas in the study). The 
majority (11/13) of the missed PCas were classified as Gleason 3+4, except two, 
which were graded as Gleason 4+4 and Gleason 4+3. Table 19 presents the amount 
of PCa and CSPCa in biopsy cores in patients missed by the optimal strategy.  
In contrast, the optimal strategy in the Boesen et al. study (bpMRI score 4–5 or 
PSA density ≥ 0.15 ng/ml/ml) gives NPV of 92% and PPV of 58% in ruling out 
CSPCa using our study material (Boesen et al., 2019). Moreover, nine CSPCas (9/229, 
4% of all diagnosed CSPCas in the study) would have been missed, and 117 men 
(117/499, 23% of the study patients) would have avoided biopsies with the strategy. 
The missed cancers were classified as Gleason 3+4, with the exception of one which 
was classified as Gleason 4+4. 
Table 19. Amount of prostate cancer and significant prostate cancer (Gleason score ≥ 3+4) in 
biopsies taken from patients who did not fulfill the biopsy criteria of the DCA based optimal 
biopsy strategy (IMPROD bpMRI Likert score 4–5 or IMPROD bpMRI Likert score 3 with 
PSA density ≥0.20 ng/ml/cc). 
Patient 
Highest Gleason 
score 
Biopsy cores with 
prostate cancer 
graded as 
Gleason ≥ 3+4 
Total prostate 
cancer positive 
biopsy cores 
Biopsy cores 
taken 
1 3+4 1 1 12 
2 3+4 7 7 16 
3 3+4 2 3 14 
4 4+4 3 4 16 
5 3+4 1 3 12 
6 3+4 1 2 12 
7 3+4 5 6 14 
8 4+3 6 6 14 
9 3+4 2 2 14 
10 3+4 1 1 14 
11 3+4 2 2 12 
12 3+4 1 7 12 
13 3+4 2 4 12 
   
Table 20. Results of different biopsy strategies and the sensitivity, specificity, and predictive values for detecting and ruling out CSPCa when IMPROD 
bpMRI Likert scores are combined with various PSA density thresholds. 
Restrict 
Biopsies to 
Biopsies Insignificant PCa Significant PCa Diagnostic Evaluation (Significant PCa) 
Performed 
n (%) 
Avoided 
n (%) 
Detected 
n (%) 
Avoided 
n (%) 
Detected 
n (%) 
Missed 
n (%) 
Sensitivity 
(CI 95%) 
Specificity 
(CI 95%) 
PPV 
(CI 95%) 
NPV 
(CI 95%) 
AUC 
(CI 95%) 
All men 499 0 84 0 229 0 Ref Ref Ref Ref Ref 
IMPROD bpMRI 
Likert score = 3-
5, or 
386 (77) 113 (23) 73 (87) 11 (13) 221 (97) 8 (3) 0.97  (0.93, 0.98) 
0.39  
(0.33, 0.45) 
0.57  
(0.52, 0.62) 
0.93  
(0.87, 0.97) 
0.68   
(0.65, 0.71) 
PSA density ≥ 
0.20 405 (81) 94 (19) 77 (92) 7 (8) 222 (97) 7 (3) 
0.97  
(0.94, 0.99) 
0.32  
(0.27, 0.38) 
0.55  
(0.50, 0.60) 
0.93  
(0.85, 0.97) 
0.65  
(0.62, 0.68) 
PSA density ≥ 
0.15 427 (86) 72 (14) 79  (94) 5 (6) 224 (98) 5 (2) 
0.98  
(0.95, 0.99) 
0.25  
(0.20, 0.30) 
0.52  
(0.48, 0.57) 
0.93  
(0.85, 0.98) 
0.61  
(0.58, 0.64) 
PSA density ≥ 
0.10 467 (94) 32 (6) 81 (96) 3 (4) 227 (99) 2 (1) 
0.99  
(0.97, 1.00) 
0.11  
(0.08, 0.15) 
0.49  
(0.44, 0.53) 
0.94  
(0.79, 0.99) 
0.55  
(0.53, 0.57) 
IMPROD bpMRI 
Likert score = 4-
5, or 
296 (59) 203 (41) 51 (61) 33 (39) 212 (93) 17 (7) 0.93  (0.88, 0.96) 
0.69  
(0.63, 0.74) 
0.72  
(0.66, 0.77) 
0.92  
(0.87, 0.95) 
0.81   
(0.78, 0.84) 
PSA density ≥ 
0.20 341 (68) 158 (32) 62 (74)  22 (26) 217 (95) 12 (5) 
0.95  
(0.91, 0.97) 
0.54  
(0.48, 0.60) 
0.64  
(0.58, 0.69) 
0.92  
(0.87, 0.96) 
0.74   
(0.71, 0.77) 
PSA density ≥ 
0.15 382 (77) 117 (23) 68 (81) 16 (19) 220 (96) 9 (4) 
0.96  
(0.93, 0.98) 
0.40  
(0.34, 0.46) 
0.58  
(0.52, 0.63) 
0.92  
(0.86, 0.96) 
0.68  
(0.65, 0.71 
PSA density ≥ 
0.10 453 (91) 46 (9) 79 (94) 5 (6) 227 (99) 2 (1) 
0.99  
(0.97, 1.00) 
0.16  
(0.12, 0.21) 
0.5  
(0.45, 0.55) 
0.96  
(0.85, 0.99) 
0.58  
(0.56, 0.6) 
(IMPROD bpMRI Likert score = 4-5) or IMPROD bpMRI Likert score = 3, with  
PSA density ≥ 
0.20 322 (65) 177 (35) 58 (69) 26 (31) 216 (94) 13 (6) 
0.94  
(0.90, 0.97) 
0.61  
(0.55, 0.67) 
0.67  
(0.62, 0.72) 
0.93  
(0.88, 0.96) 
0.78  
(0.75, 0.81) 
PSA density ≥ 
0.15 341 (68) 158 (32) 62 (74) 22 (26) 217 (95) 12 (5) 
0.95  
(0.91, 0.97) 
0.54  
(0.48, 0.60) 
0.64  
(0.58, 0.69) 
0.92  
(0.87, 0.96) 
0.74  
(0.71, 0.77) 
PSA density ≥ 
0.10 372 (75) 127 (25) 71 (85) 13 (15) 221 (97) 8 (3) 
0.97  
(0.93, 0.98) 
0.44  
(0.38, 0.50) 
0.59  
(0.54, 0.64) 
0.94  
(0.88, 0.97) 
0.70  
(0.67, 0.73) 
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5.4 Study IV 
In Study IV, we investigated the impact of prebiopsy prostate bpMRI on the 
prevalence of CSPCa in an initial biopsy session. Baseline characteristics of the study 
groups are presented in Table 21 and a flowchart of the patient inclusion is presented 
in Figure 8. The MRI group consists of 507 men and the non-MRI group of 379 men. 
There was a significant (p<0.05) difference in the mean age and a mean PSA level 
between the study groups: The mean age and the mean PSA were in the MRI group 
64 years and 7.6 ng/ml, respectively, and in the non-MRI group 68 years and 8.2 
ng/ml, respectively. Mean prostate volumes were in the MRI group and in the non-
MRI group 43 ml and 44 ml, respectively, and the difference was not significant. Due 
to the study setting, mean follow-up times differ substantially between the study 
groups, 736 days in the MRI group and 2381 days in the non-MRI group (p<0.05). 
Table 21. Baseline characteristics of the study patients. 
  non-MRI group MRI group  p 
n 379 507   
mean age years (range) 68 (39–91) 64 (29–82)  <0.001 
mean PSA ng/ml (range) 8.2 (0.42–19) 7.6 (1.2–20)  0.020 
mean prostate volume ml (range) 44 (16–120) 43 (14–150)  0.245 
mean follow-up time, days (range) 2381 (1941–2758) 736 (36–1596)  <0.001 
   
Figure 8.  A flowchart of the study patient inclusion.  
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The results of initial biopsies are presented in Table 22. Significant PCa (GGG 2-5) 
were diagnosed with initial biopsies in 48% of men in the MRI group and in 34% of 
men in the non-MRI group (p<0.001). The rate of insPCa (GGG 1) was 16% in the 
both study groups. When all the biopsy results were divided to the GGGs, significantly 
(p<0.05) higher rates of GGG 3 and GGG 4 graded PCas were discovered in the MRI 
group. 
Table 22. Histological diagnosis in initial biopsies. 
 non-MRI group MRI group p 
n 379 507  
benign (%) 190 (50) 179 (35) <0.001 
any PCa (%) 189 (50) 328 (65) <0.001 
Gleason grade group 2-5 PCa (%) 130 (34) 245 (48) <0.001 
Gleson grade group 1 (%) 59 (16) 83 (16) 0.747 
Gleson grade group 2 (%) 50 (13) 89 (18) 0.077 
Gleson grade group 3 (%) 17 (5) 57 (11) <0.001 
Gleson grade group 4 (%) 20 (5) 52 (10) 0.007 
Gleson grade group 5 (%) 43 (11) 47 (9) 0.312 
 
Upgraded biopsy results during the follow-up are presented in Table 23. In men with 
a benign or a GGG 1 histology in initial biopsies, upgrading histology in re-biopsies 
was in 5% of men in the MRI group and in 19% of men in the non-MRI group 
(p=0.001). In addition, histology of the initial biopsies upgraded to a highly aggressive 
(GGG ≥ 3) PCa in re-biopsies in 1% and 11% PCa of the men in the MRI group and 
the non-MRI group (p<0.001), respectively. We made an additional analysis on the 
non-MRI group, dividing it to men having MRI and men without MRI during the 
follow-up. Substantially more CSPCa, and also more aggressive PCas were found in 
men having MRI during the follow-up. 
Table 23.  Biopsy findings during the follow-up. 
 
MRI 
group 
non-
MRI 
group 
p 
 non-MRI group  
 
MRI 
before re-
biopsies 
subgroup 
no MRI 
before re-
biopsies 
subgroup 
p 
n 379 507   23 226 
 
benign or GGG 1 (%) in primary 
biopsies 
262 
(69) 
249 
(49) <0.001  
23  
(100) 
226  
(100)  
GGG ≥ 2 PCa in rebiopsies if primary 
biopsies benign or GGG 1 (%) 
13  
(5) 
47 
(19) 0.001  
12  
(52) 
35 
(25) <0.001 
GGG ≥ 3 PCa in rebiopsies if primary 
biopsies benign or GGG 1 (%) 
3  
(1) 
27 
(11) <0.001  
6  
(26) 
21  
(9) 0.014 
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Histological findings of prostatectomy specimen compared to the initial biopsy results 
are presented in Table 24. Upgrading histology in prostatectomy specimen was 
substantially and significantly (p=0.002) more common in the non-MRI group (57%) 
than in the MRI group (36%), and capsule invasive PCa was significantly more 
common in the non-MRI group. 
Table 24. Prostatectomy findings during the follow-up. 
 
MRI  
group 
non-MRI 
group p 
n 379 507  
prostatectomy (% of patients in the cohort) 173 (46) 77 (20) <0.001 
upgrading Gleason grade in prostatectomy specimen (% 
of prostatectomies in the cohort) 62 (36) 44 (57) 0.002 
pT3-pT4 in prostatectomy specimen (% of 
prostatectomies in the cohort) 71 (41) 43 (56) 0.030 
 
A diagnostic delay and a number of biopsy sets taken for the diagnosis of CSPCa are 
presented in Figure 9 and Figure 10. In Figure 9, a Kaplain-Meier graph of first two 
years of the follow-up indicates a trend that more CSPCas were diagnosed during the 
follow-up in the non-MRI group in comparison to the MRI group. The same trend is 
seen in Figure 10, which presents how many biopsy sets had to be taken for the 
diagnosis of CSPCa. 
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Figure 9. A Kaplan-Meier graph of a two years’ follow-up period of the study patients. The graph 
presents the prevalence of CSPCa in the study groups during the first two years of follow-
up. Reprinted with a permission. 
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Figure 10. A graph presenting how many biopsy sessions had to be performed for a diagnosis of a 
CSPCa during the follow-up. The dark grey bar presents the MRI group and the light grey 
bar presents the non-MRI group (control group). Reprinted with a permission. 
 
5.5 Study V 
In Study V, we investigated the NPV of IMPROD bpMRI as a whole and in clinical 
subgroups. A total of 865 patients were recruited to the studies and 673 of these 
patients were included into this pooled data analysis. The median delay from MRI to 
study biopsies was 10 days. Table 25 summarizes the study patient characteristics and 
Figure 11 includes a flowchart of patient inclusion to the final analysis. The mean age 
of the included men was 65 years and mean PSA level was 9.7 ng/ml. Of the study 
population, 76% were prostate biopsy and prostatic surgery naïve. Significant PCa 
was found in 320 (48%) and any grade of PCa in 425 (63%) in the study biopsies. 
Characteristics of different MRI studies is depicted in Table 26. In total, the AUC of 
IMPROD bpMRI and IMPROD Likert scoring system in CSPCa diagnostics was 
0.863. 
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Table 25. Study patient characteristics. 
age, mean (range) 65 (29–83) years 
PSA, mean (range) 9.7 (1.2–380) ng/ml 
free PSA/PSA ratio, mean (range) 14.9 (0.50–47.9) % 
prostate volume, mean (range) 44 (10–200) ml 
PSA density, mean (range) 0.24 (0.025–3) ng/l/ml 
5-alpha reductase therapy n (%) 94 (14)   
previous prostatic procedures 
 none, n (%) 513 (76) 
 prostate biopsies, n (%) 153 (23) 
 prostatic surgery, n (%) 14 (2) 
total number of biopsy cores, mean (range) 13 (2–20) 
prostate cancer status in study biopsies 
 bening, n (%) 248 (37) 
 Gleason score 3+3, n (%) 105 (16) 
 Gleason score 3+4, n (%) 130 (19) 
 Gleason score 4+3, n (%) 69 (10) 
 Gleason score 4+4, n (%) 59 (9) 
 Gleason score >4+4, n (%) 62 (9) 
Figure 11. Flowchart of patient inclusion to the final analysis. 
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Table 26. Prospective studies included in the pooled analysis. Number of patients included in the 
studies, PCa rates, and the AUC values of prebiopsy IMPROD bpMRI for a CSPCa are 
presented. 
study n 
PCa in the  
study biopsies 
n (%) 
CSPCa in the 
study biopsies  
n (%) 
AUC  
for a CSPCa 
IMPROD 162 106 (65) 81 (50) 0.873 
Multi-IMPROD 338 207 (61) 146 (43) 0.861 
IMPROD 2.0 56 42 (75) 36 (64) 0.807 
PROMANEG 117 70 (60) 57 (49) 0.865 
total 673 425 (63) 320 (48) 0.863 
 
Table 27 summarizes the parameters of IMPROD bpMRI in CSPCa diagnostics. A 
total of 80% and 62% of the study patients had IMPROD bpMRI Likert scores 
between 3–5 and 4–5, respectively. The NPVs of the IMPROD bpMRI Likert score 
groups 1–2 and 1–3 for ruling out CSPCa were 0.932 and 0.914, respectively. The 
corresponding PPVs for CSPCa in the IMPROD bpMRI Likert score groups 3–5 and 
4–5 were 0.575 and 0.713, respectively. 
Table 27. The diagnostic parameters of IMPROD bpMRI for CSPCa. 
MRI suspicion 
score study  
 
 
diagnostic parameters to a CSPCa 
NPV PPV sensitivity specificity 
IMPROD Likert 
3-5 
IMPROD  123 (76)  0.897 0.626 0.951 0.432 
Multi-IMPROD  263 (78)  0.947 0.540 0.973 0.370 
IMPROD 2.0  50 (89)  1.000 0.720 1.000 0.300 
PROMANEG  105 (90)  0.917 0.533 0.982 0.183 
total  541 (80)  0.932 0.575 0.972 0.348       
IMPROD Likert 
4-5 
IMPROD  99 (61)  0.921 0.768 0.938 0.716 
Multi-IMPROD  197 (58)  0.915 0.680 0.918 0.672 
IMPROD 2.0  44 (79)  0.833 0.773 0.944 0.500 
PROMANEG  78 (67)  0.923 0.692 0.947 0.600 
total  418 (62)  0.914 0.713 0.931 0.660 
 
Table 28 and Table 29 present the subgroup characteristics and performance 
measures of IMPROD bpMRI in the study population in the score groups of IMPROD 
bpMRI Likert 3–5 and IMPROD bpMRI Likert 4–5. In the analysis, no clear outlier 
with a higher NPV in ruling out CSPCa were present. The highest NPV of the 
IMPROD Likert score group 3–5 was in a subgroup of men with a PSA level ≥10 
ng/ml (0.966). Correspondingly, the highest NPVs of the IMPROD Likert score group 
4–5 were in subgroups of men with PSA density <0.25 ng/ml/ml (0.941) or prostate 
volume ≥40 ml (0.936). However, the subgroup of men with PSA density ≥0.25 
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ng/ml/ml stood out with low NPV in both IMPROD Likert 3–5 (0.875) and IMPROD 
Likert 4–5 (0.757) score groups.  
Table 28. Subgroup analysis of the study population. 
  n/total (%) 
significant PCas 
n/total (%) 
prostate volume ≥ 40 ml 298/625 (48%) 102/298 (34%) 
  < 40 ml 327/625 (52%) 193/327 (59%) 
PSA ≥ 10 ng/ml 180/673 (27%) 101/180 (56%) 
  < 10 ng/ml 493/673 (73%) 219/493 (44%) 
PSA density ≥ 0.25 ng/ml/ml 191/625 (31%) 131/191 (69%) 
  < 0.25 ng/ml/ml 434/625 (69%) 164/434 (38%) 
free PSA/PSA ratio ≥ 10% 415/530 (78%) 173/415 (42%) 
  < 10% 115/530 (22%) 65/115 (57%) 
age ≥ 65 years 382/673 (57%) 218/382 (57%) 
  < 65 years 291/673 (43%) 102/291 (35%) 
previous biopsies yes 153/673 (23%) 65/153 (42%) 
  no 520/673 (77%) 255/520 (49%) 
5-alpha reductase therapy yes 94/673 (14%) 44/94 (47%) 
  no 579/673 (86%) 276/579 (48%) 
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Table 29. The diagnostic parameters of IMPROD bpMRI for CSPCa in suspicion levels of IMPROD 
Likert 3–5 and IMPROD Likert 4–5 in different clinical subgroups. 
suspicion 
level 
  
NPV PPV sensitivity specificity 
IMPROD 
Likert 
3-5 
prostate volume ≥ 40 ml 0.945 0.469 0.951 0.439 
  < 40 ml 0.895 0.654 0.979 0.254 
PSA ≥ 10 ng/ml 0.966 0.662 0.990 0.354 
  < 10 ng/ml 0.922 0.541 0.963 0.347 
PSA density ≥ 0.25 ng/ml/ml 0.875 0.737 0.985 0.233 
  < 0.25 ng/ml/ml 0.938 0.489 0.957 0.393 
free PSA/PSA ratio ≥ 10% 0.938 0.525 0.965 0.376 
  < 10% 0.941 0.653 0.985 0.320 
age ≥ 65 years 0.949 0.666 0.986 0.341 
  < 65 years 0.918 0,440 0.941 0.354 
previous biopsies yes 0.900 0.504 0.954 0.307 
  no 0.941 0.596 0.976 0.362 
5-alpha reductase therapy yes 0.952 0.589 0.977 0.400 
  no 0.928 0.573 0.971 0.340        
IMPROD 
Likert  
4-5 
prostate volume ≥ 40 ml 0.936 0.648 0.902 0.745 
  < 40 ml 0.869 0.749 0.943 0.545 
PSA ≥ 10 ng/ml 0.900 0.792 0.941 0.684 
  < 10 ng/ml 0.918 0.681 0.927 0.653 
PSA density ≥ 0.25 ng/ml/ml 0.757 0.792 0.931 0.467 
  < 0.25 ng/ml/ml 0.941 0.658 0.927 0.707 
free PSA/PSA ratio ≥ 10% 0.927 0.678 0.925 0.686 
  < 10% 0.875 0.735 0.938 0.560 
age ≥ 65 years 0.909 0.793 0.950 0.671 
  < 65 years 0.918 0.580 0.892 0.651 
previous biopsies yes 0.903 0.648 0.908 0.636 
  no 0.917 0.731 0.937 0.668 
5-alpha reductase therapy yes 0.929 0.788 0.932 0.780 
  no 0.911 0.702 0.931 0.640 
 
Of the study patients classified as MRI negative by IMPROD Likert score of 1–3 
(255/673 [38% of all the study patients]), 22 had CSPCa in the study biopsies. Of 
these 22 patients, four had Gleason 5 patterns in the study biopsies. Accordingly, of 
the study patients classified as MRI negative by IMPROD Likert score of 1–2 
(132/673 [20% of all the study patients]), nine had CSPCa in the study biopsies. Of 
these nine patients, seven had Gleason 3+4 graded PCa and two Gleason 4+3 graded 
PCa. Thus, 20% of the study patients with suspected PCa could have been excluded 
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from prostate biopsies without missing any Gleason >7 PCa and missing only nine 
CSPCas (9/320 [3% of all CSPCas diagnosed in the study]) in the study biopsies. 
Negative predictive values for different patient subcohorts defined by prostate 
volume, PSA and PSA density value groups are presented in Figure 12, Figure 13 
and Figure 14. The diagnostic accuracy of IMPROD bpMRI in ruling out CSPCa 
seems to increase in patients having larger prostates. We found no similar pattern in 
increasing PSA values. Also, higher NPV was seen in patients with PSA density <0.25 
ng/ml/ml. 
Figure 12. Negative predictive value of IMPROD bpMRI for CSPCa in prostate volume subgroups. 
IMPROD Likert 4–5 graded lesion in MRI report was used as a positive for CSPCa. 
(prev=prevalence). 
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Figure 13. Negative predictive value of IMPROD bpMRI for CSPCa in different PSA level subgroups. 
IMPROD Likert 4–5 graded lesion in MRI report was used as a positive for CSPCa. 
(prev=prevalence). 
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Figure 14.  Negative predictive value of IMPROD bpMRI for CSPCa in different PSA level subgroups. 
IMPROD Likert 4–5 graded lesion in MRI report was used as a positive for CSPCa. 
Negative predictive value of IMPROD bpMRI for CSPCa in in different PSA density 
groups. IMPROD Likert 4–5 graded lesion in the MRI report was used as a positive for 
CSPCa. (prev=prevalence). 
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6 Discussion 
6.1 Main findings and discussion of the substudies 
6.1.1 Summary 
Traditional PCa diagnostics with systematic prostate biopsies is inevitably shifting 
towards an MRI and lesion-based approach, however, the role of MRI in the modern 
diagnostic protocol is still under a debate. Additionally, the globally increasing E. coli 
fluoroquinolone resistance rate and rate of infectious biopsy complications requires 
improved prophylaxis and advanced patient selection for prostate biopsies.  
In this doctoral thesis, we investigated means to improve PCa diagnostics with 
MRI and biopsy safety especially from microbiological aspects. The methods 
included were to survey a prevalence of TRUS-Bx complications,  prevalence and risk 
factors for intestinal E. coli  antibiotic resistance in men undergoing prostate biopsies, 
validate the bpMRI score and PSA density combination strategy in selecting men for 
prostate biopsies, investigate the impact of prebiopsy prostate bpMRI on the 
prevalence of CSPCa in an initial biopsy session, and investigate the NPV of 
IMPROD bpMRI as a whole and in clinical subgroups. 
In the microbiological section of the doctoral thesis, we noted quite high 
prevalence of fluoroquinolone-resistant E. coli strains among men undergoing TRUS-
Bx, which was consistent with the findings of prior studies. In addition, recent 
traveling was noted as a risk factor for fluoroquinolone resistance also in our study. 
Contrary to findings in prior studies, the rate of infectious biopsy complications was 
however low. 
In the MRI section of the doctoral thesis, we demonstrated a high NPV of 
IMPROD bpMRI in ruling out CSPCa and its diagnostic superiority with almost all 
measured variables comparing to the traditional diagnostic protocol, which is also a 
consistent finding with the prior studies. In the subgroup analysis, no clinical 
subgroups with improved bpMRI performance appeared. Additionally, PSA density 
gives only minor additional value to diagnostics in case of equivocal CSPCa 
suspicion, which validates the results of Boesen et al. (Boesen et al., 2019). 
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6.1.2 Study I 
In this prospective, multicenter study, the rate of biopsy-related complications was 
4.1% during the follow-up period of 30 days. None of the patients got a septic 
complication and only two (0.7%) had a minor infectious complication. The rate of 
patients having an E. coli strain resistant to fluoroquinolone-based antibiotics was 
reasonably high: 12%. Infectious complications were rare, although 11% of the 
patients had an E. coli strain resistant to the given antibiotic prophylaxis. Prevalence 
and risk factors for having an intestinal fluoroquinolone resistant E. coli strain in this 
study population is analyzed in more detail in Study II of this doctoral thesis. Rectal 
bleeding or hematuria occurred in eight (2.7%) patients. Three patients (1.0%) 
experienced an urinary retention.  
Almost all patients in our study (97%) had a fluoroquinolone-based antibiotic as 
a prophylactic regimen which is in line with the recommendations of the EAU 
guidelines, however, due to new regulations by the European Commission concerning 
fluoroquinolone use, the guidelines will be changed in the near future (Bonkat et al., 
2019; Mottet et al., 2018). A Cochrane review article analyzed antibiotic prophylaxis 
for reducing infectious complications (bacteriuria, bacteremia, fever, urinary tract 
infection, hospitalization) after TRUS-Bx (Zani et al., 2011). In the analysis of 
antibiotics versus placebo or no treatment, all outcomes significantly favored 
antibiotics (Zani et al., 2011). Although the fluoroquinolones were the most analyzed 
antibiotic regimen in the Cochrane review article, there was no difference between 
fluoroquinolones and 'other classes of antibiotics' (sulfonamides, piperacillin 
tazobactam and ceftriaxone) (Zani et al., 2011). The most recent studies included in 
the Cochrane analysis were from 2009 (Zani et al., 2011). Therefore, the considerably 
increased fluoroquinolone resistance rate of E. coli strains worldwide and also in 
Finland during the last decades makes the outcome slightly outdated (CDDEP, 2019; 
Hakanen et al., 2016).  
An increasing fluoroquinolone resistance rate in E. coli strains and serious 
infectious complications after TRUS-Bx is of major concern. It has been suspected 
that the increased number of serious infectious complications after TRUS-Bx results 
from the increased fluoroquinolone resistance rate of E. coli strains (Borghesi et al., 
2016; Loeb et al., 2013; Pinkhasov et al., 2012; Wagenlehner et al., 2013). On the 
other hand, the colonization of organisms resistant to prophylactic antibiotics does not 
necessarily translate into a clinical infection, which was also the outcome in this study 
(Liss et al., 2011; Liss et al., 2014). Additionally, when determining an organism’s 
ability to cause post-TRUS-Bx infection, fluoroquinolone resistance should be 
considered more as a continuum of increasing resistance for prophylactic antibiotic 
regimen, not as a binary value (Kalalahti et al., 2018).  
The exceptionally low rate of infectious complications and the absence of septic 
complications in our study may be also partly explained by the prospective nature of 
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the study and the limitations followed by the study protocol. This can be observed in 
the varying practice of antibiotic prophylaxis: fosfomycin was used in patients with 
previous traveling history, especially in the Helsinki study center where the 
fluoroquinolone resistance rate in E. coli is significantly higher. Duplessis et al. 
presented other possible explanations for the disparity between the fluoroquinolone 
resistance rate and the rate of infectious complications: It is possible that the 
concentration of ciprofloxacin in feces may exceed the minimal inhibitory 
concentration of the E. coli strains in the rectum (Duplessis et al., 2012). It is also 
possible that there are only such small numbers of resistant strains in some patients' 
rectum that those were not inoculated into the tissue (Duplessis et al., 2012). Finally, 
not all strains have the same virulence potential (Duplessis et al., 2012). 
Several means for reducing infectious complications of TRUS-Bx have been 
presented. These include alternative antibiotics in prophylaxis and giving targeted 
prophylactic antibiotic guided by preprocedural rectal swab sample (Adibi et al., 
2013; Duplessis et al., 2012; Fahmy, Kotb, et al., 2016; Fahmy, Rhashad, et al., 2016; 
Lorber et al., 2013; Sen et al., 2015; Taylor et al., 2012). Infection after TRUS-Bx is 
always an iatrogenic complication, and by taking biopsies using the transperineal 
approach this risk can be minimized. However, this method is not easily performed in 
a high-volume outpatient setting but can be considered as an option in a risk patient. 
Another method to minimize the risk is to improve pre-biopsy diagnostics developing 
novel imaging modalities to avoid unnecessary biopsies. 
Also non-infectious complications were rare in this study and the rate of 
hospitalization and emergency department visits after TRUS-Bx due to a non-
infectious complication was consistent with the previous studies (see chapter 2.2.3.3: 
Biopsy complications). However, bleeding complications occurred slightly more 
often in our study, but the total number of bleeding complications was low. Contrary 
to the study by Pinkhasov et al., (see chapter 2.2.3.3: Biopsy complications), we made 
the TRUS-Bx without interrupting anticoagulation or antiplatelet therapy if the 
international normalized ratio (INR) was in the treatment level, as the current EAU 
guidelines recommend (Mottet et al., 2018; Pinkhasov et al., 2012). 
The limitations of this study include the non-standardized prophylaxis protocol 
and the varying number of the biopsy cores. Patients known to have an increased risk 
were potentially treated differently and their follow-up may also have been more 
intense. On the other hand, the study describes quite well the prevailing clinical 
practice of antibiotic prophylaxis in study centers. However, varying practice makes 
it difficult to evaluate the prophylaxis protocol underlying the results. 
6.1.3 Study II 
In our prospective study, we found fluoroquinolone resistant strains in 13% and 3CEF 
resistant E. coli strains in 8% of the rectal swab samples of the study population taken 
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prior TRUS-Bx. Of the 3CEF resistant E. coli strains, 62% proved to be ESBL-
producers. In multivariate risk factor analysis, international traveling during the 
preceding year significantly increased the risk for having a fluoroquinolone resistant 
E. coli strain. Surprisingly, the use of any antibiotics during the preceding year 
decreased the risk. We did not find any significant risk factors for having 3CEF 
resistant E. coli. 
Previously, it has been reported that fluoroquinolone resistant coliforms can be 
found in 10.6–40.4% and ESBL producing organisms in 1.3–41.0% of rectal swab 
cultures taken prior TRUS-Bx (Batura et al., 2010; Duplessis et al., 2012; Liss et al., 
2014; Taylor et al., 2013; Tsu et al., 2015). In these studies, E. coli was the most 
common fluoroquinolone resistant and ESBL-producing gram negative organism. In 
addition, it has been reported that E. coli is the most common pathogen causing 
infectious complications after TRUS-Bx (Loeb et al., 2012). The wide range in rates 
of fluoroquinolone resistant and ESBL producing microorganisms may have several 
explanations. The variation may be caused by territorial differences in antimicrobial 
susceptibility or the timing of the publications. Since these studies were published 
during the last nine years, the globally increasing trend of antimicrobial resistance 
could also slightly affect the results (CDDEP, 2019; Fasugba et al., 2015). Finally, the 
definitions and protocols of measuring antimicrobial susceptibility varies between the 
studies. 
In the present study, international traveling clearly associated with the risk to have 
a fluoroquinolone resistant E. coli strain. We also identified a similar trend concerning 
the 3CEF resistant E. coli strains. The patients' traveling history and fluoroquinolone 
resistance of E. coli in rectal swab sample also correlate quite well with the prevailing 
global fluoroquinolone resistance rates (CDDEP, 2019). The correlation between 
international traveling and fluoroquinolone resistance has also been noted in previous 
studies. International traveling, and traveling to regions with high prevalence of 
antimicrobial resistance in particular, appears an indisputable risk factor for having 
fluoroquinolone resistant or ESBL-producing E. coli strains. 
Variation in resistance rates between the four study centers in Finland were 
remarkable, especially the high rate of fluoroquinolone resistant and 3CEF resistant 
strains in the Helsinki study center. This finding may also relate to presumably 
different traveling habits and more international population in the capital of Finland. 
Surprisingly, our results indicate that the use of antibiotics during the preceding 
year reduce the risk for having a fluoroquinolone resistant E. coli strain. Although 
Kamei et al. and Duplessis et al. found no difference in fluoroquinolone resistance 
between study groups with prior usage of fluoroquinolone or other antibiotic therapy 
during the preceding three months and one year, there are several reports arguing 
otherwise (Duplessis et al., 2012; Kamei et al., 2017). Taylor et al. presented an 
increased risk for fluoroquinolone resistant coliform in patients with ciprofloxacin 
usage during the last three months (Taylor et al., 2013). In addition, Steensels et al. 
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found an increased risk for having a fluoroquinolone resistant E. coli strain in patients 
with fluoroquinolone usage within six months prior TRUS-Bx (Steensels et al., 2012). 
Tsu et al. presented that antimicrobial usage during the preceding five years is a 
significant risk factor for colonization of fluoroquinolone resistant or ESBL-
producing organisms (Tsu et al., 2015). In our study, the data regarding the use of 
antibiotics during the preceding year was collected with a questionnaire. Most of the 
patients did not recall the specific name of the antibiotic used. As the study consent 
did not allow us to review study patients’ antimicrobial prescriptions, the data on 
antimicrobial usage was based on the patients’ recollections of their previous 
antimicrobial courses. Therefore, the previous use of antibiotics was analyzed without 
dividing the antibiotics into different classes. Since patients who have had previous 
biopsies during the last 6 months and/or had an acute prostatitis were excluded from 
the study, fluoroquinolone exposure in other common indications (e.g. normal 
respiratory tract or soft tissue infections) among the study population can be assumed 
to be relatively low. Thus, the use of antibiotics in general, without dividing the 
antibiotics to different classes, is not a very informative approach for evaluating the 
risk of fluoroquinolone resistance in particular. However, the reduced risk for 
fluoroquinolone resistance is not explainable by this study. 
In this study, smoking history, age or diabetes had no significant impact on the 
risk of having fluoroquinolone resistant or 3CEF resistant strains. Although there are 
previous studies addressing this issue, the results are controversial. In rectal swab 
samples prior TRUS-Bx, Taylor et al. were unable to detect differences in 
fluoroquinolone resistance rates with age or diabetes (Taylor et al., 2013). Tsu et al. 
detected a statistically significant increase in E. coli antimicrobial resistance with 
diabetics but no correlation with age (Tsu et al., 2015). Duplessis et al. detected an 
increase in the fluoroquinolone resistance rate with age (Duplessis et al., 2012). These 
studies did not analyze smoking as a risk or preventive factor for antimicrobial 
resistance. 
Our study has several limitations. Firstly, our only source of data on the risk 
factors included patient questionnaire forms is thus susceptible for recall bias. In 
addition, we analyzed recent antibiotic usage as a whole, without dividing it into 
different categories. Secondly, our study concentrates on the most common pathogen, 
E. coli, although it is not the only microorganism causing infectious complications 
following TRUS-Bx. Thirdly, there are territorial differences in antibiotic 
susceptibility rates and population stability. Also practices of antibiotic usage vary 
among countries. This study was conducted in Finnish centers which affects the 
generalization of the results. Finally, limitations in the inclusion/exclusion criteria 
may also affect the generalization of the results. 
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6.1.4 Study III 
The object of the study is to improve patient selection to prostate biopsies, aiming to 
reduce unnecessary biopsies in cases of equivocal PCa suspicion in MRI and thus 
reduce biopsy complications and insPCa diagnoses. Boesen et al. retrospectively 
investigated an optimal biopsy strategy combining the bpMRI score and PSA density 
(Boesen et al., 2019). The current study is an external validation study for the results 
published by Boesen et al. using our retrospective, multicenter data (Boesen et al., 
2019).  
We aimed to evaluate the NPV of IMPROD bpMRI protocol combined with PSA 
density in men with clinical suspicion of PCa. The negative predictive value for ruling 
out CSPCa in suspicion levels of IMPROD bpMRI Likert 3–5 and IMPROD bpMRI 
Likert 4–5 were 93% and 92%, respectively, while the corresponding PPVs were 57% 
and 72% respectively. The optimal biopsy strategy by DCA was to restrict biopsies to 
men with IMPROD bpMRI Likert 4–5 lesions or IMPROD bpMRI Likert 3 lesions 
with PSA density ≥ 0.20 ng/ml/ml. This combination demonstrated an NPV of 93% 
and PPV of 67% while a total of 177 men (35%) would have avoided biopsies. 
Although there were minor differences with the threshold values for an optimal biopsy 
strategy between the current and the original Boesen et al. study, we can conclude that 
the results are in agreement: combining bpMRI with PSA density leads to improved 
PCa risk stratification compared with the use of bpMRI alone (Boesen et al., 2019). 
However, the additional value of PSA density was marginal. 
In recent studies, PSA density seems to be a better predictor for CSPCa than PSA 
alone, especially in higher PSA values and re-biopsy setting (Jue et al., 2017; 
Nordström et al., 2017). However, the additional value of PSA density to IMPROD 
bpMRI Likert score was marginal in the current study, potentially due to relatively 
high NPV of our IMPROD bpMRI protocol compared to PSA density. As a PSA 
derivative, PSA density bears the same clinical issues that PSA itself carries, e.g. no 
cut-off value in excluding CSPCa (Thompson et al., 2004). However, high PSA 
density values should still be taken into account in the prostate biopsy decision in spite 
of MRI findings. 
An optimal biopsy strategy in the Boesen et al. study was to restrict biopsies to 
men with a bpMRI score of ≥ 4 or PSA density ≥ 0.15 ng/ml/ml (Boesen et al., 2019). 
This strategy demonstrated NPV of 95% and PPV of 56% for CSPCa. Using the same 
strategy in our study setting, it gives NPV of 92% and PPV of 58% for detecting and 
ruling out CSPCa. The results are practically equal.  
The optimal biopsy strategy in the current study (IMPROD bpMRI Likert  score 
≥ 4 or IMPROD bpMRI Likert score of 3 with PSA density ≥ 0.20 ng/ml/ml) 
demonstrated NPV and PPV of 91% and 61%, respectively in the study by Boesen et 
al. (Boesen et al., 2019). These results are similar to those of our study (NPV 93% and 
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PPV 67%). Unfortunately, a DCA with the above biopsy strategy was not presented 
in the aforementioned study (Boesen et al., 2019). 
Some differences in the study cohorts should be noted. Although the PSA median 
was practically equal between the studies, there were differences in prostate volumes 
resulting in lower PSA density (0.12 ng/ml/ml) in the Boesen et al. study when 
compared to ours (0.18 ng/ml/ml) (Boesen et al., 2019). Higher median PSA density 
resulted in higher prevalence of PCa, which is clearly visible in Table 16. In addition, 
sensitivity of systematic biopsies increases in smaller prostates, but the effect of 
prostate volume to MRI sensitivity is difficult to estimate. As expected, a PCa 
detection rate was higher in the current study compared to the one by Boesen et al., 
63% vs. 57%, respectively (Boesen et al., 2019). The difference in the rates of CSPCas 
was 35% in the aforementioned study but 46% in the current study (Boesen et al., 
2019). The differences in lower PCa detection rate and also the higher median prostate 
volume in the Boesen et al. material may originate from differences in PCa screening 
in the populations, or potentially because of more men with benign prostate 
hyperplasia in the cohort of Boesen et al. (Boesen et al., 2019). This might also explain 
the higher rate of bpMRI 1–2 scores in the aforementioned study (Boesen et al., 2019). 
In addition, the difference in PCa detection rate limits the comparability of the results 
of the current and the validated study: when the cancer prevalence decreases, the NPV 
of MRI increases, which inevitably affects the results (Moldovan et al., 2017). 
The current study has several limitations: This study is retrospectively designed 
from prospectively collected material; however, the setting was similar in the 
validated study. We used the IMPROD bpMRI Likert scoring system which is not 
externally validated, while Boesen et al. used (modified) PI-RADS version 2 scoring 
system (Boesen et al., 2019). Unfortunately, a distribution of bpMRI scores was not 
reported in the validated study, which complicates the comparison. Additionally, the 
study patient characteristics and PCa prevalence differ significantly between the 
current and the validated study. In the studies, TRUS-Bx was used as a reference 
standard, which provides only limited information about the whole prostate gland 
pathology; thus the true prevalence of CSPCa remains unclear. This should be taken 
into account when using it as a reference to interpret NPV of MRI. Finally, in the 
current study, cognitive biopsy targeting was used in the majority of the centers, and 
this could lead to lower cancer detection rate in small lesions, while in the validated 
study, MRI-TRUS fusion was used (Boesen et al., 2019). However, in prior studies, 
no significant difference between various methods of MRI targeted biopsy for CSPCa 
detection were found (Monda et al., 2018; Wegelin et al., 2019). 
6.1.5 Study IV 
In the study, we compared, in a non-randomized setting, a prospectively collected 
patient group having a prebiopsy IMPROD bpMRI with target biopsies used in 
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initial PCa diagnostics (MRI group) to a retrospectively collected control cohort in 
whom initial PCa diagnostics were from an era, when there was no prostate MRI in 
clinical use in our center (non-MRI group). All the patients had biopsies due to 
suspicion of PCa and were prostate biopsy naïve. The study cohorts varied 
significantly in mean age, mean PSA level and follow-up time. Taking this into 
account, we presented a quite clear and significant (p<0.05) difference in the rate of 
CSPCa in initial biopsies between the study groups: 48% in the MRI group and 34% 
in the non-MRI group. In addition, significantly more patients got a CSPCa 
diagnosed during the follow-up and an upgrading PCa histology in a prostatectomy 
specimen in the non-MRI group. Because of the variability between the study 
group’s baseline characteristics and follow-up time, in addition to non-randomized 
study setting and retrospective collection of the control cohort, this study should be 
considered more as a descriptive study and therefore far-reaching conclusions 
should not be made. 
The results of our study were as expected in the light of prior studies. In the MRI 
group, there were more CSPCas diagnosed in the initial biopsies. However, due to the 
study design, where a combination of standard and targeted biopsies in the MRI group 
was performed, there was no difference in the rate of insPCa between the study 
groups. In an analysis of the follow-up period, extra care should be taken when making 
conclusions due to the significantly longer follow-up and the higher mean age of the 
men in the non-MRI group. However, there was a trend, in which more CSPCas were 
diagnosed with the initial biopsies in the MRI group, and more with re-biopsies in the 
non-MRI group. Also, highly aggressive (GGG ≥ 3) PCas were missed substantially 
more often with the initial biopsies in the non-MRI group. 
Many patients from the non-MRI group had an MRI performed during the follow-
up and in that subgroup, there were substantially more CSPCa, and also aggressive 
PCas than in men in the group with no MRI performed during the follow-up. The 
selection bias might have affected the result – a remaining clinical suspicion of a non-
diagnosed aggressive PCa drives more easily to novel diagnostic methods. 
In general, high quality prospective, randomized studies had presented convincing 
results of prebiopsy MRIs’ high sensitivity to CSPCa in biopsy naïve patients as 
presented in chapter 2.3.2: MRI in prostate cancer diagnostics. These results are not 
only presenting the superiority of MRI to detect CSPCa, but also a poor sensitivity of 
the traditional diagnostic protocol. Even if the study settings in the studies reported in 
chapter 2.3.2 vary from our study, the results are in line with ours. 
Upgrading histologies and capsule invasive PCas in prostatectomy specimens 
were substantially and significantly more common in the non-MRI group. Again, 
differences between the study groups should be taken into account: prostatectomies 
were done more in the MRI group which might be explainable by the younger mean 
age in the MRI group. However, the higher rate of men with PCa histology upgraded 
in prostatectomy, and also the lower rate of prostatectomies done in the non-MRI 
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group, could have been influenced by a ‘too benign’ biopsy result, taking into account 
the lower rate of CSPCas diagnosed in the non-MRI group. Similar results are seen in 
other studies: Xu et al. retrospectively investigated prostatectomy specimens between 
patient groups having standard TRUS-Bx or transperineal multiparametric MRI 
targeted biopsies (Xu et al., 2018). In the study, upgrading histology in prostatectomy 
was in 26.9% of men in a prebiopsy MRI group and in 73.1% of men in a standard 
biopsy group (Xu et al., 2018). Also Borkowetz et al. compared prostatectomy 
specimens in patient groups having standard TRUS guided biopsies with and without 
additional multiparametric MRI guided transperineal target biopsies (Borkowetz et 
al., 2016). In the study, a combination biopsy group and a systematic biopsy group 
got upgrading histology in prostatectomy in 18% and 44% of cases, respectively 
(Borkowetz et al., 2016). 
As a conclusion, the results of the current study fortify the view that MRI with 
target biopsies gives a great additional value to systematic biopsies in the initial 
diagnostics of CSPCa, comparing it to the traditional initial diagnostic protocol which 
includes only systematic biopsies. It presented superiority with almost all the 
measured variables. The diagnostic delay to correct the histological diagnosis is 
important due to a significant role of correct histology in treatment planning: a delayed 
diagnosis gives time for progression to undiagnosed CSPCa and suspicion of CSPCa 
could drive to unnecessary treatments for insPCa. More importantly, a prevailing 
suspicion of CSPCa after negative biopsies is not only unpleasant for the patient, but 
it is also a burden to the healthcare system. Nevertheless, the combination gives no 
solution to another diagnostic issue; diagnosing insPCas, as seen also in the current 
study: no difference was seen in the rates of diagnosed GGG 1 PCas between the study 
groups. The solution to the issue could be in taking only lesion-targeted biopsies 
which have been investigated with promising results in the PRECISION trial 
described earlier (Kasivisvanathan et al., 2018). However, we are not aware about the 
true prevalence of CSPCa in the MRI-targeted biopsy group, so we are looking 
forward to the follow-up data of the PRECISION trial. Meanwhile, additional 
parameters are needed to estimate the risk for CSPCa when insPCa is diagnosed with 
or without an MRI susceptible lesion present. 
6.1.6 Study V 
In this pooled data analysis of 673 patients from four consecutive, prospective and 
registered studies, we investigated the feasibility of bpMRI with an IMPROD bpMRI 
protocol and IMPROD bpMRI Likert scoring system in the detection of CSPCa in 
patients with suspicion of PCa without a prior PCa diagnosis. We demonstrated an 
AUC of 0.863 to the IMPROD bpMRI Likert scoring system in diagnostics of CSPCa 
in the study biopsies. The overall NPVs for ruling out CSPCa in the IMPROD bpMRI 
Likert score groups 1–2 and 1–3 were 0.932 and 0.914, respectively. In the subgroup 
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analysis, no clear outlier cohorts with a higher NPV were present, which can be 
explained by the high NPV of IMPROD bpMRI for ruling out CSPCa in the whole 
study population. However, IMPROD bpMRI seems not to be as accurate in ruling 
out CSPCa in a subgroup of patients with PSA density ≥0.25 ng/ml/ml. The low NPV 
in this subgroup could be explained by a major difference in the prevalence of CSPCa 
comparing it to a subgroup with PSA density <0.25 ng/ml/ml (69% vs. 38%), which 
affects the NPV. 
The NPV of prostate MRI is discussed in detail in chapter 2.3.2: MRI in prostate 
cancer diagnostics. Because of the differences between the study settings, only very 
limited conclusions in comparison to the other studies can be made. However, 
comparing the outcomes of our study with the prior prostate prebiopsy MRI studies 
with the mpMRI protocol, our IMPROD bpMRI has favorable results in the exclusion 
of CSPCa. Moreover, there is some evidence that an additional value given by contrast 
medium for sensitivity of MRI in diagnostics of CSPCa could be minimal (see chapter 
2.3.3: Biparametric MRI protocol). However, the benefits of our (bpMRI) protocol 
were the quickness of the MRI scan due to the lack of contrast medium and usage of 
transrectal biopsy approach which is more convenient for outpatient use. 
To our knowledge, only a few studies with systematical analysis of additional 
parameters aiming to increase feasibility of prostate prebiopsy MRI have been 
conducted (see chapter 2.3.4: Diagnostic performance of MRI combined with 
additional parameters). More importantly, biopsies in these studies were mostly 
performed via the transperineal approach and with an mpMRI. Again, because of the 
great variation in the study settings and definitions, as well as the lack of prospective 
and systematic studies on bpMRI with additional parameters, direct comparison to our 
study outcomes cannot be done.  
A key finding in our study is that, for patients with suspected PCa, IMPROD 
bpMRI Likert score 1–2 finding in the IMPROD bpMRI ruled out the CSPCa in the 
study biopsies with almost 93% certainty. In addition, no highly aggressive (Gleason 
score >7) PCas were missed. Therefore, using prebiopsy IMPROD bpMRI, 20% of 
prostate biopsies in our study material could have been avoided. 
Our study has several limitations. The most important limitation is that 
prostate biopsies gives only limited information on the prostate gland as a whole 
and that should be taken into account when using the biopsies as a reference to 
interpret NPV of MRI. However, it should be noted that transperineal mapping 
biopsies is not a feasible method in normal clinical practice. Also, it should be 
stated that we used mainly the cognitive MRI fusion method to target suspicious 
lesions. Moreover, inter-observer variability in performing an MRI targeted 
biopsy and reporting IMPROD bpMRI have not yet been evaluated. In addition, 
the transrectal approach may not be optimal when taking biopsies from the anterior 
or apical lesions. 
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6.2 Implications and future perspectives 
Prostate cancer is the only solid organ cancer where diagnosis is not based on imaging 
or visual inspection (e.g. endoscopy) but systematic biopsies of the part of the organ 
where a cancer commonly – but definitely not always – is located. Even worse 
outcomes in accuracy are in PSA and DRE, the clinical parameters that usually rise a 
suspicion of PCa. Introduction of PSA dramatically increased the number of PCa 
diagnoses at the beginning of the 1990s, however, a corresponding decrease is not 
seen in PCa mortality. Discrepancy between the trends is mainly explained by an 
indolent nature of many PCas and also the advancing age of the male population, 
which increases the PCa prevalence as age is the most significant risk factor for PCa. 
Thus, in many cases, PCa could be considered as a chronic disease of ageing men 
without a need of any treatments. However, it is a major fallacy to consider PCa as 
one disease. It is more like a continuum of diseases from indolent neoplasms to highly 
aggressive cancers, while PCa is still a cancer causing second most commonly men’s 
cancer-related deaths in Finland. Thus, in PCa diagnostics, histology is an even more 
substantial factor due to its significant influence on prognosis, comparing it to other 
common cancers. 
The recent implementation of MRI into PCa diagnostics has made a shift towards 
the lesion-based approach; however, systematic biopsies are still a cornerstone in 
diagnostics and taking only lesion targeted biopsies in an initial biopsy session is not 
recommended by the guidelines. It is very likely that PCa diagnostics will transform 
to solely imaging-based diagnostics, biopsing and maybe also (focal) treatments. 
From today’s aspect, MRI seems to be the imaging method for future diagnostics and 
treatment planning. However, the availability of MRI seems to be a key issue in future. 
Contrary to mpMRI, which is the gold standard in prostate imaging, bpMRI is faster 
to perform and interpret which could provide some improvement to the availability 
issue. 
For now, as previous high-quality prospective studies have been presented, MRI 
targeted biopsies seem not to be sensitive enough in ruling out CSPCa – additional 
systematic biopsies are still needed with MRI targeted biopsies. In addition, the issue 
is not only in the NPV of MRI for CSPCa which was presented to be very good, but 
also in the accuracy in targeting biopsies. In addition, multifocality of PCa should be 
taken into account: the targeted (largest) lesion or lesions not always contain the most 
malignant histology in the gland. Additionally, a significant proportion of MRI 
suspicious lesions includes only insPCa histology in targeted biopsies. Is that due to 
a targeting error or when the clinician can rely on that the nature of the MRI lesion is 
established by the targeted biopsies?  
Another issue is the MRI quality and variation in radiologic experience, which 
could vary from prospective studies performed mainly in university hospitals with 
experienced radiologists, high quality MRI-scanners and strictly defined MRI 
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protocols. This is taken into account when developing the open-access IMPROD 
bpMRI protocol with the IMPROD bpMRI Likert scoring system. However, further 
development and standardization of MRI sequences and targeting methods could 
change the current status. 
In the current revolution of PCa diagnostics, a critical question is, what level of 
uncertainty is adequate to sustain in PCa diagnostics? We can compare NPVs of 
diagnostic protocols in e.g. breast, colorectal or lung cancer, but then, in addition to 
falling to ”Hume’s guillotine”, we do not take into account the very different nature 
of the mentioned cancers comparing to PCa and, above all, differences among various 
patient groups in suspicion of CSPCa. This question will lead us to the origin of DCA, 
the biostatistical method utilized in diagnostic studies, where we choose a certain 
grade of uncertainty we are able to sustain before choosing a valid diagnostics test. It 
is an approach that should be used more in studies concerning diagnostic tests of PCa 
to perform a unique diagnostic strategy for different age and risk groups. For example, 
there is a substantial difference of Gleason 3+4 graded PCa diagnosis in a 45- and 75-
year-old man. In a 45-year-old man, even Gleason 3+3 graded PCa diagnosed with 
prostate biopsies is maybe something not to be totally ignored, due to a risk of 
sampling errors and a potential tumor progression in the course of time. However, in 
a 75-year-old man a Gleason 3+4 cancer is hardly lethal, and in case of multiple 
comorbidities, the range of treatments is much more limited. 
Although the complication rates of prostate biopsies have been reported to be 
increasing, according to our results, biopsies seem to be quite a safe procedure and 
prostate biopsies should not usually be abandoned due to a risk of complications. 
Antibiotic prophylaxis seems to be efficient, however recent restrictions from the 
European Commission about fluoroquinolone usage in prophylaxis TRUS-Bx require 
a reassessment of the current fluoroquinolone-based prophylaxis protocol. So far, 
fosfomycin seems to be the most promising alternative to fluoroquinolones. 
Additionally, a rectal swab culture targeted prophylaxis is also a valid alternative. 
More high-quality prospective studies are needed to find an efficient substitute to 
fluoroquinolones. However, antibiotic prophylaxis should still be modified according 
to individual risk factors of a patient, especially the traveling history. More generally, 
these are the fundamentals that should also be taken into account in all modern 
emergency medicine, when treating (urinary tract) infections with an empiric 
antibiotic regimen. 
Prebiopsy prostate MRI should be performed on all men when a suspicion of PCa 
has emerged, if the diagnosis of a PCa is not obvious e.g. due to a very high PSA level 
or an obviously cancerous finding in DRE. Moreover, MRI targeted biopsies find 
more highly aggressive PCa than systematic biopsies, and thus it is simply wrong to 
omit prebiopsy MRI, if available, in PCa diagnostics. Biparametric MRI protocol is 
sensitive enough for most cases. Based on the age and risk group, more than one 
approach guiding the interventions followed by the MRI result should be investigated, 
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preferably using DCA or a corresponding analyzing method. Firstly, when prevalence 
rises, NPV of MRI declines, thus men under a high risk or high level of suspicion of 
CSPCa should be biopsied even if the MRI was negative. Relevant factors taken into 
account in estimating the risk for CSPCa are a suspicious DRE finding, high PSA 
level and/or PSA density, family history, race, and known genetic predisposition. 
Additionally, suspicious results in the novel biomarker test should be taken into 
account in the risk assessment. Secondly, in younger men, also systematic biopsies 
should still be taken in addition to targeted biopsies especially to cover targeting errors 
and cancer multifocality. Finally, in older men and men with multiple comorbidities, 
it should be assessed, if only lesion-targeted biopsies are enough due to lesion size 
being a significant prognostic factor, and the probability for targeting error could be 
lower in larger lesions. In addition, in the mentioned patient group, decision to biopsy 
a Likert/PI-RADS 3 graded lesion, should be based on some additional parameter than 
MRI; so far, PSA density seems to be promising. In the future, serum and urine 
biomarkers might be an interesting approach to be used in combination with the MRI 
score in patient selection for prostate biopsies. From a point of view of an individual 
man, the most significant risk for an (unnecessary) biopsy could be a diagnosis of 
insPCa and its consequences, not a lethal complication. 
Finally, we should acknowledge that the value of pre-biopsy MRI extends beyond 
the initial diagnostics phase. With MRI, the result of biopsies is more reliable, which 
helps further planning of treatment or follow-up in case of benign biopsies. Also, the 
prebiopsy-MRI is very valuable when treatment options and treatment execution is 
planned.  
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7 Conclusions 
Fluoroquinolone resistance and/or 3CEF resistance in intestinal E. coli strains in men 
undergoing TRUS-Bx in Finland is remarkable. International traveling is appearing 
an indisputable risk factor for having an intestinal fluoroquinolone resistant E. coli 
strain. 
The risk for having a serious infectious complication after TRUS-Bx is very low, 
despite the high fluoroquinolone resistance rate. Also, non-infectious complications 
were uncommon.  
IMPROD bpMRI demonstrated a very good NPV in ruling out CSPCa and it gives 
a great additional value to the initial diagnostics of CSPCa, comparing to systematic 
biopsies. It demonstrated superiority with almost all the measured variables. IMPROD 
Likert score 1–2 excludes highly aggressive (Gleason score >7) PCa. No clear outlier 
was present when NPV of IMPROD bpMRI were analyzed in clinical subgroups. 
Combining PSA density with IMPROD bpMRI improved NPV mainly in men with 
an equivocal suspicion in IMPROD bpMRI. However, the additional value of PSA 
density was marginal.  
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